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Abstract
Rationale: CMF (cyclophosphamide: CP; methotrexate: MTX; 5-fluorouracil: 5-FU) is a
chemotherapy combination associated with the cognitive impairments which many cancer
patients experience after treatment. A reduction in hippocampal neurogenesis is a known
means by which cytotoxic drugs alter cognition and is the mechanism investigated in the
present study. There is currently no way of treating or preventing the cognitive deficits
produced by chemotherapy and a simple pharmacological approach to achieving this could
potentially have significant benefits for patients.
Objectives: The studies in the present thesis use an animal model to investigate the effects of
the individual agents in the CMF combination on spatial working memory and the
proliferation and survival of neural precursors involved in hippocampal neurogenesis. It was
also investigated whether the cognitive impairment produced by chemotherapy could be
reversed or prevented by the antidepressant fluoxetine.
Methods: In 4 separate experiments, adult male Lister-hooded rats were chronically
administered with CP (30mg/kg, 4 or 7 i.v. doses), MTX (75mg/kg, 2 i.v. doses) or 5-FU
(25mg/kg, 5 i.p. doses). Some rats were co-administered with fluoxetine (lOmg/kg/day, in
drinking water) for different time periods. Spatial memory was tested using the novel location
recognition (NLR) task and the spontaneous alternation in the T-rnaze memory tasks.
Proliferation and survival of hippocampal cells was quantified using immunohistochemistry
and the levels of doublecortin (OCX) and brain-derived neurotrophic factor (BDNF) were
quantified in the hippocampus and frontal cortex using Western blotting. Neural stem cells
(NSC) were also isolated from the adult mouse hippocampus, to examine the direct effects of
5-FU, fluoxetine and its active metabolite, norfluoxetine (0.0 I - IOOJ,lM)in vitro.
v
Results: Rats treated with 5-FU and MTX showed impairment in the NLR task but not the
spontaneous alternation in the T-maze task. They also exhibited a reduction in cell
proliferation (Ki67-positive cells) and survival (BrdU-positive cells) in the dentate gyrus,
compared to saline treated controls, but no difference was seen in the levels of DCX ofBDNF.
The induced cognitive and cellular impairments were not seen when fluoxetine was co-
administered with the chemotherapy. The impairments caused by 5-FU were counteracted
when fluoxetine was co-administered before and during 5-FU treatment but not when it was
only administered after treatment. CP did not impair performance in the NLR task or
hippocampal cell proliferation; however it significantly reduced cell survival. 5-FU,
fluoxetine and norfluoxetine all decreased cell viability in vitro.
Conclusions: These results demonstrate that MTX and 5-FU have more pronounced effects
on spatial memory and hippocampal cell proliferation than CP in the CMF combination.
Furthermore these impairments can be reversed by fluoxetine in a mechanism of prevention
but not recovery. Although further work is required, it would be beneficial to establish an in
vitro model of chemotherapy-induced cognitive impairment to justify this conclusion and to
investigate the potential benefits offluoxetine in cancer patients.
vi
Chapter 1
General introduction
1.1 Chemotherapy-induced cognitive impairment
In the present thesis a rat model is created to study the effects of different chemotherapy
agents on cognition, cell proliferation and cell survival in the adult hippocampus. The
selective serotonin reuptake inhibitor (SSRI) antidepressant, fluoxetine, is investigated to
determine its ability to prevent both the cellular and behavioural deficits found after
chemotherapy treatment.
1.1.1 An introduction to chemobrain
It is estimated that more than one in three people will develop a form of cancer within their
lifetime (Cancer Research UK, 2011). As treatment is continually improving, leading to a
reduced risk of reoccurrence and a higher survival rate for patients, it is becoming increasingly
important to research possible improvements for the quality of life of cancer survivors.
Many cancer patients have a tumour removed surgically followed by adjuvant chemotherapy.
Although this treatment is often effective, chemotherapy is notorious for its many side effects.
One area of side effects, reported by a substantial number of patients, is problems with
cognition including working memory, concentration and general confusion (Matsuda et al.
2005). Chemotherapy-induced cognitive impairment is also colloquially called "chemobrain"
or "chemofog" (Anderson-Hanley et al. 2003) and can occur from immediately after
chemotherapy treatment to ten years after completion of treatment (Ahles and Saykin 2002).
It has been described in patients who have received treatment for solid tumours including
breast, lung, prostate and ovarian cancers (Argyriou et al. 2011), with the majority of clinical
studies being carried out on survivors of breast cancer (Castellon et al. 2005). This cognitive
deficit is usually subtle (Matsuda et al. 2005), but it has been reported to affect the ability of
cancer survivors to return to work and resume a normal life (Boykoff et al. 2009). It has been
difficult to evaluate the prevalence of chemotherapy-induced cognitive impairment and
estimations suggest between 17% and 75% of patients who have received chemotherapy
treatment suffer from some form of cognitive decline (van Dam et al. 1998; Wieneke and
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Dienst 1995). One reason for this may be the controversy that initially surrounded
chemotherapy-induced cognitive impairment. Clinical studies are confounded by a number of
variables which could contribute to the cognitive deficit observed in patients. Such factors
include behavioural aspects such as the stress and fatigue cancer patients are likely to
experience during the course of treatment, as well as the effect of the cancer itself. This led to
some dispute about the existence and prevalence of chemotherapy-induced cognitive
impairment (Hermelink et al. 2007; Jenkins et al. 2006) and consequently the proposition to
standardise research methods including the neuropsychological tests used (Shilling et al. 2006;
Wefel et al. 2011). With the significantly increased number of clinical studies carried out
recently (Table 1.1), which take into consideration these possible confounding factors, strong
evidence in support of the existence of chemotherapy-induced cognitive impairment is now
available.
1.1.2 Clinical studies of chemotherapy-induced cognitive impairment
One of the earliest studies of chemotherapy-induced cognitive impairment was carried out by
Peterson and Popkin (1980), who estimated between 5% to 86% of cancer patients experience
neurophsychological deficits due to chemotherapy treatment. This huge range was attributed
to the different combinations of chemotherapeutic agents used, variations in the type of
cancer, with the possibility of metastasis, and the effect of other drugs co-administered with
the chemotherapy. During the subsequent 30 years a large number of studies have been
carried out, summarised in Table 1.1, with many controlling a number of these variables. In
the majority of these studies, the controls consisted of cancer patients who had received
treatment other than chemotherapy such as surgery or radiation treatment. This was necessary
to reduce the possibility of stress, anxiety and depression of the cancer patients confounding
results (Ahles et al. 2002; Schagen et al. 2002b). Furthermore, the groups compared were
appropriately matched in terms of demographics, such as their levels of education and age
group, although these attributes were not found to affect the results (Ahles et al. 2002;
Schagen et al. 2002b). In many studies groups were also often divided into pre- and post-
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menopausal patients (Collins et al. 2009; Schilder et al. 2009) and those with and without
adjuvant hormonal treatment (Bender et al. 2001; Schilder et al. 2009). Hormonal therapy is
thought to be a significant confounder of chemotherapy-induced cognitive impairment as it
may itself be able to induce cognitive decline (Collins et al. 2009). It is possible that some
patients included within these studies had been concomitantly prescribed with antidepressants
which could have affected their cognition and this was not taken into account (Table 1.1).
Wieneke and Dienst (1995) specifically investigated the effects of two chemotherapy
combinations used to treat breast cancer: 5-Fluorouracil (5-FU), doxorubicin and
cyclophosphamide (FAC) and CP: cyclophosphamide, MTX: methotrexate and 5-FU (eMF).
They found that 75% of patients suffered deterioration in a range of cognitive tests 6 months
after they received these drugs, An important study by van Dam et al. (1998) compared the
effects of both standard <Jose and high dose chemotherapy, 2 years after treatment. They
found that the standard dose impaired 17% of patients in comparison to 32% of patients who
had been treated with the high dose, with respect to attention, visual memory and motor
function. This dose-dependent effect was confirmed by Ahles et al. (2002), who studied long-
term survivors of breast cancer. Patients who had received a larger number of chemotherapy
cycles performed significantly lower on a range of neuropsychological tests.
More recent studies investigating the CMF chemotherapy combination were carried out by
Hurria et al. (2006b) and Kreukels et al. (2008). Hurria and colleagues studied older women
with breast cancer, finding 25% of them to be impaired in psychomotor speed, visuospatial
abilities and visual memory, 6 months after completion of chemotherapy. Kreukals and his
group compared breast cancer patients treated with CMF to healthy controls and found them to
be impaired in a battery of cognitive tests 1 and 4 years after treatment.
Due to the nature of clinical studies, small sample size may limit the information obtained
from the results. However, four meta-analyses of the literature have been compiled, and these
have concluded that chemotherapy consistently affects working, visual and verbal memory
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and processing speed in survivors of cancer (Anderson-Hanley et at. 2003; Falleti et at. 2005;
Jansen et at. 2005b; Stewart et al. 2006). Although the mechanisms which contribute to this
cognitive dysfunction still remain largely unknown, a list of potential mechanisms has been
suggested by Jansen et at. (2005a). These include chemotherapy-induced anaemia or
menopause, cytokine-induced inflammatory response and leukoencephalopathy.
Leukoencephalopathy refers to structural alterations in cerebral white matter as was
demonstrated by Inagaki (2007) using magnetic resonance imaging (MRI) in cancer survivors
who received adjuvant chemotherapy treatment. Alterations in cerebral white matter has been
demonstrated with MRJ after treatment with a number of chemotherapy drugs and is
accompanied by headaches, nausea and changes in mental status (Kastrup and Diener 2008;
Onujiogu et at. 2008; Rajasekhar and George 2007; Soussain et at. 2009). However the
majority of these symptoms resolve after time (Rajasekhar and George 2007; Soussain et al.
2009).
Although there is now strong evidence in the clinical literature for chemotherapy-induced
cognitive impairments, clinical investigations are not without their limitations. Many
variables including the dose, type and administration of chemotherapy, the cancer itself and
patient individuality (e.g. age, menopausal status) have proved difficult to control, thereby
contributing to a reduced sample size. It is also difficult to find appropriate controls to
compare with chemotherapy treated patients. Furthermore, it is unethical to use invasive
procedures to examine the underlying mechanisms of the impairment and methods to
counteract it. For these reasons several animal models have been utilised to investigate
different areas of chemotherapy-induced cognitive impairment, including the studies presented
in this thesis.
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Study Time period Control Elperlmental Cognitive Impalnnent Neuropsychological Patient reported
post-chemo IrouP IroUPS Wo/description) domains measures
de Ruiter 10 years BC patients HD chemo: Control: 5% Verbal function Memory
etal., treated without FEC+CTC HD chemo: 11% Memory Attention
2011 chemotherapy Attention/concentration Thinking
Processing speed Language
Mental flexibility
Tager et a) Prior to BC patients SO (various SO chemo motor ability Verbal, visual and Perceived
al.,2010 chemo treated without combinations) decreased over time working memory memory ability
b) 6 months chemotherapy Attention/concentration
c) I year Motor
Language
Visuospatial ability
Ahles et a) I month BC patients SD (various SD chemo had a short- Verbal ability Anxiety
al.,2010 b) 6 months treated without combinations) term impact on verbal Verbal, visual and Fatigue
c) 18 months chemotherapy ability working memory Cognitive ability
and healthy Processing speed
females Sorting
Distractibility
Reaction time
Quesnel a) Prior to BC patients SD (various SO chemo groups had Verbal and visual Cognitive
etal., chemo treated without combinations) impaired verbal fluency memory failures
2009 b) chemotherapy Executive function Quality of life
Immediately Attention/concentration Adult
after Processing speed intelligence
c) I month Verbal fluency
Collins et a) I month BC patients SO (various a) Control: 14% Executive function Not applicable
al.,2009 b) I year received combinations) a) SD chemo: 34% Language
adjuvant b) Control: II % Motor
hormonal b) SD chemo: 10% Processing speed
therapy Verbal, visual and
working memory
Visuoseatial abil itv
Schilder 2 years Healthy SDchemo: AC Control: 6% Verbal memory Memory
et al., females Randomised SDchemo/ Mental flexibility Concentration
2009 with tamoxifen tamoxifen: 28% Verbal fluency Thinking
or exemestane SDchemo/ Processing speed language
exemestane: 28% Motor speed
Kreukels a) I year a) Healthy SOchemo: a) Control: 10% a) Verbal function Not applicable
et al., b) 4 years females CMF a) SD chemo: 33% Memory
2008 b) SDchemo b) SO chemo patients Attention/concentration
patients who impaired at I year were Processing speed
were still more cognitively Mental flexibility
cognitively impaired b) P3 latency
unimpaired at P3 amplitude
I year Reaction time
Information processina
Schagen 3 years TC patients SD chemo: No difference between Verbal function Memory
et al., received BEP groups Memory Attention
2008 a) surgery Attention/concentration Thinking
b) surgery + Processing speed Language
radiotherapy Mental flexibility
Bender et a) Immediately BC patients SD (various SD chemo: Impaired Visual memory Memory
al.,2006 after treated without combinations) verbal working memory Verbal working memory
b) I month chemotherapy SD (various SD chemo/ Cognitive/intellectual
c) I year combinations) tamoxifen: Impaired memory
with tamoxifen visual memory and
verbal working memory
Jenkins et a) Immediately Healthy SD (various a)Healthy: 18% Intelligence Cognitive
al.,2006 after females and combinations) Control: 26% Verbal, visual and failures
b) 18months BC patients SD chemo: 20% working memory
treated without b)Healthy: 11% Executive function
chemotherapy Control: 14% Processing speed
SD chemo: 18%
Hurria et 6 months Published SOchemo: SO chemo: 25% Orientation Psychological
al.,2006 norms CMF Registration state
SO (various Attention
combinations) Calculation
Visuospatial ability
Language
Psychomotor speed
Shilling et 18 months Healthy SDchemo: Control: 19% Intell igence Cognitive failure
al.,2oo5 female CMFfFEC SD chemo: 34% Verbal, visual and
controls working memory
Executive function
Processing speed
Donovan 6 months BC patients SOchemo: No difference between Episodic memory Cognitive
et al., treated without CMF groups Motor function complaints
2005 chemotherapy SD (various Language
combinations) Motor function
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Language
Visuospatial ability
Executive and motor
function
Castellon 2-5 years Healthy SO (various Not quantified Visual memory No correlation
et al., female combinations) Visuospatial function between self-
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scores
Tchen, et 1-2 years Healthy SD chemo: Symptoms not related to Attention/ concentration Subtle cognitive
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et al., treated without CMF SOCMF: 13% Memory Attention
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FEC HDFEC+CTC: 14% Processing speed Language
HO chemo: Mental flexibility
FEC+CTC
Ahles and 10 years Cancer SD (various Control: 14% Verbal memory Working
Saykin, patients combinations) SD chemo: 39% Psychomotor function memory
2002 received local
therapy
Schagen I week BC patients SDchemo: Control: 9% Verbal function Memory
etal., treated without FEC SO chemo: 17% Memory Attention
2001 chemotherapy HOchemo: HD chemo: 32% Attention/concentration Thinking
FEC+CTC Processing speed Language
Mental flexibility
Brezden a) During Healthy SDchemo: Controls:ll% a) Memory and Not applicable
et al., chemo female CEF/CMF a) SO chemo:48% language
2000 b) 2 years controls b) SO chemo: 50% b) Language and visual-
motor cognition
Schagen 1.9 years BC patients SDchemo: Controls: 12% Attention/concentration Concentration
et al., treated without CMF SD chemo: 28% Mental flexibility Memory
1999 chemotherapy Processing speed
Memory
Motor and verbal
function
van Dam 2 years BC patients SDchemo: Controls: 9% Attention/concentration HDand SD
et al., treated without FEC SD chemo: 17% Processing speed groups:
1998 chemotherapy HDchemo: HD chemo: 32% Visual memory Concentration
FEC+CTC Motor function Memory
Thinking
Wieneke 6 months Published SDchemo: SD chemo: 75% Attention/concentration Not applicable
and norms FAC/CMF Verbal and visual
Dienst, memory
1995 Visuospatial ability
Processing speed
Kaasa et After Cancer SDchemo: SD chemo impaired Trail Making Not applicable
al.,l988 treatment patients treated cisplatin and cognition Visual Retention
without etoposide Verbal Learning
chemotherapy
Table 1.1 Summary of clinical studies investigating the incidence of cognitive deficits caused
by high dose (HO) and standard dose (SO) chemotherapy (chemo) adapted from Rugo and
Ahles (2003), listed in chronological order from most recent. It is possible that some patients
in these studies were concomitantly prescribed with antidepressants, which may have affected
their cognition, however this was not taken into account in these studies. Abbreviations:
Cancers; BC: breast cancer, TC: Testicular cancer. Chemotherapy combinations; AC:
adriamycin, cyclophosphamide, BEP: bleomycin, etoposide and cisplatin, CMF:
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cyclophosphamide, methotrexate, 5-FU, CTC: cyclophosphamide, thioTEPA, carboplatin,
FAC: 5-FU, doxorubicin, cyclophosphamide, FEC: 5-FU, epirubicin, cyclophosphamide
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1.1.3 Animal models of chemotherapy-induced cognitive impairment
The recent use of in vivo animal models has provided a faster, more detailed method to
research chemotherapy-induced cognitive impairment. In addition, they have enabled the
investigation of the underlying mechanisms and neuropathological changes to discover the
neurological basis for cognitive dysfunction (reviewed in Seigers and FardeIl2011). Existing
models (summarised in Table 1.2) have used a number of cytostatic drugs, investigating the
effects of both single agents and drugs used in combination. A range of cognitive tasks have
been used to investigate different learning and memory paradigms, and in most studies
animals are impaired in tasks associated with hippocampal spatial learning, such as the Morris
water maze (MWM) and novel location recognition (NLR) task. In contrast it appears that
animals were not as robustly impaired in fear conditioning tasks which are dependent on areas
such as the amygdala and hippocampus, including the conditioned emotional response (CER),
passive avoidance and delay conditioning tasks (Parkes and Westbrook 2011). This provides
evidence that the hippocampus may be more involved in the mechanism underlying
chemotherapy-induced cognitive impairment than other brain regions such as the amygdala.
This is particularly relevant as working and visuospatial memory are frequently targeted in
clinical studies of chemotherapy-induced cognitive impairment (Anderson-Hanley et al. 2003;
Falleti et al. 2005; Jansen et al. 2005b; Stewart et al. 2006) (see Table 1.1) which are functions
of the hippocampus (Baddeley et al. 2011; Loureiro et al. 2011; Sharma et al. 2010).
In a number of these studies, the neurobiological changes and possible anatomical loci for the
cognitive impairments have also been investigated, and these have included the effect of
chemotherapy on neurogenesis. Nearly all studies have found that administration of
chemotherapy to rodents produces behavioural deficits. One study that is an exception to this
is by Lee et al. (2006) in which an improvement in ability to perform the MWM was found
after either 5-FU or CP treatment. The reasons for the difference in this result are unclear but
have not been replicated and have received adverse comments in the subsequent literature
(Reiriz 2006).
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Table 1.2 Summary of rodent models investigating the effect of chemotherapy on cognition,
listed in chronological order from most recent. Abbreviations: Chemotherapy agents; MTX:
methotrexate, 5-FU: 5-fluorouracil, CP: cyclophosphamide, Ara-C: cytosine arabinoside,
Lev: Leucovorin, MAM: methylazoxymethanol acetate. Cognitive tasks; MWM: Morris
water maze, NOR: novel object recognition, NLR: novel location recognition, NMTS: non-
matching to sample, dNMTS: delayed non-matching to sample, CER: conditioned emotional
response, CFC: contextual fear conditioning. Other; CSF: cerebrospinal fluid, BDNF: brain
derived neurotrophic factor, DCX: double cortin.
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1.1.3.1 The role of antimetabolites in chemotherapy-induced cognitive impairment
Antimetabolites are metabolic substances which disrupt nucleic acid synthesis or nucleotide
synthesis, leading to an arrest in the cell cycle (Perry and McKinney 2008). The most
commonly investigated antimetabolites in rodent models of cognitive dysfunction are MTX
and 5-FU (described in detail in section 1.2.3 and 1.2.4 of the present chapter), administered
either individually or in combination (Table 1.2). These chemotherapy agents were selected
for use in the present study. A large number of studies have shown that MTX can cause
cognitive impairment in an array of cognitive tasks (Fardell et al. 20 I0; Li et al. 20 lOa;
Madhyastha et al. 2002; Seigers et al. 2008; Seigers et al. 2009; Sieklucka-Dziuba et al. 1998;
Yanovski et al. 1989), when animals were tested between 3 and 225 days after completion of
chemotherapy treatment. Li et al. (20 IOb) found that MTX impaired performance in the
spatial NLR task but not in the novel object recognition (NOR) task (for detailed descriptions
of these tasks see section 1.8 of the present Chapter). Conversely, there is one study by Lee et
al. (2006) where MTX treated rats showed an improvement compared to controls in the MWM
and this group also observed that MTX had no effect on the Stone maze task. In addition,
Foley et al. (2008), did not see an effect of MTX alone on operant conditioning, but found it to
potentiate the effects of 5-FU. Another study showed that rats treated with MTX were
unimpaired in appetitive or aversive conditioning (Stock et al. 1995) although here an
extremely low dose was used (0.005mg/kg).
Previous studies have also found that 5-FU impaired cognition in rodents in NLR (EIBeltagy
et al. 2010; Mustafa et al. 2008) and CER (ElBeltagy et al. 20 I0) tasks and operant
conditioning (Foley et al. 2008), 1 to 5 days after administration. Conversely, one study
observed that rats treated with 5-FU were unimpaired in the Stone maze but showed an
improvement in the MWM (Lee et al. 2006).
When 5-FU and MTX were administered together, Winocur et al. (2006) found treated mice
showed cognitive impairment in spatial MWM, non-matching to sample (NMTS) and delayed
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non-matching to sample (dNMTS) tasks but were unimpaired in cue memory and
discrimination learning. Furthermore, in a later study, the same group found that these
behavioural deficits could be counteracted with co-administration of donepezil, a drug most
commonly used to treat Alzheimer's disease (Winocur et al. 2011). Another study showed that
MTX enhanced the reduction in operant conditioning caused by 5-FU (Foley et al. 2008). In
contrast, Gandal et al. (2008) found this combination had no effect on performance in the
NOR and contextual fear conditioning (CFC) tasks.
In many of these studies, neurobiological changes in brain tissue which are associated with the
alterations in cognition after MTX and 5-FU administration have been investigated. Both
MTX (Seigers et al. 2008; Seigers et al. 2009; Seigers et al. 20 1Ob) and 5-FU (EIBeltagy et al.
2010) were reported to reduce proliferation of hippocampal cells in the dentate gyrus.
However, this was not found for 5-FU in one study (Mustafa et al. 2008). MTX was also
shown to decrease levels of folate in both cerebrospinal fluid (CSF) and blood serum (Li et al.
2010a; Li et al. 201 Ob) and reduce the concentrations of the neurotransmitters, noradrenaline,
dopamine, and serotonin (S-HT) and the S-HT metabolite S-hydroxyindoleacetic acid in the
brain (Madhyastha et al. 2002). Furthermore, Han et al. (2008a) observed that 5-FU caused
delayed damage to progenitor cells and to myelinated tracts in the central nervous system.
One study found the antimetabolite cytosine arabinoside (Ara-C) impaired remote recall, but
not spatial learning and recent memory in the MWM in rats. In addition, they showed that
Ara-C treated rats had retraction of the apical dendrites in the neurons in the anterior cingulate
gyrus but not in the pyramidal neurons in the hippocampal region CA 1 (Li et al. 2008).
1.1.3.2 The role 0/ alkylating agents in chemotherapy-induced cognitive impairment
Alkylating agents directly damage a cell's DNA by forming covalent bonds with guanine
nucleotide bases. They can be monofunctional, reacting with only one DNA strand or
bifunctional, forming alkyl cross-linkages between both DNA strands (Perry and McKinney
2008). CP (described in detail in section 1.2.2 of the present chapter) is the most investigated
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alkylating agent in the literature of animal models of chemotherapy-induced cognitive
impairment (Table 1.2) and was used in the experiments in this thesis. The range of cognitive
tests and dosing regimens used has produced different outcomes. This drug has been shown to
cause cognitive impairment in inhibitory avoidance tasks at 1 day post CP treatment (Reiriz
2006), in passive avoidance (Konat et al. 2008) and in the NOR (Yang et al. 2010) task.
However, CP did not reduce performance in inhibitory avoidance tasks at 7 days post CP
treatment (Reiriz 2006) or in the Stone maze (Lee et al. 2006) and it even caused an
improvement in performance in the MWM (Lee et al. 2006). Studies have also shown that CP
decreases cell proliferation in the hippocampus (Yang et al. 20 I0), although it did not affect
apoptosis (Yang et al. 2010) and it enhanced neural synaptic function in young rats (Lee et al.
2006).
Another alkylating agent, thioTEPA was investigated by Mondie et al. (2010). Rats treated
with thioTEPA were impaired in the NOR and NLR tasks and all had reduced hippocampal
cell proliferation. MacLeod et al. (2007) observed that CP in combination with the
topoisomerase inhibitor, doxorubicin, inhibited performance in the CFC but not the CER task
and also reduced proliferation of hippocampal cells. Konat et al. (2008) found the same
combination impaired passive avoidance, although interestingly, this was prevented by co-
administration of the antioxidant, N-acetyl cyteine.
1.1.3.3 The role of topolsomerase inhibitors, antimicrotuble agents and methylating
agents in chemotherapy-induced cognitive impairment
Although topoisomerase inhibitors, antimicrotuble agents and methylating agents were not
used in the studies reported in the present thesis, their effects on cognition have been looked at
in previous rodent models. Topoisomerase inhibitors inhibit the enzymes topoisomerase I and
II, which catalyse the cleaving and rebinding of the DNA double helix, regulating DNA
replication and RNA transcription. Inhibition of these enzymes causes cell necrosis, apoptosis
or cell cycle arrest (Perry and McKinney 2008). Doxorubicin is a topoisomerase inhibitor
16
used in rodent models of cognitive impairment. Liedke et al. (2009) found it impaired
inhibitory avoidance in rats at 1 and 7 days after administration but not 3 hours. However a
different study found that it had no effect on passive avoidance in mice (Sieklucka-Dziuba et
al. 1998). Its effects have also been investigated when it is administered in combination with
CP and are discussed in the previous paragraph.
Antimicrotubule agents are compounds often derived from plants. They prevent cell division
during M phase by interfering with microtubules which form the mitotic spindle necessary for
separation of replicated DNA (Perry and McKinney 2008). Paclitaxel is such an agent but to
date, only one animal study has investigated this drugs effect on cognitive function, showing
that rats treated with paclitaxel were unimpaired in the five choice serial reaction time test
(Boyette-Davis and Fuchs 2009).
Although the methylating agent methylazoxymethanol acetate (MAM) is not used as a
chemotherapeutic agent, it is a cytostatic and has been used in rodent models of cognitive
dysfunction to block neurogenesis. In all the models hippocampal cell proliferation was
successfully reduced (Bruel-Jungerman et al. 2005; Ko et al. 2009; Shors et al. 200 I; Shors et
al. 2002). One study showed that MAM impaired NOR performance in rats, but this was
improved and neurogenesis was increased by environmental enrichment (Bruel-Jungerman et
al. 2005). Shors and his group demonstrated that rats treated with MAM were impaired in
CER, CFC and trace fear conditioning but not MWM, plus maze and delay conditioning
(Shors et al. 2001; 2002).
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1.2 Drugs used in the present study implicated in chemotherapy-induced cognitive
impairment
1.2.1 Cyclophosphamide,methotrexate and s-fluoruractt (eMF)
Of all the drug combinations investigated in clinical studies of chemotherapy-induced
cognitive impairment, it is difficult to determine which cytostatic agent, or indeed, which
particular combinations of agents lead to cognitive dysfunction. Some studies have focused
on single chemotherapy combination regimens (Kreukels et al. 2008; Schagen et al. 2008;
Schagen et al. 1999), whilst others have obtained results from a number of combination
regimens grouped together (Ahles et al. 2010; Bender et al. 2006; Quesnel et al. 2009; Tager
et al. 2010). Most of the existing studies have investigated the effects of drugs used as
adjuvant chemotherapy for treatment of breast cancer (Castellon et al. 2005) and have most
frequently investigated the effects of the CP, MTX and 5-FU (CMF) combination (Brezden et
a1. 2000; Donovan et a1. 2005; Hurria et a1. 2006b; Kreukels et a1. 2008; Schagen et al. 2002a;
Schagen et al. 1999; Shilling et al. 2005; Tchen et al. 2003; Wieneke and Dienst 1995). The
majority of these studies have found that CMF causes a deficit in one or more
neuropsychological domain (Brezden et al. 2000; Hurria et a1. 2006b; Kreukels et al. 2008;
Schagen et al. 2002a; Schagen et al. 1999; Shilling et al. 2005; Wieneke and Dienst 1995).
Furthermore, there is evidence for the involvement of these cytostatic drugs in cognitive
dysfunction and reduced neurogenesis in animal studies (Table 1.2). In the work of this thesis,
the effects of these three chemotherapy agents are investigated.
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1.2.2 Cyclophosphamide
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Figure 1.1 Chemical structure of CP (N,N-bis(2-chloroethyl)-1 ,3,2-oxazaphosphinan-2-amine
2-oxide)
CP (Fig. 1.1) is a widely used chemotherapeutic drug developed in the late 1960s. It is used to
treat a range of cancers including leukaemia, lymphomas, soft tissue and osteoginic sarcomas,
paediatric malignancies and adult solid tumours; in particular breast and lung carcinoma
(Allwood et al. 1997). It also acts as an immunosuppressant agent, by attacking leukocytes in
the treatment of non-malignant diseases including rheumatoid arthritis, chronic interstitial
pneumonia, multiple sclerosis as well as for organ transplant (Anderson et al. 1995). It is
easily absorbed, given orally or by i.v. route and has a relatively low toxicity compared to
other anti-cancer drugs, so is often given in a high dose to both adults and children (Anderson
et at. 1995). It is able to cross the blood-brain barrier due to its low molecular weight (Perry
and McKinney 2008). It has a half-life of 3 to 10 hours in humans and its primary active
metabolite, phoshoramide mustard, has a half-life of 8 to 9 hours (Fischer et at. 2003).
CP is a very effective chemotherapeutic, but it can also cause some side-effects,
predominantly due to its most toxic metabolite, acrolein. These include myelosuppression
and sterility and if given during pregnancy, it can also cross the placenta and cause
malformations in the foetus (Matalon et al. 2004). A frequent complication of this drug is due
to its toxicity to bladder epithelial cells causing hemorrhagic cystitis, although this can be
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prevented (Hu et al. 2008; Toren and Norman 2005; Wantuch et al. 2007). CP is carcinogenic
itself as it has the ability to produce free oxygen radicals (Matalon et al. 2004).
1.2.2.1 Mechanism of action of CP
CP is an alkylating agent and belongs to the group of anti-cancer drugs, oxazaphosphorines. It
is initially metabolised by the liver by cytochrome P4S0 into 4-hydroxycyclophosphamide and
its tautomer, aldophosphamide. Aldophosphamide is further metabolised within peripheral
tissue and tumour cells to phoshoramide mustard and acrolein (Matalon et al. 2004).
Phoshoramide mustard is the major metabolite to kill neoplasmic cells by forming covalent
linkages of alkyl groups, between and within DNA strands of mitotic cells. This disrupts the
DNA and causes the cell to undergo apoptosis. As with all alkylating agents, this is
independent ofthe stage of cell cycle (Matalon et al. 2004).
Aldophosphamide is oxidised by aldehyde dehydrogenase (ALDH), therefore CP can only be
efficient in cells which contain low levels of ALDH. This also allows relatively low toxicity
as bone marrow stem cells, liver cells and intestinal epithelial cells all contain a large amount
of ALDH. ALDH3, a type of ALDH which can breakdown CP into non-toxic metabolites, is
present in the brain (Bunting and Townsend 1996).
1.2.3 5-Fluorouracil
Figure 1.2 Chemical structure of 5-FU (5-fluoro-IH-pyrimidine-2,4-dione)
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5-FU (Fig. 1.2) has been used for over 40 years to treat breast, colorectal, head and neck,
bladder, gastrointestinal and ovarian cancer and hepatoma (Fischer et al. 2003). When used as
adjuvant chemotherapy to treat breast cancer, it is systemically administered by the i.v. route
along with other chemotherapy agents. The most common regimens involve the combinations
CMF, 5-FU, epirubicin and CP (FEC) and 5-FU, doxorubin and CP (FAC) (Guarneri et al.
2007). It able to cross the blood-brain barrier by passive diffusion and reaches a concentration
of 48% CSF: plasma ratio after being administered as a bolus dose (Patel et al. 1998).
However, it has a short half-life of 10 to 25 minutes in serum, for both humans (Diasio and
Harris 1989) and rats (Celio et al. 1983) and is broken down in the liver by dihydropyridimine
dehydrogenase (Longley et al. 2003). Chronic administration of 5-FU is reported to cause
neurological toxicity with cerebellar ataxia, myelosuppression and rarely encephalopathy
(Perry and McKinney 2008), which is unsurprising given the high levels of 5-FU which are
possible in the brain. Other toxicities of 5-FU include diarrhoea, hand foot syndrome and
cardiac complications (Perry and McKinney 2008).
1.2.3.1 Mechanisms of action of5-FU
5-FU is a fluorinated analogue of uracil (Fig. 1.3) which acts as an antimetabolite. It is
intracellularly converted into its three main active metabolites; fluorodeoxyuridine
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine
triphosphate (FUTP) (Fig. 1.3). These active metabolites are cytotoxic to the cell by
disrupting thymidine synthetase (TS) and RNA synthesis (Longley et al. 2003).
TS inhibition is the major mechanism of action for 5-FU (Fig. 1.3). TS catalyses the
conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate
(dTMP), which is necessary for the synthesis of the DNA pyrimidine base, thymidine. The
conversion of dUMP to dTUMP IS facilitated by the methyl donor,5,10-
methylenetetrahydrofolate (CH2THF). The active metabolite FdUMP binds to TS, blocking
the binding site of dUMP and inhibiting the synthesis of dTMP, during S-phase of the cell
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cycle leading to cell death resulting in lethal DNA damage. Furthermore, inhibition of TS
leads to the build up of dUMP. dUMP and 5-FU metabolite FdUTP can be misincorporated
into DNA, causing the strands to break, leading to cell death (Longley et al. 2003) (Fig. 1.3).
Despite its short half-life, 5-FU can lead to reductions in TS levels for several days (Longley
et al. 2004).
The folate co-factor, CH2THF is required for optimal binding of FdUMP to TS, enhancing
FdUMP's effects. Leucovorin (LCV) is a synthetic co-factor of folate which can enhance the
effects of the 5-FU metabolite by this mechanism. It is therefore often administered clinically
with 5-FU to potentiate its cytotoxic effect (Herrmann et al. 1988) (Fig. 1.3). It is to be noted
that LCV is also given after MTX chemotherapy treatment as a rescue therapy and not to
potentiate its effects.
The third active metabolite of 5-FU, FUTP, is extensively misincorporated into RNA. This
disrupts the normal processing of the RNA affecting cellular metabolism and viability
(Longley et al. 2003).
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Figure 1.3 Mechanisms of action of the antimetabolite 5-FU, modified from Longley et al.
(2003). Normally deoxyuridine monophosphate (dUMP) is converted to deoxythymidine
monophosphate (dTMP) which is necessary for synthesis of the DNA pyrimidine base,
thymidine. This is catalysed by thymidine synthetase (TS) and facilitated by the binding of
5,10-methylenetetrahydrofolate (CH2THF) to TS. The major active metabolite of 5-FU,
fluorodeoxyuridine monophosphate (FdUMP), competitively binds to TS (also facilitated by
the binding of CH2THF) inhibiting the production of dTMP, leading to DNA damage and cell
death. This disruption also causes a build up of dUMP. Both dUMP and another active
metabolite of 5-FU, fluorodeoxyuridine triphosphate (FdUTP) get incorporated into the DNA
causing lethal damage. The third active metabolite of 5-FU, fluorouridine triphosphate
(FUTP), is misincorporated into RNA affecting cellular metabolism and viability. Leucovorin
(LCV) increases intracellular levels of CH2THF, enhancing binding of FdUMP to TS,
enhancing the effects of the 5-FU metabolite (Longley et al. 2003).
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1.2.4 Methotrexate
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Figure 1.4 Chemical structure ofMTX «2S)-2-[(4- phenyl)formamido]pentanedioic acid)
MTX (Fig. lA) has been in use since the 1950s and is used to treat many cancers including
breast, head and neck, bladder and colorectal and meningeal leukaemia (Fischer et al. 2003).
It is also used to terminate pregnancies and as anti-inflammatory and/or
immunosuppressive treatment for autoimmune diseases (Genestier et al. 2000). Methotrexate
is well absorbed when administered orally, by the i.v. route or intrathecally (Perry and
McKinney 2008). It has a half-life of approximately 3 hours (Fischer et al. 2003). It can be
neurotoxic, inducing cerebellar ataxia. Other effects include mylosuppression and
encephalopathy and renal and pulmonary toxicities (Fischer et al. 2003).
1.2.4.1 Mechanisms of actionofMTX
Like 5-FU, MTX also affects the TS pathway (Fig. 1.5). TS catalyses the formation of dTMP
which is facilitated by the binding of CH2 THF (Genestier et al. 2000). This converts CH2 THF
to dihydrofolate (FH2) which is reduced by dihydrofolate reductase (DHFR) in the presence of
nicotinamide adenine dinucleotide phosphate (NADPH) to tetrahydrofolate (THFA). THFA is
necessary for DNA synthesis and repair (Cheok and Evans 2006). MTX inhibits the enzyme
DHFR, preventing synthesis of THF A. In addition, inhibition of DHFR prevents regeneration
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of CH2THF from FH2 which is required for the synthesis of the DNA base thymidine causing
cell death during S-phase of the cell cycle (Genestier et al. 2000) (Fig. 1.5).
LCV antagonises MTX by increasing the intracellular level of CH2THF and replenishing
folate pools depleted by MTX. Therefore LCV is often administered clinically as a rescue
therapy after patients have been treated with MTX (Genestier et al. 2000) (Fig.1.5). This is
unlike the co-administration of LCV during 5-FU treatment, where it used to enhance the
effects of the chemotherapy.
(THFA--,
_--- "'-
cDHFR 'r.::-~! \fH2,
- 11MTX ---I 'E>HFR -'
-'"
CH2THF
~ 7- dTMP
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Figure 1.5 Mechanisms of action of the antimetabolite MTX. This diagram was created by
use of information from Genestier et al. 2000. 5,10-methylenetetrahydrofolate (CH2THF) is
converted to dihydrofolate (FH2) when it binds to thymidine synthetase (TS) to catalyse the
formation of deoxythymidine monophosphate (dTMP). FH2 is reduced by dihydrofolate
reductase (DHFR) to tetrahydrofolate (THF A), which is necessary for DNA synthesis and
repair. DHFR is inhibited by MTX, preventing synthesis of THF A. DHFR inhibition also
prevents regeneration of CH2THF from Fm which is required for the synthesis of the DNA
base thymidine causing cell death. Leucovorin (LCV) replenishes intracellular folate pools
and increases levels of CH1THF, antagonising the effects ofMTX (Genestier et al. 2000).
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1.3 Adult hippocampalneurogenesis
The experiments in this thesis investigate the effects of the chemotherapy agents in the eMF
medication combination on memory. A possible underlying cause for the cognitive
impairments observed is the cytotoxic effect of these chemotherapy drugs on hippocampal
neurogenesis, which will therefore be discussed below.
1.3.1 Neural stem cells (NSC)
New neurons in the adult brain originate from dividing precursor cells, therefore neural stem
cells (NSC) are the basis for adult hippocampal neurogenesis. Stem cells are undifferentiated
cells which have the ability to continually divide by mitosis and differentiate into numerous
cell types (Kosodo et al. 2004; Mongiat and Schinder 2011). Stem cells have different levels
of diversity depending on from where they originate. A newly fertilised egg is totipotent and
is able to generate all the cells of an organism (Scholer 2007). Stem cells from an embryo
more than a few days old are classed as pluripotent. These cells are descended from totipotent
cells and can give rise to almost all cell types. Multipotent cells can differentiate into a limited
number of cell types but not all body tissue (Rao 2004). There are also oligopotent cells
which have the ability to differentiate into a few cell types and unipotent cells, which are able
to self-renew, but only into their own cell type (Scholer 2007).
The most important attribute to a stem cell is that it has the unlimited ability to self-renew
whilst remaining undifferentiated (Rao 2004). However, some scientists classify them as also
having the potency to generate a minimum of two different types of cell (McKay 1997;
Weissman et al. 2001), which would indicate that unipotent cells would not be within the stem
cell definition. Embryonic stem cells can be defined as true stem cells as they are pluripotent
and are able to continuously self-renew. Adult stem cells, however, can only be multipotent,
oligopotent or unipotent and their capacity for self-renewal is limited and are therefore better
described as precursors. Although precursor cells do not have the ability to continuously self-
renew, they have a large capacity for proliferation at a greater rate than stem cells. Therefore,
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they can greatly increase a population of cells and are referred to as "transit amplifying cells"
(for review see Kempermann 2006; Kriegstein and Alvarez-Buylla 2009).
During brain development, division of NSC can be symmetric, resulting in two identical
daughter stem cells or asymmetric, producing one stem cell and one transit amplifying
progenitor cell (Fig. 1.6). These progenitor cells can further divide symmetrically to produce
two identical daughter cells, similar to the mother cell or divide asymmetrically to produce a
similar daughter cell and one with different characteristics to the mother. In addition, these
progenitor cells can symmetrically divide into two cells identical to each other but different
from the mother (Kempermann 2006) (see Fig. 1.6). This is referred to as a neurogenic
division and these cells have the ability to differentiate into neurons (Kosodo et al. 2004).
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Figure 1.6 Diagram illustrating the symmetric and asymmetric divisions of stem cells and
progenitors in brain development, modified from Kempermann (2006). Neuroepithelial stem
cell division can be symmetric, resulting in two identical daughter cells similar to the mother
or asymmetric resulting in a stem cell and a transit amplifying progenitor cell. These
progenitor cells can than divide symmetrically to produce identical daughter cells similar to
the mother or asymmetrically to produce one cell similar to the mother and one with different
characteristics. Progenitor cells can also undergo neurogenic symmetric division generating
two cells which differ from the mother which can differentiate into neurons.
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1.3.2 Adult Neurogenesis
It was once thought that new neurons could not be created in the mammalian adult brain and
once complex neural systems had been formed they could not be modified. Indeed, it was
assumed that the central nervous system had no plasticity after embryogenesis (Altman 1962).
However, in the sixties, Josef Altman discovered the generation of new neurons in the adult rat
brain using radioactive labelled thymidine-incorporation (Altman 1962; Altman and Das
1965). This was termed adult neurogenesis, and although originally met with some
scepticism, it is now accepted that new neurons are formed in the CNS in all mammals studied
to date (Ehninger and Kempermann 2008). Adult neurogenesis not only refers to the
proliferation of neural progenitors, but the migration, differentiation and functional integration
of these new neurons (Knobloch and Jessberger 2011).
Generation of neurons in the adult CNS has been documented in numerous species from
invertebrates, fish (Wullimann 2009; Zupanc 2006) and reptiles (Garcia-Verdugo et at. 1989)
to birds (Goldman 1998) and mammals, including rodents (Altman and Das 1965), primates
(Gould et al. 1999) and humans (Curtis et al. 2011; Eriksson et al. 1998). However, the
occurrence of postnatal neurogenesis appears to be inversely related to brain complexity and is
restricted to limited brain regions in higher vertebrates. For example, in fish, it is reported that
almost all brain regions are prolific (Fernandez et at. 2011; Zupanc 2006), whereas in
mammals neurogenesis appears to be limited to specific areas (Gage 2000; Imayoshi et at.
2009). The predominant neurogenic regions in the mammalian adult brain are the dentate
gyrus within the hippocampus and the subventricular (SVZ) zone of the lateral ventricles
(Imayoshi et at. 2009). Neurons born in the mammalian SVZ migrate along the rostral
migratory stream to the olfactory bulb, where they differentiate into granule cell and
peri glomerular cell intemeurons (Zhao et at. 2008). Newly generated neurons in the
mammalian hippocampus are born in the subgranular zone (SGZ) and migrate up the granular
cell layer (GCL) in the dentate gyrus. Additionally, there is evidence that adult neurogenesis
occurs in other brain regions such as the neocortex in primates (Gould et at. 1999) and the
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rodent hypothalamus (Fowler et al. 2008), although relatively little is known about the
functional relevance of these new neurons compared to those in the hippocampus.
1.3.3 Anatomy, circuitry and neurogenesis in the adult hippocampus
The hippocampus is a structure located in the medial temporal lobe of the mammalian brain,
so called because of its resemblance to a seahorse. There are two hippocampi, one residing in
each hemisphere of the brain. They consist of the cornu ammonis (CA) region comprising of
CAl, CA2, CA3 and CA4 (or hilus) sub-regions and the dentate gyrus (Toni and Sultan 2011)
(Fig. 1.7). The major form of neocortical input to the hippocampus is from the entorhinal
cortex through the perforant path axon bundle (Fig. 1.8). These axons synapse onto granule
cell neurons in the dentate gyrus which are the main constituent for the granule cell layer of
the hippocampus. The granule cell axons, or mossy fibres, project to the pyramidal cells of the
CA3 sub-region, then to the CAl, through the Schaffer collateral pathway. The signal is
returned from the CA 1 sub-region to the entorhinal cortex via the subiculum (Aimone et al.
2011; Toni and Sultan 4011) (Fig. 1.8). This circuitry constitutes the main flow of
information through the hippocampus.
The dentate gyrus is the gateway to hippocampal circuitry. It consists of two blades, which
occlude as it progresses caudally. The neurogenic region of the dentate gyrus is the SGZ
which is between the granule cell layer (GCL) and the hilus (Fig. 1.7). The neural precursors
in this region consist of two types of cell. Type 1 cells are radial glia-like stem cells, also
known as B cells which have astrocytic properties with respect to their morphology and
labelling (expressing glial fibrillary acidic protein, or GFAP) (Fukuda et al. 2003; Suh et al.
2009). Type 2 cells (or D cells) are non-radial transit amplifying progenitors which arise from
asymmetric division of the stem cells. They are highly proliferative and differentiate into
neurons after limited self-renewal. They can be identified by expression of the early neuronal
marker, doublecortin (DCX) and do not express the glial marker GFAP (Fukuda et al. 2003).
After 1 to 3 days the type 2 D cells start to differentiate and move up through the GCL as
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immature neurons. They extend dendrites into the molecular layer at 1 to 3 weeks of age and
develop an axon which contributes to the mossy fibre pathway, feeding back to the CA3 sub-
region, eventually differentiating into mature granule cell neurons or G cells at about 4 weeks
old (Suh et al. 2009; Toni and Sultan 2011) (Fig. 1.7).
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Figure 1.7 Photograph of the adult rat hippocampus highlighting the cornu ammonis (CA)
sub-regions, CAl, CA2 and CA3 and the dentate gyrus (DG) modified from Abrous et al.
(2005). Below is a diagram illustrating the proliferation, migration and differentiation of
newly generated neurons modified from Suh et al. (2009). Type 1 (TI) radial glia-like stem
cells and type 2 (T2) non radial transit amplifying progenitor cells proliferate in the
subgranular zone (SGZ) of the DG. At I to 3 days, they start to migrate up through the
granule cell layer (GCL). As they migrate as immature neurons, they differentiate and start to
protrude axons up through the GCL to the molecular layer (ML) and CA3 sub-region at I to 2
weeks. By 4 weeks they are mature granule cell neurons.
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Figure 1.8 Diagram of hippocampal circuitry. The signal enters the hippocampus from the
entorhinal cortex via the dentate gyrus, along the perforant pathway. It then travels along the
mossy fibre pathway to the cornu ammonis 3 (CA3) sub-region then to the CAl region along
the ShatTer collateral pathway. From the CA I the signal is returned to the entorhinal cortex
via the subiculum (Toni and Sultan 2011).
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1.3.4 Techniques/or the detection of neurogenesis
1.3.4.1 Thymidine and bromodeoxyuridine
Adult neurogenesis was first detected by using tritiated thymidine (Altman 1962). In this
method, radioactively labelled thymidine is systemically injected into the blood stream and is
incorporated into the DNA of dividing cells during S-phase of the cell cycle. It can then be
detected by autoradiography. However, this technique became impractical as it is very
difficult to combine with other markers specific to cell type is now rarely used. Currently, the
most commonly used method to investigate neurogenesis is immunohistochemistry labelling
with 5-bromo-2-deoxyuridine (BrdU). Like tritiated thymidine, BrdU is a thymidine analogue
which is systemically administered. It competes with endogenous thymidine to be
incorporated during S-phase into the DNA of dividing cells. BrdU can be detected by
antibodies and visualised by fluorescence. Therefore, a major benefit of this technique is that
it can be combined with different markers when viewed on a confocal microscope
(Kempermann 2006).
The dose of BrdU administered to rats has varied between studies. It has been reported that
single doses of 20, 50 and 100mglkg (body weight, i.p.) label 8, 40 and 65% of cells in S-
phase in the dentate gyrus of the adult rat, respectively (Cameron and McKay 2001). For a
full saturation of S-phase labelled cells, doses of up to 300mglkg need to be administered
(Cameron and McKay 2001). However very high doses of BrdU can be toxic to cells,
although this can be overcome by administering multiple injections of a lower dose over days
or hours (Taupin 2007). This method is also beneficial for long-term studies as BrdU labelled
cells can still be detected 2 years after injection in rats (Kempermann 2006).
There are, however a few concerns using the BrdU technique. There has been suggestion that
BrdU may detect cell repair and apoptosis (Cooper-Kuhn and Georg Kuhn 2002). In addition,
it has been proposed that BrdU may disrupt the permeability of blood-brain barrier (Gould and
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Gross 2002). Despite these potential experimental confounds, BrdU labelling remains the
most commonly used method for detection of neurogenesis.
1.3.4.2 Endogenous cell markers
As well as BrdU detection, immunohistochemistry can also be utilised to investigate
endogenous antigens within cells which are specific to cell type or stage of the cell cycle.
These can be used when observing cell proliferation at the time of death and are summarised
in Fig. 1.9. Markers of the early stages of neurogenesis include nestin (an intermediate
filament protein specific to NSC) and GFAP (an intermediate filament protein which is only
expressed in glial cells). DCX is a microtubule associated protein expressed in transit
amplifying progenitors which are differentiating into immature neurons and Neuronal Nuclei
(NeuN), a nuclear protein, is present in both immature and mature neurons (Zhao et al. 2008).
Endogenous markers used independently or in conjunction with BrdU have enabled
investigation of each stage of neurogenesis in the adult rat hippocampus (illustrated in Fig.
1.9).
Ki67 is a protein which is expressed in all stages of the cell cycle but not in resting cells
(Scholzen and Gerdes 2000). This makes it an excellent marker for cell proliferation and one
of the most widely used tools. However, unlike BrdU, it cannot be used to trace cells over
long periods.
35
Stagesof [
neuronal
development
Markers of
neuronal
development
~ p_r_O_I_if_e_ra_t_io_n ~I~1 D_i_ff_e_re_n_t_i_at_i_o_n __ ~
Mitotic cells Postmitotic cells
;:, . q~J
i:~
Immature
neuron
Transit amplifying
Progenitor cell
Mature
neuron
•
•
•
•I:
•
•
•
DCX :
GFAP, Msil
Ki67, HH3, peNA
Nestin
• Calretinin Calbindin•
• TOAD64 Parvalbumin
•
• Tujl NSE
• NeuN MAP2•
• Tujl
•
NeuN
Figure 1.9 Diagram illustrating markers of different stages of granule cell development from
stem cell proliferation to mature neuron, modified from Abrous et aI. (2005). In studies in the
present thesis Ki67 was utilised as it is expressed in all stages of the cell cycle, but not resting
cells, however it is not specific to neurons. Doublecortin (DCX) was also selected for use in
work in the present thesis as it is expressed in neural progenitor cells and immature neurones.
Abbreviations; GFAP: glial fibrillary acidic protein, Msi 1: musashi 1, HID: histone H3,
PCNA: proliferating cell nuclear antigen, DCX: doublecortin, TOAD64: turned on after
division-64 kDa, TujI: neuronal class III B-tubulin, NeuN: neuronal nuclei, NSE: neuron-
specific enolase, MAP2: microtubule-associated protein 2.
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1.3.4.3 Cell proliferation markers used in the present studies: Brdll, Ki67 and DCX
In the experiments discussed in this thesis, immunohistochemistry was used to detect BrdU
and Ki67 in the rat hippocampus and DCX was quantified in the hippocampus and frontal
cortex by Western blot analysis. DCX is ideal for investigating neurogenesis as it is a marker
for young neurons and highly expressed in neurogenic regions in the adult rat brain and is
expressed almost exclusively in neural progenitor cells and immature neurones (Nacher et al.
2001). Ki67 was used as a proliferative marker to quantify proliferating hippocampal cells at
the time of death. As it is endogenous, it is non-invasive to the cell and it is present in all
mammalian neuronal tissue (Scholzen and Gerdes 2000). With respect to adult neurogenesis,
Ki67 is present in proliferating stem cells and transit amplifying progenitor cells but not in
immature neurons (Abrous et al. 2005) (Fig. 1.9). For comparison, BrdU was selected as it
allowed the tracing of cells dividing at a different time point than at the time of animal death.
BrdU was administered at the beginning of the experiments to investigate the survival of the
cells proliferating at that time. Initially, a single i.p. dose of 250mg/kg was used, but in the
later experiments this was switched to 3 daily doses of 100mg/kg in order to label more
dividing cells whilst avoiding toxicity. Neither Ki67 nor BrdU are specifically expressed in
neurons and in the immunohistochemistry protocols of Ki67 and BrdU, the cells were not
double labelled with a neuronal marker. However, it has been reported that 89% of
proliferating cells in the rat hippocampus become neurons (Snyder et al. 2009).
1.3.4.4 NSC in vitro
To investigate many aspects of NSCs including their development potential, homeostasis and
their direct response to pharmaceuticals, it is often necessary to grow them in cell cultures.
NSCs are isolated and grown either as an adherent monolayer or in floating, aggregated
neurospheres (Galli et al. 2003). They are cultured in serum free medium in the presence of
growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF-2) to
prevent them from differentiating and to encourage proliferation. To culture a monolayer, stem
cells must be grown on surfaces with substrates such as laminin and fibronectin which allow
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them to adhere to and often differentiate on the bottom of a flask or well (Palmer et al. 1999).
The neurosphere method of culturing spherical clusters of cells was first described by
Reynolds and Weiss (1992) and is now widely used as it rapidly produces large numbers of
dividing cells and simplifies preparations of single cells (Gritti et at. 2008; Reynolds and
Weiss 1992). However, it is to be noted that not all cells in floating neurospheres are NSCs.
The spheres are originally generated from dividing NSCs and other dividing NSCs which
collide and adhere together. These can undergo symmetric division or divide asymmetrically
to generate a stem cell and progenitor. Therefore a neurosphere contains about 10 to 50% of
cells with NSC-like properties combined with differentiating progenitors and even some
differentiated neurons and glia, depending on the size of the neurosphere and its length of time
in culture (Galli et al. 2003) (Fig. 1.10). Most of the proliferating cells are found on the
outside of the neurosphere, whereas the differentiating cells are within (Gritti et al. 2008;
Kempermann 2006). However, dissociation and re-plating of the neurosphere cell cultures
causes the more differentiated cells to die and thus the undifferentiated NSC are forced to
proliferate, generating secondary neurospheres (Fig. 1.10). This passage process can be
repeated for over a year to produce large cultures of proliferating stem cells, or the growth
factors can be removed allowing the neurospheres to differentiate into neurons, astrocytes and
oligodendrocytes (Galli et al. 2003).
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Figure 1.10 Diagram illustrating growth of neurospheres in culture adapted from Galli et al.
(2003). Single neural stem cells (NSC) are grown in serum free medium in the presence of
growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF-2)
and proliferate to generate a spherical cluster of dividing cells. They also collide with other
proliferating cells to produce larger neurospheres. These consist of cells with NSC-like
properties, differentiating progenitors and differentiated neurons and glia. Neurospheres can
be dissociated and re-plated under the same conditions, causing the more advanced
differentiating cells to die, leaving the NSC to proliferate into secondary neurospheres. This
process can be repeated to produce large numbers of proliferating cells. Alternatively the
growth factors can be removed allowing the neurospheres to differentiate into neurons,
astrocytes and oligodendrocytes (Galli et al. 2003).
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1.4 The scale and regulation 0/ neurogenesis
It has been estimated that in the dentate gyrus of the young adult rat, 9,000 new cells are
generated per day with an approximate cell cycle time of 25 hours (Cameron and McKay
200 I). Many of these differentiate into adult neurons, however a large proportion undergo cell
death. It has been reported that nearly 50% of new newly generated neurons die in the first 4
weeks before reaching maturity (Dayer et al. 2003). Indeed, it appears that neuronal death is
as important as neuronal birth in functional neurogenesis and only specific newborn neurons
will be recruited into circuitry in the hippocampus (Dupret et al. 2007). It is to be noted that
the scale of neurogenesis differs between species. Studies by Snyder et al. (2009) have shown
that although neurogenesis occurs in the hippocampus of both rats and mice, there is a larger
quantity of young neurons in rats. Furthermore, they are reported to mature faster, have better
survival rates and are more likely to be integrated into hippocampal circuits (Snyder et al.
2009). This species difference needs to be taken into account when comparing models of
neurogenesis. Furthermore, processes of neurogenesis can be regulated by a range of
endogenous and external factors reviewed in the following sections.
1.4.1 External/actors which regulate neurogenesis
Adult neurogenesis is a dynamic process which is responsive to a number of factors which are
external from the organism. These refer to environmental manipulations such as physical
activity, learning, irradiation and environmental enrichment which can alter the proliferation,
differentiation or survival of newly generated neurons (key studies from rat models are
summarised in Table 1.3). Environmental enrichment describes objects such as toys,
platforms or a running wheel that laboratory animals are exposed to in contrast to standard
laboratory conditions (Bruel-Jungerman et al. 2005) and is reported to have a positive effect
on neurogenesis (Bruel-Jungerman et al. 2005; Veda et al. 2005).
Stress is another factor which is reported to affect adult neurogenesis (reviewed in Dranovsky
and Hen 2006; Samuels and Hen 2011). A study by Heine et al. (2005) demonstrated that a
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multiple unpredictable stress paradigm caused cell proliferation in the rat hippocampus to be
reduced by 32%. This was supported by another study by Rosenbrock et al. (2005) who
showed that hippocampal cell proliferation in the dentate gyrus was reduced by chronic
intermittent restraint of rats. Furthermore, progression of newborn neurons can be
manipulated by pathogenesis including models of depression, ischemia and induced seizures,
as well as physiological states such as ageing Table 1.3. Although these factors are not looked
at directly in the experiments in this thesis, certain aspects have been considered, such as
keeping the stress of the animals to a minimum so as not to confound results.
External factors which affect neurogenesis also include pharmacological and recreational
drugs. Examples of these include antidepressants, alcohol, opiates and cannabinoids (Table
1.3). In addition certain cytostatic agents may reduce neurogenesis and are investigated within
this thesis. The antidepressant, fluoxetine, is also investigated as a neurogenic enhancer and is
discussed in detail in section 1.6 of the present chapter.
1.4.2 Endogenous/actors which regulate neurogenesls
In addition to external factors, there are also a number of endogenous factors which influence
the proliferation, differentiation and survival processes of neurogenesis and are summarised in
Table 1.4. These include hormones such as corticosterone and oestrogen and
neurotransmitters such as S-hydroxytryptamine (S-HT), glutamate and noradrenaline. In
addition, certain growth factors and neurotrophin factors have been shown to have positive
and negative influences on neurogenesis including brain-derived neurotrophic factor (BDNF),
vascular endothelial growth factor (VEGF), ciliary neurotrophic factor (CNTF), EGF, FGF-2
and insulin-like growth factor one (IGF -1). Of particular interest in this study is BDNF which
is discussed in the following section (1.4.3).
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External factor Proliferation Differentiation Survival References
Regulation of systems, behaviour and pathogenesis
Environmental Increase Increase Increase Drapeau et al. (2007)
enrichment and Dupret et al. (2007)
learning Ueda et al. (2005)
Physical activity Increase Increase Increase Kim et al. (2010)
Uda et al. (2006)
Stress Decrease No effect No effect Heine et al. (2005)
Rosenbrock et al. (2005)
Depression Decrease Decrease Decrease Jaako-Movit et al. (2006)
KeilhotT et al. (2005)
Irradiation Decrease Decrease Limoli et al. (2004)
Madsen et al. (2003)
Age Decrease Decrease Driscol et al. (2006)
Heine et al. (2004)
Seizures Increase Increase Increase Scott and Burnham. (2006)
Snyder et al. (2009)
Ischemia Increase Increase Jin et al. (2001)
Zhu et al. (2003)
Legal and illegal drugs
Antidepressants Increase Increase Increase EIBeltagy et al. (20 I0)
Malberg et al. (2000)
Wang et al. (2008)
Alcohol Decrease Decrease McClain et al. (2011)
Morris et al. (2010)
Cannabinoids Increase/no No effect Downer et al. (2007)
effect Jiang et al. (2005)
Kochman et al. (2006)
Opiates Decrease Eisch et al. (2000)
Kahn et al. (2005)
Table 1.3 Summary of key studies which illustrate the effect of external factors which
regulate neurogenesis in the adult rat hippocampus. Information for this table was partially
sourced from Zhao (2008)
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Endogenous Proliferation Differentiation Survival References
factor
Hormones
Oestrogen Increase No effect Mazzucco et al. (2006)
Tanapat et al. (1999)
Corticosterone Decrease Decrease Ambrogini et al. (2002)
Cameron and Gould
(1994)
Hellsten et at. (2002)
Neurotransmitters
5-HT Increase Increase Banasr et al. (2004)
Brezun and Daszuta (1999)
Jha et al. (2006)
Glutamate Decrease Decrease Cameron et al. (1995)
Gould et al. (1994)
Noradrenaline Increase No effect No effect Kulkarni et al. (2002)
Acetylcholine No effect Increase/no Increase/no Cooper-Kuhn et al. (2004)
effect effect Kotani et at. (2008)
Growth or neurotrophin factors
BDNF Increase Increase Increase Lee et at. (2002)
Scharfman et at. (2005)
VEGF Increase Increase Increase Cao et at. (2004)
Jin et al. (2002)
Schanzer et at. (2004)
EGF No effect Decrease Kuhn et at. (1997)
FGF-2 Increase Rai et at. (2007)
IGF-I Increase Increase Increase Aberg et al. (2003)
Lichtenwalner et al. (200 I)
CNTF Increase Increase Increase Chohan et al. (20 II)
MUller et at. (2009)
Table 1.4 Summary of key studies which illustrate the effect of endogenous factors which
regulate neurogenesis in the adult rat hippocampus. Information for this table was partially
sourced from Balu and Luki (2009). Abbreviations; 5-HT: 5-hydroxytryptamine,
BDNF: brain-derived neurotrophic factor, VEGF: vascular endothelial growth factor, EGF:
epidermal growth factor, FGF-2: fibroblast growth factor-2, IGF-l: insulin-like growth factor
one, CNTF: ciliary neurotrophic factor.
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1.4.3 The role of BDNF in neurogenesis
Brain-derived neurotrophic factor (BDNF) is a polypeptide growth factor widely expressed in
the hippocampus. Despite its name, it is also produced in peripheral tissues such as liver,
muscle and adipose (Cassiman et al. 2001; Lommatzsch et at. 1999; Ukropec et at. 2008). In
the dentate gyrus, it is produced by both mature granule cell neurons (Conner et at. 1997) and
by surrounding glia and endothelial cells (Linnarsson et al. 2000). It is reported to nurture
newly generated neurons by increasing their proliferation (Lee et al. 2002; Scharfman et at.
2005), differentiation (Lee et al. 2002) and survival (Sairanen et al. 2005) and preventing
apoptosis (Linnarsson et al. 2000). Indeed, it is one of the most extensively studied
neurotrophins and BDNF levels in the SGZ tend to correlate with cell proliferation
(Kempermann 2006). Infusion of BDNF into the hippocampus of adult rats is shown to
enhance proliferation of cells (Scharfman et al. 2005). Furthermore, in studies using
heterozygous BDNF knockout mice, both proliferation and the amount of 4 week old neurons
was reduced in the knockouts compared to the wild type (Lee et al. 2002; Rossi et al. 2006).
Conversely, Sairanen et al. (2005) found BDNF knockout mice had increased numbers of
proliferating cells, reporting that the only effect of BDNF was on neuronal survival.
Functionally, BDNF expression has been reported to be increased by antidepressants, whereas
BDNF expression is reduced by chronic stress and depression (Duman and Monteggia 2006;
Lee and Kim 20 I0; Sairanen et al. 2005). In rodents BDNF expression is also associated with
the process of learning and memory. It is upregulated with enriched environment and
enhanced learning and memory paragdims (Cheng et al. 2003; Lu et al. 2008; Rossi et al.
2006) and has also been shown to be involved in long-term potentiation (LTP) which is
required for consolidation of short-term to long-term memories (Farmer et al. 2004; Korte et
al. 1996; Lu et al. 2008) (see section 1.5.2 of the present chapter).
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1.5 Adult hippocampal neurogenesis and memory
In the studies of this thesis the effects of chemotherapy on cognition are investigated, in
particular the effects of hippocampal-dependent spatial working memory. In the present
section, memory and the role of the hippocampus in memory processing are reviewed.
1.5.1 Types of memory
Learning is the acquisition of new information and memory is the retention of this
information. The process of memory formation and retrieval occurs in three main stages:
encoding, storage and retrieval. Encoding is the acquisition, processing and consolidation of
information, storage is the formation of a permanent record of this information and retrieval is
the recall of the information into consciousness or to execute an activity (reviewed in
Gazzaniga et al. 2009).
Memory can be divided into three main types: sensory, short-term and long-term memory
(Fig. 1.11). Sensory memory is perceived information which lasts only a few milliseconds to
seconds which degrades rapidly unless given attention and transferred to short-term memory
(Atkinson and Shiffrin 1971). Short-term memory has a limited capacity and is stored for
seconds to minutes. If not encoded into long-term memory by rehearsal, the information is
lost (Walker and Stickgold 2006) (Fig. l.ll). Working memory is a form of short-term
memory originating from sensory information or retrieved from long-term memory. It is a
limited-capacity storage of information to perform mental operations which process and utilise
this held information (Gazzaniga et al. 2009).
In contrast to short-term memory, long-term memory is a stable form of information with a
much larger capacity and is able to hold information indefinitely (up to a whole lifespan)
(Mecklinger 2010). Long-term memory can be divided into two broad categories: declarative
(explicit) and procedural (implicit). Declarative memory can be subdivided into semantic
memory, which consists of facts and general knowledge and episodic memory, which consists
of memories for autobiographical events. Both semantic and episodic memories are dependent
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on the medial temporal lobe (a structure that includes the hippocampus) and diencephalon
(Henke 20 I0). In contrast, procedural memory is the memory of learned skills of motor tasks
(e.g. how to ride a bike) or cognitive skills (e.g. reading) which is independent from the medial
temporal lobe (Henke 2010).
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Figure 1.11 Types of memory. Perceived information is held in sensory memory for a few
milliseconds to seconds and is lost unless given attention and is transferred to short-term
memory. Short-term memory lasts from seconds to minutes and is consolidated to long-term
memory if rehearsed, otherwise it will be lost. Working memory is a form of short-term
memory necessary to perform mental operations. It requires information retrieved from long-
term memory and from sensory memory. Long-term memory has a large capacity and can last
indefinitely (Gazzaniga et al. 2009).
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1.5.2 The role of the hippocampus in memory
Declarative memory, as discussed in the preceding section, requires the hippocampus whereas
procedural memory is independent of the hippocampus (Henke 2010). Memory acquisition
and forgetting in the hippocampus is reliant a process of LTP and long-term depression (LTD)
(Lynch 2004). LTP is a process in which synapses are strengthened and is required for
memory consolidation. In contrast, LTD is regarded as a complimentary mechanism to LTP
and selectively weakens specific synapses (Bear et al. 2007).
The hippocampus is also believed to playa strong role in spatial learning and memory. This
has been demonstrated by a number of studies involving hippocampal lesions. One study
compared the ability of rats, with and without hippocampal lesions to perform spatial and non-
spatial working memory tasks. Those with hippocampal lesions showed severe impairment in
performance of the forced choice alternation task, a task of spatial working memory, but they
were not impaired in the dNMTS non-spatial working memory task (Aggleton et al. 1986).
Other studies have observed that rodents with hippocampal lesions were also impaired in the
MWM, radial maze and spontaneous alternation in the T-maze spatial working memory tasks
(Bannerman et al. 2004; Deacon and Rawlins 2005; Lalonde 2002; Morris et al. 1982; Olton
and Papas 1979).
The NLR task is a spatial variant of the NOR task (discussed in detail in section 1.8 of the
present chapter) and rodents with hippocampal lesions show a reduction in ability to perform
the NLR task but not the NOR task (Dere et al. 2007; Mumby et al. 2002). These studies
provide strong evidence of the involvement of the hippocampus in spatial memory. This is
further supported by the existence of place cells in the hippocampus. These are neurons which
selectively respond when a rat is in a specific location in its environment (O'Keefe 1979).
Although at present, there is no evidence for place cells in the human hippocampus; studies of
patients with hippocampal damage provide evidence that the hippocampus also plays a critical
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role in spatial memory in humans (Abrahams et al. 1997; Astur et a1. 2002; Goldstein et al.
1989; Maguire et al. 1996).
1.5.3 The involvement of neurogenesis in learning and memory
Adult neurogenesis in the hippocampus has given rise to questions about its functional
relevance. There are now major implications for the involvement of neurogenesis in systems
of stress, depression and learning and memory (reviewed in Aimone et a1. 2011; Balu and
Lucki 2009; Dranovsky and Hen 2006; Koehl and Abrous 2011). A number of rodent studies
have shown that stress caused by factors such as isolation, footshock or physical restraint
reduces neurogenesis in the SGZ (David et a1. 2010; Mirescu and Gould 2006). However, a
causal relationship between neurogenesis and behaviour was shown by Santerelli et al. (2003).
This group observed that animals which had been irradiated to ablate hippocampal
neurogenesis did not respond to antidepressant drugs in a test of anxiety (Santarelli et a1.
2003). This landmark study demonstrated the importance of neurogenesis in behaviour. The
relationship between antidepressants and neurogenesis is discussed in more detail in section
1.6.3 of the present chapter.
Possibly the most widely studied functional implication of neurogenesis is its involvement in
learning and memory. Memory consolidation and working memory are both functions largely
mediated by the hippocampus (Clark et a1. 2007; Deng et al. 2010) (see section 1.5.2 of the
present chapter). The functional relevance of synaptic plasticity to memory is well
documented in the hippocampus, but the idea of plasticity on a cellular level is still relatively
new. Numerous studies in rodents have observed correlations between hippocampal
neurogenesis and cognition, extensively reviewed by Zhao et al. (2008) and Castilla-Ortega et
al. (2011), with the majority finding that environmental factors which increase hippocampal
cell proliferation also have a positive effect on hippocampal dependent learning. In addition,
genetic knockout mice with decreased hippocampal proliferation were impaired in memory
tasks (Castilla-Ortega et al. 2011; Zhao et al. 2008).
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Ablation of neurogenesis, achieved by toxicity or irradiation, is relatively straightforward and
has been used in numerous studies to investigate the role of neurogenesis in learning and
memory. Irradiation of proliferating hippocampal cells in the rat has been shown to impair
spatial memory in the MWM (Madsen et al. 2003; Snyder et al. 2005). A recent study by
Drew et al. (2011) showed that irradiation of hippocampal neurogenesis in mice impaired their
performance in the CFC task when a single-trial procedure, but not when multiple-trial
procedures were used, indicating that adult hippocampal neurogenesis is only required for
CFC in mice when they have received training. Conversely, another study demonstrated that
hippocampal irradiation in mice impaired CFC but not CER which would suggest that
neurogenesis is necessary for hippocampal-dependent learning. However, the same animals
were not impaired in the MWM or Y-maze. One possible explanation of these contradictory
findings is that hippocampal neurogenesis is required for some, but not all hippocampal
functions (Saxe et al. 2006).
The antiproliferative drug MAM has also been exploited in reducing neurogenesis in rodent
models of learning and memory and its effects are summarised in Table 1.2 and discussed in
section 1.1.3 (animal models of chemobrain).
In a study by Dupret et al. (2007) MWM spatial learning was shown to depend on
proliferation, survival and apoptosis of new hippocampal neurons, and blocking of apoptosis
impaired memory and cell survival and proliferation induced by learning. The same group
(Dupret et al. 2008) used a genetic mouse model to demonstrate that adult-born hippocampal
neurons are necessary for complex, but not simple spatial memory functions. Furthermore,
Kee et al. (2007) found that not only were newly generated neurons incorporated into
hippocampal circuitry during MWM learning, but they were preferentially recruited over pre-
existing granule cell neurons. These animal models all give strong evidence of a role for adult
neurogenesis in the mediation of hippocampal spatial learning.
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In humans there is a great deal less evidence of the functional relevance of adult neurogenesis.
However, it is widely accepted that the hippocampus as a structure has a vital role in memory
(see section 1.5.2 of the present chapter). The hippocampus is believed to playa role in spatial
working (Carrozzo et a!. 2005), verbal (Meyer et a!. 2005) and recognition (Reed and Squire
1997) memory. Patients affected by chemotherapy-induced cognitive impairment experience
problems primarily in working, visual and verbal memory as discussed in section 1.1 and
presented in Table 1.1 of the present chapter. This correlation gives primary evidence that the
hippocampus may be directly involved in the mechanisms behind chemotherapy-induced
cognitive impairment. Furthermore, neurogenesis is known to occur in the hippocampus of
humans (Eriksson et al. 1998) and thus could be a prospective target for cytotoxic drugs
administered to treat cancer. Therefore, although the evidence linking chemotherapy,
hippocampal neurogenesis and memory impairment is not direct, there is strong evidence for a
mechanism connecting them together and this is the basis for the animal model presented in
this thesis.
50
1.6 Fluoxetine
The selective serotonin reuptake inhibitor (SSRI) antidepressant, fluoxetine (Fig. 1.12), is
reported to increase neurogenesis and enhance cognition in both human and animal subjects
with a cognitive deficit (Monleon et al. 2007; Mostert et al. 2008). In the experiments in this
thesis (Chapters 3 and 4) it was co-administered with MTX and 5-FU to counteract the
chemotherapy induced reduction in neurogenesis and cognitive ability.
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Figure 1.12 Chemical structure of the selective serotonin reuptake inhibitor (SSRI)
antidepressant, fluoxetine.
1.6.1 Selective serotonin reuptake inhibitors
SSRIs are antidepressants used for the treatment of depression and anxiety disorders and they
are the most widely used group of antidepressants (Preskorn et al. 2004). As well as
depression they have also been used to treat psychological disorders including obsessive
compulsive disorder, panic attacks and post traumatic stress disorder. These conditions are all
related by involvement of serotonin (5-HT) and its receptors (Wong et al. 2005). Indeed the
main mechanism of action though which SSRIs act is by regulation of 5-HT uptake. In
normal circumstances, when a neuron is activated, 5-HT is released from the presynaptic
neuron and after diffusing across the synaptic cleft binds to receptors on the post synaptic
terminal. 5-HT is then rapidly removed from the synapse via reuptake transporters. SSRI
antidepressants bind to these transporters decreasing their affinity for 5-HT, causing 5-HT to
accumulate in the synapse (Stahl 1998). On binding to its receptors on the postsynaptic
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neuron, 5-HT can stimulate BDNF gene expression via cyclic adenosine monophosphate
(cAMP), protein kinase A (PKA) and cAMP response element binding protein (CREB)
pathways (see Fig. 1.13) (Duman et al. 2001b). Fluoxetine (Fig. 1.12) is one of the most
frequently prescribed SSRls (Preskom et al. 2004) and is metabolised in the liver by
cytochrome P450 into its one active metabolite, norfluoxetine (Gordon and Hen 2004; Ni and
Miledi 1997). Norfluoxetine has a half-life of 7 to 15 days in humans (Burke et al. 2000) and
15 hours in rat (Caccia et al. 1990) and antidepressant action takes 2 to 4 weeks to develop in
both humans and rodents (Conley and Hutson 2007). Fluoxetine (and norfluoxetine) were
used in some of the experiments presented in this thesis (Chapters 3, 4 and 5).
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Figure 1.13 Diagram illustrating the upregulation of intracellular BDNF by antidepressant
drugs (Duman et al. 2001). Antidepressants can inhibit the re-uptake of serotonin (5-HT) or
noradrenaline (NE) into the presynaptic neuron. This increases the availability of these
neurotransmitters to bind to mood regulating receptors on the post synaptic neuron (5-HT
receptors shown in the diagram as 5-HT7 and 5-HTsA and adrenal receptors ~AR and u] AR).
This binding results in increase of the cyclic adenosine monophosphate (cAMP), protein
kinase A (PKA) cascade and the Ca2+ dependent or microtubule-associated protein (MAP)
kinase cascade. Both these cascades upregulate the expression of cAMP response element
binding protein (CREB) and BDNF gene expression (Duman et al. 2001).
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1.6.2 Fluoxetine and adult hippocampal neurogenesls
An additional mechanism by which fluoxetine could act is by up-regulating hippocampal
neurogenesis (Castren and Rantarnaki 2010; David et al. 2010; Dranovsky and Hen 2006;
Malberg 2004; Santarelli et al. 2003). The exact pathways by which this is achieved remains
uncertain but it has been shown to increase the proliferation of rapidly dividing type 2
progenitors in the SGZ while leaving the slowly dividing NSC unaffected (Encinas et al.
2006). This effect may be via upregulation of BDNF which increases neurogenesis (see
section 104.3 of the present chapter). BDNF availability is regulated by fluoxetine by the
increased binding of 5-HT to receptors, which up-regulates intracellular MAP kinase or cAMP
cascades. This increases CREB in the cell nucleus and leads to increased transcription of
BDNF (Duman et al. 200 Ib; Merz et al. 20 II ) (see Fig. 1.13).
Evidence supporting that the action of fluoxetine is mediated by neurogenesis has come from a
number of animal models. Santarelli et al. (2003) observed that blocking neurogenesis with
irradiation also blocked the effect of fluoxetine in reducing anxiolytic behaviour. In contrast
Holick et al. (2007) used a similar method to Santaralli et al., ablating neurogenesis with
irradiation, and found that the action of fluoxetine on performance in the forced swim and
novelty-induced hypophagia tests did not require neurogenesis. One group showed that
chronic fluoxetine treatment increased the hippocampal expression of a number of genes
associated with the promotion of neurogenesis including BDNF (Miller et at. 2007) and
numerous studies have demonstrated increased neurogenesis in the rodent hippocampus after
treatment with fluoxetine (Chen et al. 2006; Hitoshi et al. 2007; Levkovitz et al. 2002;
Marcussen et al. 2008; Miller et al. 2007). Work in vitro has also shown that fluoxetine
increases proliferation in NSC that are 10 days old but not when they are 1 day old (Manev et
al. 2001). The correlation between animals exposed to stress and the reduction in the rate of
hippocampal neurogenesis (Aimone et al. 2011; Balu and Lucki 2009; Gould and Tanapat
1999) also provides evidence to suggest that adult neurogenesis is involved in the action of
fluoxetine.
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1.6.3 Cognitiveenhancement by fluoxetine
Due to the correlation between fluoxetine and neurogenesis and neurogenesis and memory, it
is reasonable to question if fluoxetine is able to enhance cognition. Although fluoxetine is not
thought to have a cognitive effect on healthy subjects (Monleon et al. 2007), some studies
provide evidence that fluoxetine improves cognition when this has been impaired. In clinical
studies, fluoxetine has been reported to improve deficits in memory in patients suffering from
moderate to severe depression (Gallassi et al. 2006; Levkovitz et al. 2002; Vythilingam et al.
2004), mild cognitive impairment (Mowla et al. 2007), traumatic brain injury (Horsfield et al.
2002) and post traumatic stress disorder (Vermetten et al. 2003).
In addition several experiments have been carried out to investigate the effects of fluoxetine
on memory in rodents, reviewed by Monleon et at. (2007). Collectively these yield a range of
results which could be due to the type of memory tested in the tasks or be due to animals
having no cognitive impairment before fluoxetine administration (Monleon et at. 2007).
Positive effects of fluoxetine on cognition have also been reported in rodent models when
memory impairment has been caused by stress (El Hage et at. 2004), hypoxia and stroke (Li et
at. 2009; Strek et al. 1989), olfactory bulbectomy (Broekkamp et al. 1980; Garrigou et al.
1981), scopolamine and electroconvulsive shock (Nowakowska et al. 1996). Furthermore, a
recent study in our laboratory found that fluoxetine can improve the memory impairment
caused by 5-FU administration in rats (EIBeltagy et al. 2010).
Due to the ability of fluoxetine to enhance neurogenesis and counteract cognitive deficits, it
was chosen for the experiments presented in this thesis to potentially counteract the deficits in
hippocampal cell proliferation and memory caused by chemotherapy agents, 5-FU and MTX.
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1.7 Animals chosenfor this study
In order to investigate the cognitive and neurobiological effects of chemotherapy-induced
cognitive impairment, it was necessary to select a suitable model. To date, most of the animal
studies utilised rat or mouse models (Seigers and Fardell 2011), so a rodent model was
considered appropriate for consistency and comparability with these studies. It was not
considered necessary to use an animal model with a higher level of sentiency to investigate
mild cognitive impairment. Moreover, a vast amount of literature is available on a range of
established behavioural tests for these species. In this thesis, the effects of chemotherapy on
adult neurogenesis are investigated. It has been shown that new-born adult hippocampal
neurons are more numerous in rats than mice and they are more likely to be recruited into
learning circuits (Snyder et al. 2009). Specifically, Lister-hooded rats were chosen as they
have superior eyesight compared to albino, outbred rat strains and are highly inquisitive,
which is beneficial in behavioural tests where they are intended to respond to environmental
stimuli (Manahan-Vaughan and Schwegler 2011; Neophytou et al. 2000). Although clinical
studies on chemotherapy-induced cognitive impairment are often in breast cancer patients,
male rats were chosen in this study to avoid the effects of the oestrogen cycle on behaviour
and neurogenesis (Galea et al. 2008). For these reasons, adult male, Lister-hooded rats were
used in the in vivo experiments discussed in this thesis.
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1.8 Behavioural tests used in this study
To establish a rodent model of chemobrain, animals' cognition was tested in each experiment.
A variety of cognitive tests were used to investigate different types of memory, with particular
focus on spatial working memory, which is a part of hippocampal function (Clark et al. 2007)
(see section 1.5.2 of the present chapter). This approach was taken to make the study relevant
to clinical studies of chemotherapy-induced cognitive impairment, in which memory tasks
involving the hippocampus such as working and visuospatial memory are often affected
(Baddeley et al. 20 II; Loureiro et al. 20 II; Sharma et al. 20 I0) (see Table 1.1). None of the
tests used relied on positive or negative reinforcers so as not to confound results. Aversive
stimuli, such as foot shocks, instil fear in and cause stress to an animal which would be
undesirable for the model in this study. Firstly, because, although specific types of fear
conditioning, such as contextual fear conditioning, involve the hippocampus, they are more
strongly reliant on the amygdala (McHugh et al. 2004). Secondly, stress can reduce
hippocampal neurogenesis (Zhao et al. 2008), a factor which will also be investigated in this
study. Food or sweet liquid is often given as a positive reinforcer, which might skew results,
as chemotherapy and fluoxetine have both been shown to suppress appetite and food intake
(Garattini et al. 1989). Furthermore, starving an animal overnight may cause it stress which
again could affect neurogenesis. Therefore, all the behavioural tests used in this thesis relied
on the rats' natural preference for novel stimuli (Hughes 2007).
1.8.1 Novel object recognition (NOR) task
The NOR task used in the first experiment in this thesis was a modified version of the one
developed by Ennaceur and Delacour (1988). It is a two trial object recognition task, and has
previously been used in our laboratory to assess working memory. In the familiarisation trial
the time the animals spend exploring two identical objects in an arena is recorded. Animals
are removed from the arena and after an inter-trial interval they are returned for the choice
trial, in which one of the objects is replaced with a new object and exploration time of each is
again recorded. If a rat has unimpaired working memory, it will normally explore the novel
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object for longer during the choice trial. However, the test is not hippocampal dependent
(Dere et al. 2007) and it was possible that it may affect the rats' performance in the NLR task
as the arena and objects used were the same. Therefore this task was not used in the second
and subsequent experiments in this thesis.
1.8.2 Novel location recognition (NLR) task
The NLR task is a spatial variant of the NOR task developed by Dix and Aggleton (1999). It
requires animals to remember the positions of two identical objects in the initial familiarisation
trial, and therefore preferentially explore the object with the novel location in the choice trial
after an inter-trial interval. Lesions in the hippocampus have been shown to impair
performance in the NLR task (Dere et al. 2007; Mumby et al. 2002). More specifically, it has
been reported that dentate gyrus lesions reduce the rats' ability in the task (Lee et al. 2005).
The dentate gyrus is one place where adult neurogenesis continually occurs providing further
evidence that adult neurogenesis is involved in memory formation. Hence this task was
particularly appropriate for this study. Furthermore, the NLR task is short, only taking 2 days
to complete with habituation. Therefore it was possible to examine neurogenesis in the
hippocampus at a comparable time point to the behavioural tests.
1.8.3 Spontaneous alternation in the F-maze
The T-maze has been utilised in rodents to test a range of cognitive paradigms (Deacon and
Rawlins 2006). In this thesis, spatial working memory was investigated using spontaneous
alternation in the T-maze. This test relies on rodents' natural ability to alternate their choice
destination arm of the T-maze in subsequent trials (Dember and Fowler 1958). Similar to the
NLR task, animals are impaired in spontaneous alternation after hippocampal lesions (Deacon
and Rawlins 2005; Lalonde 2002), making the task appropriate for this study. Again, the task
is short, with each animal tested within 10 min. This task was used in the final two
behavioural studies in this thesis.
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1.9 Aims and objectives
The studies presented in this thesis were carried out to investigate the effects of agents in the
CMF chemotherapy combination; CP, MTX and 5-FU, on memory and neurogenesis in the
adult rat hippocampus. Co-administration of the SSRI antidepressant, fluoxetine, was
investigated as a potential method to counteract any chemotherapy-induced cognitive and
neurobiological changes. In addition, an in vitro model was used to study the direct effects of
chemotherapy, fluoxetine and its active metabolite, norfluoxetine, on primary hippocampal
NSC from the adult mouse. The principal objectives of the present studies were as follows:
1. To establish a rodent model of chemotherapy-induced cognitive impairment.
2. To investigate the effects of the individual chemotherapies from the CMF treatment
combination on hippocampal dependent spatial memory utilising the NOR, NLR and
spontaneous alternation in the T-maze behavioural tasks.
3. To determine if any changes in cognition correlate with the proliferation and survival of
new cells in the adult hippocampus, using Ki67 and BrdU immunohistochemistry, thereby
providing evidence that alterations in neurogenesis may be an underlying mechanism for these
deficits.
4. To investigate if the cognitive and cellular deficits induced by chemotherapy can be
prevented or reversed by the co-administration of fluoxetine and to determine the optimum
time period to administer the drug.
5. To create an in vitro model to observe the direct effects of 5-FU, tluoxetine and
nortluoxetine on the viability and proliferation of adult NSC from the mouse hippocampus.
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Chapter 2
The effects of cyclophosphamide on spatial working
memory and hippocampal cell proliferation in the rat
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2.1 Introduction
In the present chapter two studies are discussed which were carried out to investigate the
effects of the chemotherapy agent, cyclophosphamide (CP) on cognition and cellular changes
in the hippocampus using a rat model. Firstly, a preliminary study was performed to assess
the toxicity of CP and to optimise the novel object recognition (NOR) and novel location
recognition (NLR) spatial memory tasks. The second study in this chapter is a continuation
from the work completed in the preliminary experiment, investigating the cognitive effects of
CP, using a modified version of the NLR task. Furthermore, in the second study cell
proliferation and survival in the dentate gyrus of the hippocampus were examined and levels
of DCX were quantified in the hippocampus and frontal cortex.
Patients who have received adjuvant chemotherapy as part of their treatment for cancer often
report problems in cognition, encompassing memory impairment, a short concentration span
and general confusion (Taillibert et al. 2007). These effects can last up to several years after
completion of the treatment (Ahles and Saykin 2002; Matsuda et at. 2005). However
combination therapies are often used in clinical treatment, so the actions of individual drugs
are unclear. CP, MTX and 5-FU (CMF) are all chemotherapy drugs, commonly used in
combination to treat breast cancer (Goldhirsch et al. 1998). This combination is reported to
have an effect on cognition in human studies (Kreukels et al. 2008; Schagen et al. 2002a;
Schagen et at. 1999). Previous work in our laboratory and elsewhere has shown that both
MTX and 5-FU have a negative effect on memory and proliferation in the hippocampus
(EIBeltagy et at. 2010; Mustafa et at. 2008; Seigers et al. 2008) and the experiments presented
in the present chapter focus on the effects ofCP.
Cl' is an alkylating agent, with its metabolites causing alkyl crosslinks within and between
DNA strands of dividing cells, an action that causes them to apoptose (Matalon et at. 2004)
(see section 1.2.2, Chapter I). CP is used to treat several types of cancer including breast and
lung carcinoma (Allwood et at. 1997) and is able to cross the blood brain barrier (Janelsins et
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al. 2010). CP is used clinically in chemotherapy combinations which have been reported to
cause chemotherapy-induced cognitive impairment (Ahles and Saykin 2002; Brezden et al.
2000; de Ruiter et al. 2011; Hurria et al. 2006a; Kreukels et al. 2008; Schagen et al. 2002b;
Schagen et al. 1999; Shilling et al. 2005; Wieneke and Dienst 1995). Neuropsychological
domains affected include verbal, visuospatial and working memory, processing speed and
attention/concentration (Table 1.1). However, the effects of CP alone on cognition have not
been examined in patients. Rodent models have also been used to investigate the effects of
chemotherapy on cognition (summarised in Table 1.2) with many researchers observing that
chemotherapy causes animals to be impaired in a range of cognitive tasks, although other
studies found chemotherapy had no effect and in a single study improvement was even seen in
the MWM task (Lee et al. 2006; Seigers and Fardell 2010). The hippocampus is believed to
play an important role in visuospatial and working memory in humans (Baddeley et al. 2011;
Loureiro et al. 20 II; Sharma et al. 20 I0). In many of the pre-clinical studies investigating
chemotherapy-induced cognitive impairment the ability of rodents to perform tasks which are
reliant on the hippocampus such as the NLR and MWM that are most greatly affected,
compared with tasks such as fear conditioning tasks which are more dependent on the
amygdala (Parkes and Westbrook 2011) (see Table 1.2, Chapter 1).
Furthermore, many of these studies also found that chemotherapy reduced proliferation of
neural progenitors in the dentate gyrus of the hippocampus (ElBeltagy et al. 2010; Seigers et
al. 2010a; Yang et al. 2010). This reduction in hippocampal neurogenesis has been considered
as one possible cause of the cognitive impairment seen. Throughout life, neuronal progenitors
in the SGZ of the dentate gyrus divide to produce new neurons, which get integrated into
existing neural circuits (Lledo et al. 2006b) and are thought to have a functional role in
learning and memory consolidation (Ehninger and Kempermann 2008; Zhao et al. 2008).
Ablation of neurogenesis by means of irradiation (Wojtowicz 2006), hippocampal lesions
(McGregor et al. 2004; Morris et al. 1982) or cytotoxic drugs (BrueI-Jungerman et al. 2005;
Ko et al. 2009) has been shown to cause impairment in cognition. Previous work in our
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laboratory also found that rats administered with 5-FU chemotherapy had reduced
hippocampal levels of DCX, (Mustafa et al. 2008). DCX is a microtubule-associated protein
which is expressed transiently in newly differentiated neurons (Zhao et al. 2008). Therefore
its reduction by 5-FU strengthens the argument that chemotherapy is able to negatively affect
neurogenesis.
In both studies presented in this chapter, CP was administered chronically in a rat model to
mimic clinical administration. A dosage of 30mglkg was chosen which is sufficient to cause
weight loss but is well below the predicted median lethal dose of 200mglkg (Branda et al.
2002) and below the amount administered which causes pain or cystitis (Wantuch et al. 2007).
It is also within the range of doses (8-200mglkg) which have been previously shown to have
an effect in cognition in rodents, although the majority of these studies used a dose within the
range of 10-40mglkg (see Table 1.2, Chapter I). Plasma concentrations of the active
metabolite of CP, phosphoramide mustard, have been shown to peak at 23flM, 40 min after
i.p. injection in rat, although a slightly higher dose of 50mglkg was used in the study (Powers
and Sladek 1983) and the brain/plasma concentration-integral ratio of phosphoramide mustard
was found to be 0.18 (Genka et al. 1990). CP is reported to have an increased effect on
proliferation and had less toxicity when adult rats were dosed at 14.00 h compared with 8.00 h
(Perez-Lopez et al. 1984), therefore in the studies in this chapter all injections were
administered between 14.00 and 16.00 h.
The NOR and NLR tasks described in section 1.8, Chapter 1, were used to test working
memory of the rats after CP administration. However, in the preliminary study, the animals
were unable to perform the tasks even before treatment, indicating that the tasks needed
optimising in order for conclusions to be drawn. Consequently, in the second study presented
in this chapter, the NLR task was amended and the NOR task was removed to eliminate the
possibility of confounding the results by using both tasks in the same animals.
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2.2 Preliminary study to assess the toxicity of CP and optimise the NOR and NLR tasks
2.2.1 Materials and methods
2.2.1.1 Animals and treatment
Male Lister-hooded rats (150-200g; Charles River, UK, total n= 16) were administered CP (30
mg/kg, 4 i.v, doses each 3-4 days apart, into the tail vein, at a volume of 3mllkg, dissolved in
0.9% sterile saline; Medac, Germany) or 0.9% sterile saline at an equivocal volume (both
groups n=8). CP/saline was administered under gaseous isofluorane (4% to initiate
anaesthesia then reduced to 2%). This method of administration was previously used in our
laboratory (EIBeltagy et at. 2010; Mustafa et at. 2008). Both groups were administered BrdU
(250mg/kg, i.p., at a volume of 4mllkg; Sigma Aldrich, UK) immediately after their first
CP/saline injection.
Rats were group housed (4 per cage) in cages (dimensions: 52 x 32 x 20 cm) with sawdust
bedding and maintained with a 12 h light/dark cycle (7.00/19.00 h). Room temperature (21±2
0c) and humidity (60±5%) were kept constant. Food (2018 rodent diet, Harlan) and water was
provided ad libitum. They were weighed every 1-3 days from arrival and allowed to habituate
1 week prior to behavioural testing. All procedures were in accordance to UK Home Office
Guidance regulations and with local ethical committee approval under project license 40/2715
and personal license 40/8883.
2.2.1.2 Behavioural testing
2.2.1.2.1 Novel object recognition (NOR) task
The NOR task described (Fig. 2.1) is a two trial object recognition task adapted from Ennaceur
and Delacour (1988). The apparatus consisted of an arena (a semi-transparent Perspex box;
dimensions: 49 width x 66 length x 40 height cm) and the objects were weighted water bottles
(l5cm high, 7cm diameter) dark blue, with white tape horizontal stripes, or light pink with no
stripes. Arenas and water bottles were cleaned with 20% ethanol prior to each experiment and
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between trials to remove olfactory cues. Experiments were conducted at an illumination of 80
Lux between 9.00 and 14.00 h.
NOR testing was carried out 8 days before drug treatment and 3 days after the final eP/saline
injection. Rats were habituated to the arena for I h, 24 h prior to testing. During the 3 min
familiarisation trial rats were placed in the arena to explore two identical objects (objects A
and B in results) in opposite comers. Rats were returned to their home cage for 15 min and
then returned to the arena for the 3 min choice trial. In this trial, one of the objects was
replaced with a novel object (which of the objects was novel was randomised). Exploration
was defined as the rat directing its nose in the direction of the object less than I cm from the
object, and actively exploring it (Dix and Aggleton 1999). Gnawing or climbing the object
was not considered exploration. Exploration times of both objects and trials were recorded
blind by 2 people, and averaged using a stopwatch from digitised recordings, so no observer
was in the room during the trials. The exploration data of all animals was included in the
analysis.
2.2.1.2.2 Novel location recognition (NLR) task
The NLR task (Fig. 2.2) is a spatial variant of the NOR task and was adapted from Dix and
Aggleton (Dix and Aggleton 1999). The same apparatus and method was used as in the NOR
task, with the variance being that in the choice trial, neither object was replaced (weighted,
pink water bottles) but one was moved to a novel location in the arena. The starting location of
the objects was randomised. It was carried out 4 days after the NOR tasks. The exploration
data of all animals was included in the analysis.
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Figure 2.1 The novel object recognition protocol (NOR) was carried out over 2 days. Rats
were habituated in the arena for 1 h. They were removed for 24 h and two identical objects
were placed in 2 corners of the arena. Rats were replaced in the arena and allowed to explore
the objects for 3 min (familiarisation trial) then removed again for 15 min. When returned
again, one object had been replaced with a novel object and rats were again left to explore for
3 min (choice trial).
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Figure 2.2 The novel location recognition protocol (NLR) was carried out over 2 days. Rats
were habituated in the arena for 1 h. They were removed for 24 h and two identical objects
were placed in 2 corners of the arena. Rats were replaced in the arena and allowed to explore
the objects for 3 min (familiarisation trial) then removed again for 15 min. When returned
again, one object had been moved to a different comer and rats were again left to explore for 3
min (choice trial).
66
2.2.1.3 Statistical analysis
Body weight was analysed using two-way repeated measures ANOV A. When ANOV A was
significant Bonferonni post-hoc test was performed. Student's paired I-tests were used to
compare exploration times of animals in the familiarisation and choice trials in both NOR and
NLR tasks. Student's unpaired I-tests were used to compare total exploration time and
average velocity of the animals. Preference indices (PI) were created for the NOR task by
expressing time spent exploring the novel object in the as a percentage of the sum of
exploration time of novel and familiar objects and from the NLR task by expressing time spent
exploring the object in the novel location as a percentage of the sum of exploration time of
novel and familiar locations in the choice trial, to create a single value to compare between
groups. PI values were compared to 50% chance using a one-sample r-test and PI of both
groups were compared using Student's unpaired r-test, Statistical analysis and graphs were
created using GraphPad Prism 5 and significance was regarded as p<0.05.
2.2.2 Results
2.2.2.1 Cyclophosphamide does not reduce weight gain
Cl' had no effect on the amount of weight gained compared to vehicle treated controls
(F r,238=4.16, two-way repeated measures ANOV A, Fig. 2.3), although it was close to
significant p=0.079. However, a significant effect of time and treatment x time interaction
was confirmed (F17•238=5l5.33, F17•238=10.39 respectively, p<O.OOOl for both). The animals
remained in good health throughout the study never lost more than 10% of their maximum
body weight.
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Figure 2.3 Body weights of rats (mean ± SEM, n=8) throughout the study. Arrows indicate
CP/saline injections. CP had no effect on the amount of weight gained compared to vehicle
treated controls (F1.238=4.16,two-way repeated measures ANOV A). The effect of time and
the treatment x time interaction was significant (F17,238=515.33,F17,238=10.39 respectively,
p<O.OOOIfor both).
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2.2.2.2 NOR task
No significant difference was found between the exploration times for either object for both
groups in the familiarisation trials of the NOR task both before and after CP/saline treatment
(Student's paired r-test, Fig. 2.4a and c). In the choice trial before treatment both groups spent
more time exploring the novel object but this was not significant (Student's paired r-test, Fig.
2.4b). This was supported by PI analysis from the choice trial before treatment, as neither the
PI of the CP nor the saline group significantly differed from 50% chance (one-sample r-test,
Fig. 2.4e) nor did the PI differ between groups (Student's unpaired r-test), In the choice trial
after treatment, the saline treated controls spent significantly more time exploring the novel
object (p<O.05, Student's paired t-test, Fig. 2.4d) and the PI was significantly different from
chance (p<0.05, one-sample r-test, Fig 2.4f) whilst CP treated animals showed no significant
difference in exploration of either object (Student's paired r-test, Fig. 2.4d) nor was the PI
significantly different from chance (one-sample z-test, Fig 2.4f). The PI of the saline and ep
treated animals were not significantly different after treatment (Student's unpaired Hest).
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Figure 2.4 Exploration times (mean ± SEM, n=8) of the rats for each object for the novel
object recognition (NOR) task from before (a and b) and after (c and d) CP/saline treatment.
In the familiarisation trials (a and c) there was no significant difference in exploration time of
Saline CP
either object for either group (Student's paired t-test). In the choice trial before treatment (b),
neither groups spent significantly longer exploring the novel object (Student's paired z-test).
In the choice trial, after completion of treatment (d), vehicle treated animals spent significantly
longer exploring the novel object (p<0.05), but there was no significant difference in
exploration time for the CP treated animals (Student's paired t-test). Preference indices (PI,
mean ± SEM, n=8) were created by expressing time spent exploring the novel object as a
percentage of the sum of exploration time of novel and familiar objects in the choice trial
(Bruel-Jungerman et al. 2005). Before treatment (e), the PI of vehicle-treated animals and
those to be CP-treated animals did not differ from 50% chance (p<O.05, one-sample t-test) or
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between groups (Student's unpaired r-test), After treatment the PI of the CP and saline-treated
groups did not differ from each other (Student's unpaired r-test, 0. The PI of the saline-treated
group differed from 50% chance after treatment (p<O.05, one-sample r-test) whereas the PI of
the CP-treated group did not.
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2.2.2.3 NLR task
There was no significant difference between the exploration times for either object for both
groups in the familiarisation trials of the NLR task both before and after CP/saline treatment
(Student's paired r-test, Fig. 2.5a and c). In the choice trial before treatment, the group to be
treated with CP spent significantly longer exploring the object in the novel location (p<0.0 1,
Student's paired r-test) whilst the group to be treated with saline showed no significant
difference in exploration of either object (Student's paired r-test, Fig. 2.Sb). The PI were
significantly higher in animals to be treated with CP before treatment compared to the saline
group (p<0.0 I, Student's unpaired r-test, Fig 2.5e). Before treatment the PI of the group to be
treated with CP were significantly difference from 50% chance (p<O.OS, one-sample r-test),
whereas the vehicle-treated group were not. It is to be noted that at this stage the groups had
not been administered with CP/saline. In the choice trial after treatment both groups spent
more time exploring the novel object but this was not significant (Student's paired r-test, Fig.
2.5d). The PI of the saline and CP treated group did not differ from 50% chance (one-sample 1-
test, Fig 2.Sf) or between groups after treatment (Student's unpaired r-test).
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Figure 2.5 Exploration times (mean ± SEM, n=8) of the rats for each object for the novel
location recognition (NLR) task from before (a and b) and after (c and d) CP/saline treatment.
In the familiarisation trials (a and c) there was no significant difference in exploration time of
either object for either group (Student's paired r-test), In the choice trial, before treatment (b),
the vehicle treated group showed no significant difference in exploration time of either object
(Student's paired t-test), whilst the CP treated group spent significantly longer exploring the
object in the novel location (p<0.01, Student's paired r-test), In the choice trial, after
completion of treatment (d), neither group spent significantly longer exploring the object in
the novel location (Student'S paired z-test). Preference indices (PI, mean ± SEM, n=8) were
created by expressing time spent exploring the object in the novel location as a percentage of
the sum of exploration time of novel and familiar locations in the choice trial (Bruel-
Jungerman et al. 2005). The PI values were significantly higher in animals to be treated with
CP before treatment (e) compared to the saline group (ttp<O.Ol, Student's unpaired t-test).
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Before treatment the PI of the group to be treated with CP were significantly difference from
50% chance (p<0.05, one-sample r-test), whereas the vehicle-treated group were not. After
treatment (f), the PI of vehicle-treated animals and the CP-treated animals did not differ from
50% chance (p<0.05, one-sample r-test) or between groups (Student's unpaired r-test),
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2.2.3 Discussion
In the present preliminary study, the NOR and NLR working memory tasks were used to
investigate the effects of ep on cognition using a rat model. Behavioural experiments were
carried out before and after ep treatment to ensure that the animals were able to perform the
task. The usual expected outcome for these tasks would be that animals with no impairment in
cognition would spend a similar amount of time exploring objects in the familiarisation trial,
but spend significantly longer exploring the novel object or object in the novel location in the
choice trial (Dix and Aggleton 1999; Ennaceur and Delacour 1988). From results of the NOR
task in the present experiment, animals explored both objects for a similar amount of time in
the familiarisation trials before and after treatment. In the choice trial before treatment (where
no cognitive impairment should be seen) both groups appeared to explore the novel object for
longer, although this was not significant. When the group numbers were combined (n=16) this
difference became significant (p<O.05, Student's paired r-test, data not shown), suggesting
significant variation between animals and indicating the task may be more reliable with larger
n numbers (an n number of 8 was used in the present experiment). In the choice trial of the
NOR task carried out after treatment, the saline treated animals spent significantly longer
exploring the novel object. This would normally suggest that the Cl' treated animals display
cognitive impairment; however, as neither of the groups was able to perform the task before
treatment, this result remains inconclusive.
In the familiarisation trial of the NLR tasks before and after treatment, no significant
difference was seen between exploration times for either object, which was expected. In the
choice trial before treatment the group to be treated with Cl' was able to differentiate the
objects in a novel and familiar location, although the group to be treated with saline could not.
When the exploration times of the two groups were combined the overall difference in
exploration time became significant (p<O.05, Student's paired t-test, data not shown), again
indicating large variation between animals and suggesting that a larger number of animals
were needed per group. Using data from the choice trial before treatment a power analysis was
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performed to determine the number of animals that would be required to obtain significance of
p<0.05. Data from the vehicle and control group combined suggested that a sample size of 33
would be required for an 80% chance for statistical significance. In the choice trial after
treatment, both groups appeared to preferentially explore the object with the novel location,
but this was not significant and a power analysis showed the probability of the effect of Cl'
was only 30%, so no conclusions can be drawn from this study. Additionally, there may have
been other complications with the tests. The tests were carried out 3 days apart and as the
same objects were used for both tests, the animals may have remembered the object locations
from the NOR task in the NLR task, which might have confounded the results. Based on this
finding, in the rest of the experiments presented in this thesis, only one of these two tasks, the
NLR task, was used.
ep is reported to cause weight loss when used in chemotherapy combinations clinically
(Vettori et al. 2010) and in rat models (Lee et al. 2006). However, in the present study, rats
treated with ep did not gain weight at a significantly lower rate than the control animals. This
could indicate that the dose given was not clinically relevant and could be slightly increased,
or be given for a longer time period in future studies.
In conclusion, although there was a slight indication that ep causes the ability of rats to be
impaired in the NOR task, it is unjustifiable to draw these conclusions from this result as the
animals were not able to perform the task before treatment. The experimental procedure used
in the present study needs to be altered by increasing the number of rats in each group and
only performing one behavioural test, so the possibility of the animals remembering previous
objects and their locations is eliminated. These issues are addressed in the subsequent studies
presented in this thesis.
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2.3 The effects 0/ cyclophosphamide on hippocampal cell proliferation and spatial
working memory in rat
2.3.1 Introduction
In the preliminary study presented in this chapter, both the NOR and NLR tasks were used to
test working memory of CP treated rats, however, the animals were not able to perform the
tasks correctly even before treatment, indicating the task needs to be modified and higher
numbers of rats need to be used. In the present study, a modified version of the NLR task was
used to test spatial memory 6 days after the final CP injection. The NLR task was selected
over the NOR task due to its dependence on the hippocampus (Dere et al. 2007). The number
of CP injections was increased from 4 to 7 since no significant weight loss was observed in the
preliminary study, although the dose of 30mglkg remained the same. The modifications to the
NLR task from that used in the previous study were as follows; the number of animals in each
group was increased from 8 to 12; a visual cue (a square of black card) was placed on the wall
of the room in which the test took place to aid rats with orientation; the habituation period 24 h
before the familiarisation trial was decreased from 1 h to 30 min to reduce stress to the animal;
a second habituation period of 3 min was added 1 min before the familiarisation trial. The
NOR task was not utilised to avoid results being confounded by any recognition of the objects
and their locations between tests.
Ki67 is a protein which is expressed in all stages of the cell cycle (Scholzen and Gerdes 2000)
and was used to quantify cells which were proliferating in the dentate gyrus at the end of the
experiment (see section 1.3.4.2, Chapter 1.). To investigate the effect of CP on the survival of
newly generated hippocampal cells, BrdU was injected at the beginning of CP treatment to be
incorporated into cells proliferating at that time. The surviving cells which expressed BrdU at
the end of the experiment were quantified. Levels of DCX were quantified in the
hippocampus to investigate changes in differentiation of newly born neurons In the
hippocampus and also in the frontal cortex to indicate the regional specificity of changes
induced by CP.
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2.3.2 Materials and methods
2.3.2.1 Animals and treatment
Male Lister-hooded rats (12S-1S0g; Charles River, UK, total n=24) were administered CP (30
mg/kg, 7 i.v. doses each 2 days apart, into the tail vein, at a volume of I.Sml/kg, dissolved in
0.9% sterile saline; Medac, Germany) or 0.9% sterile saline at an equivocal volume (both
groups n=12). Both groups were administered BrdU (2S0mg/kg, i.p., at a volume of 4ml/kg;
neutralised to pH 7.0 with O.IM NaOH, Sigma Aldrich, UK) immediately after their first
CP/saline injection. All injections were given under gaseous isofluorane (4% to initiate
anaesthesia then reduced to 2%) and administered between 14.00 and 16.00 h.
Rats were housed as described in section 2.2.1.1 of the present chapter. They were weighed
daily from arrival and allowed to habituate 2 weeks prior to behavioural testing. All
procedures were in accordance to UK Home Office Guidance regulations and with local
ethical committee approval.
2.3.2.2 Behavioural testing
2.3.2.2.1 NLR task
The NLR task was carried out as described in section 2.2.1.2.2 of the present chapter, with a
modified habituation procedure (Fig. 2.6). Animals were habituated for 30 min, 24 h prior to
testing (during which EthoVision 4.1 was used to measure the mean velocity of the rats) and
for a further 3 min,S min before the familiarisation trial (King et al. 2004). A black square of
card was added on the wall of the room during trials to provide a prominent cue for spatial
orientation. Exploration times of both objects and trials were recorded blind to the identity of
the rat twice using a stopwatch and averaged. The exploration data of all animals was included
in the analysis.
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Figure 2.6 A modified version of the novel location recognition (NLR) task. Rats were
habituated in the arena for 30 min and for a further 3 min 24 h later. They were then removed
for 1 min whilst two identical objects were placed in 2 comers of the arena. Rats were
replaced in the arena and allowed to explore the objects for 3 min (familiarisation trial) then
removed again for 15 min. When returned again, one object had been moved to a different
comer and rats were again left to explore for 3 min (choice trial).
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2.3.2.3 Brain tissue preparation
Rats were killed by rapid concussion and cervical dislocation the day after behavioural testing.
Brains were removed, cut sagittally and one half was cryopreserved in 30% sucrose solution
for three hours at 4DC, then submerged in OCT-compound (VWR International Ltd, UK) and
snap frozen in liquid nitrogen-cooled isopentane. These were stored at _80DC until being
sectioned along the coronal plane using a Leica CM 100 cryostat (Leica Microsystems, UK) at
20~m thickness at _20DC.The sections were thaw mounted onto 3-aminopropylmethoxysaline
(APES)-coated slides and stored at -20'C until used for immunohistochemistry. From the
contralateral brain, the hippocampus and frontal cortex were dissected, placed in eppendorfs
and immediately snap frozen in liquid nitrogen and stored at -80DC until used for Western
blotting.
2.3.2.3.1 Immunohistochemistry
For both Ki67 and BrdU staining a systematic random sampling technique was used (Mayhew
and Burton 1988). Every 20th section throughout the entire length of the dentate gyrus was
selected, resulting in a total of 9-11 sections per brain. All immunohistochemistry incubations
were carried out at room temperature in a light-proof humidity chamber.
2.3.2.3.2 Ki67
All dilutions and washes (each time performed thrice) were carried out with phosphate
buffered saline (PBS). Sections were fixed using 0.5% paraformaldehyde (PFA) for 3 min,
washed then incubated with monoclonal mouse anti-Ki67 primary antibody (l: 100; Vector
laboratories, UK) for 1 h, followed by a further wash and I h incubation with Alexa 555
donkey anti-mouse (I:300; Invitrogen, UK). Sections then had a final wash, were mounted
with (diamidinophenylindole) OAPI (Lfiug/ml) nuclear marker (Vector laboratories, UK)
and cover-slipped.
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2.3.2.3.3 ~rc1l!
All washes were performed three times with O.IM sodium borate adjusted to pH 8.5 (borate
buffer) unless otherwise stated. Sections were fixed in 4% PFA for 3 min, washed, then DNA
was denatured by incubation in 2M hydrochloric acid (He I) containing 0.3% tritonXIOO
(Sigma Aldrich, UK) for 20 min, immediately followed by 10 min incubation with 5M HC!.
Sections were then washed and neutralised for 12 min in the borate buffer then blocked with
5% bovine serum albumin (BSA; Sigma Aldrich, UK) in PBS containing 0.15% triton X-IOO
for 30 min. After washing sections were incubated for 16-20 h with polyclonal sheep anti-
BrdU primary antibody (1: I00; Abeam, UK) in the blocking solution, followed by washing
and incubation with Alexa 488 donkey anti-sheep secondary antibody (1 :300; Invitrogen, UK)
in PBS. Sections then had a final wash in PBS, were mounted with OAPI and cover-slipped.
All staining was viewed and quantified at x 40 on a Nikon EFO-3 fluorescence microscope.
BrdU and Ki67 positive cells which co-localised with the OAPI nuclear staining within both
blades of the dentate gyrus (or within a 3 cell diameters of the inner edge) were counted. By
combining cell counts per section for the whole dentate gyrus and multiplying by 20, an
estimate of total co-stained cell numbers was produced (Huang and Herbert 2006). All
counting was performed blind.
2.3.2.4 Western blot analysis of DCX expression in hippocampus andfrontal cortex
2.3.2.4.1 Sample preparation, Lowry assay and protein separation
Sample preparation was carried out on either ice or at 4 ·C. Hippocampus and frontal cortex
samples (n=6) were homogenised in lysis buffer (see Appendix I) to produce a 100mglml
solution. The samples were rotated on a spinning wheel for 20 min then centrifuged at
13,000g for 10 min. 20~1 of the supernatant was taken to be used for the Lowry test. The
remainder of the supernatant was added to an equal volume of 2X solubilisation buffer (see
Appendix I) and stored at -20·C.
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Protein concentrations within each sample were determined using a Lowry assay (Lowry et al.
1951). A standard curve of BSA dilutions (ranging from 0 to 0.5 mg/ml, in distilled water,
total volume 200 Ill) was created. The 20111homogenised sample was diluted (1: 10) in distilled
water. lrnl of Lowry AB solution (see Appendix I) was added to the sample and all standards
and incubated at room temperature for 10 min. 100 III of Folin reagent (diluted 1:1 with
distilled water) was added to each sample and incubated at room temperature for 45 min.
Each standard and sample was loaded in triplicate into a 96 well plate and the optical density
was read at 7S0nm wavelength using a Dynex MRX Model 96 Well Plate Reader (MTX Lab
Systems Inc., USA). Protein concentration was detected colourimetrically and presented with
Revelation software (MTX Lab Systems Inc., USA). All samples were then normalised with
2X solubilisation buffer diluted with lysis buffer (I: I)
The samples were denatured by heating to 95°C for five minutes, then vortexed and
centrifuged for 1 min at 13,000g. ISIlI of each were loaded onto a 10% SOS-polyacrylamide
gel (see Appendix I) and run parallel to I III of a molecular weight marker (PageRuler plus
Prestained protein ladder manufactured by Fennentus UAB, Lithuania). Protein separation
occurred for 45 min (200Y at room temperature) with gel immersed in electrophoresis buffer
(see Appendix I). Subsequently the proteins from the gel were transferred onto a
nitrocellulose membrane (Hybond, Amersham Biosciences, UK) for 60 min (IOOY at 4°C) in
transfer buffer (see Appendix I). Successful transfer of protein was confirmed with Ponceau
solution (Sigma-Aldrich, USA).
2.3.2.4.2 Immunodetection, quantification ofprotein and data analysis
The nitrocellulose membrane was blocked at room temperature, rocked for I h in 5% milk
solution (dried milk powder in Tris-buffered saline tween-20 (TBST) solution, see Appendix
I). All antibodies were diluted by TBST with 5% milk powder. The nitrocellulose was rocked
overnight at 4·C with polyclonal rabbit anti-DCX (I: 1000; Cell Signalling) and mouse anti-~-
actin (1: 1000; Cell Signalling) primary antibodies, washed several times with TBST to remove
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primary antibodies. It was then rocked in IRDye 700CW goat anti-rabbit and IRDye 800CW
goat anti-mouse (both 1:20000; LI-COR Biosciences) for 1 h and again washed in TBST. The
membrane was scanned on an Odyssey scanner (LI-COR) at wavelengths of 700nm (red
emission) and 800nm (green emission) and analysed using Odyssey software (Application
version 3.0). p-actin (43 kOa) was used as a loading control that DCX (47 kDa) protein bands
could be normalised against.
Tissue samples of the hippocampus and frontal cortex from both CP and vehicle treated
groups were run on the same gel and repeated 3 times. Protein was quantified (and presented)
using Odyssey software (Application version 3.0) by measuring the intensity of the protein
band. Intensity levels of DCX expression was measured at a wavelength of 700nm and
normalised against p-actin measured at 800nm. Mean DCX protein expression of the samples
is presented.
2.3.2.5 Statistical analysis
Statistical analysis and graphs were created using GraphPad Prism 5 and significance was
regarded as p<0.05. Body weight was analysed using two-way repeated measured ANOV A.
When ANOVA was significant Bonferonni post-hoc test was performed. Student's paired t-
tests were used to compare exploration times of animals in the familiarisation and choice
trials. Preference indices (PI) were created by expressing time spent exploring the object in
the novel location as a percentage of the sum of exploration time of novel and familiar
locations in the choice trial, to create a single value to compare between groups (Bruel-
Jungerman et at. 2005). PI were compared to 50% chance using a one-sample t-test. Student's
unpaired t-tests were used to compare PI, total exploration time and average velocity of the
animals and DCX expressed from Western blotting.
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2.3.3 Results
2.3.3.1 Cyclophosphamide reduces weight gain
Both treatment and time had a significant effect on body weight (F1•418=5.51, p<O.05
F I9•418=367.9, p<O.OOI respectively, two-way repeated measures ANOVA, Fig. 2.7) and a
significant effect of treatment x time interaction was also confirmed (F I9•418=30.23, p<O.OOI).
Animals remained in good health throughout the study and never dropped more than 10% of
their highest body weight.
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Figure 2.7 Body weights of rats (mean ± SEM, n=12) throughout the study. Arrows indicate
CP/saline injections. Treatment and time significantly affected body weight (F1.418=5.51,
p<0.05 FI9•418=367.9, p<O.OOOl respectively, two-way repeated measures ANOVA) and the
treatment x time interaction was also significant (FI9•418=30.23, p<O.OOOl).
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2.3.3.2 CP does not affect spatial working memory
In the familiarisation trials, both before and after animals were treated with Cl' or saline,
neither the groups explored the objection in locations A or B for significantly longer, showing
no preference for either location (Student's paired r-test, Fig. 2.8a and 2.9a). In the choice trial
before treatment, both groups spent longer exploring the object in novel location (p<0.00 1,
Student's paired r-test, Fig. 2.8b). In the choice trial after treatment both groups spent
significantly longer exploring the novel object (p<0.05, Student's paired z-test, Fig. 2.9b). The
exploration time data was converted into PI for further analysis (Fig. 2.8c and 2.9c). Both the
vehicle and ep treated groups significantly differed from 50% chance in the choice trials
(p<0.001), both before and after treatment, indicating neither group had impaired cognition.
No significant difference was found between the PI of each group (Student's unpaired r-test)
before and after treatment. No difference was found in total exploration time or mean velocity
of the vehicle and ep treated animals both before and after treatment (Fig. 2.8d and 2.9d and
Fig.2.l0).
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Figure 2.8 Exploration times (mean ± SEM, n=12) of the rats for each object in the
familiarisation (a) and choice (b) trials in the novel location recognition (NLR) task, before
CP/saline treatment. There was no significant difference in exploration time of either object
for both groups in the familiarisation trial (Student's paired r-test). In the choice trial, both
groups spent significantly longer exploring the object in the novel location (p<O.OOl, Student's
paired r-test), Preference indices (PI, (c), mean ± SEM, n=12) were created by expressing time
spent exploring the object in the novel location as a percentage of the sum of exploration time
of novel and familiar locations in the choice trial (Bruel-Jungerman et at. 2005). The PT were
not significantly different between groups (Student's unpaired r-test) but PI of both groups
were significantly different from chance (p<O.OO1, Student's unpaired r-test). The total
exploration time (mean ± SEM, n=12) for both trial combined (d) did not differ significantly
between groups (Student's unpaired z-test),
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Figure 2.9 Exploration times (mean ± SEM, n:::::12)of the rats for each object in the
familiarisation (a) and choice (b) trials in the novel location recognition (NLR) task, after
treatment with eP/saline. There was no significant difference in exploration time of either
object for both groups in the familiarisation trial (Student's paired t-test). In the choice trial,
both groups spent significantly longer exploring the object in the novel location (p<O.OS,
Student's paired t-test). Preference indices (PI, Cc), mean ± SEM, n:::::12)were created by
expressing time spent exploring the object in the novel location as a percentage of the sum of
exploration time of novel and familiar locations in the choice trial (Bruel-Jungerman et at.
2005). The PI were not significantly different between groups (Student's unpaired t-test) but
PI of both groups were significantly different from chance (p<O.OS, Student's unpaired z-test),
The total exploration time (mean ± SEM, n:::::12)for both trials combined (d) did not differ
significantly between groups (Student's unpaired z-test).
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Figure 2.10 Velocity (mean ± SEM) of rats (n=12) was not significantly different between
groups either before (a) or after (b) CP/saline treatment (Student's unpaired r-test),
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2.3.3.3 CP does not reduce cell proliferation in the SGZ
Ki67 was used to investigate the effect of CP on the number of cells proliferating in the SGZ
of the dentate gyrus (Fig. 2.11a-c). No significant difference was found for the amount of
Ki67-positive cells between the groups (Student's unpaired r-test, Fig. 2.11 d), suggesting that
the CP regimen in the present study does not affect cells dividing in the dentate gyrus 7 days
after it was administered.
2.3.3.4 CP reduces the survival of new-born hippocampal cells
BrdU was injected on the day of the first CP/saline injection to investigate the survival of the
cells which were dividing at that time (Fig. 2.12a-c). Animals receiving CP had significantly
fewer BrdU-positive cells in the dentate gyrus (p<O.05, Student's unpaired r-test, Fig. 2.12d),
indicating that CP reduced the survival of the cells dividing in the SGZ of the dentate gyrus at
the start of treatment.
2.3.3.5 Expression 0/DXC
Western blotting analysis was performed to determine the effects of CP on levels of DCX in
the hippocampus and frontal cortex (Fig. 2.13). Whole brain was used as a positive control for
DCX, but it is not shown on this immunoblot. Protein levels of DCX, a cytoskeletal protein
transiently expressed in immature neurons, were normalised by comparison with the p-actin
loading control. A student's unpaired r-test showed no significant difference in DXC
expression between the CP treated group and saline treated controls in either the hippocampus
(Fig. 2.13c) or the frontal cortex (Fig. 2.13d).
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Figure 2.11 Representative photographs of the nuclei of cells in the SGZ of the dentate gyrus
from the vehicle group (blue, a), Ki67-positive cells (red, b) and the photos merged (c). Bar
scales indicate 20llm. There was no significant difference (Student's unpaired t-test) between
groups of the total numbers of Ki67-positive cells (mean ± SEM, n=12, d).
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Figure 2.12 Representative photographs of the nuclei of cells in the dentate gyrus from the
vehicle group (blue, a), BrdU-positive cells (green, b) and the photos merged (c). Bar scales
indicate 20j.lm. Total numbers of BrdU-positive cells (mean ± SEM, n=12) in the dentate
gyrus were estimated from cell counts (d). Rats receiving CP had significantly fewer BrdU-
positive cells (p<O.OS, Student's unpaired r-test) in the SGZ than the saline-treated control
group.
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Figure 2.13 Example photomicrograph of immunblot bands from Western blotting (a)
showing expression of DCX (red, at 47 kDa) and ~-actin (green, at 43 kDa). Levels of DCX
(mean ± SEM, n=6) in the hippocampus (b) and frontal cortex (c) of control and CP treated
animals, normalised by ~-actin loading control, were not significantly different (Student's
unpaired r-test).
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2.4 Discussion
In the present study a rat model was used to investigate the effects of CP on cognition and the
survival and proliferation of newly generated hippocampal cells.
One memory task (the NLR task) was used in the present study, it was chosen over the NOR
task to test spatial working memory, as it is hippocampal dependent (Dere et al. 2007; Mumby
et al. 2002). Furthermore, it does not rely on any positive or negative reinforcers which may
confound results. The results showed that before any treatment both groups of animals were
able to distinguish an object in a novel location from that in a familiar, demonstrating that they
were able to perform the task correctly. After treatment, animals which had received a series
of CP injections still spent significantly longer exploring the object in the novel location, and
did not significantly differ from the control group. This indicates that the dose and
administration ofCP used in the present study did not affect the rats' ability in this task. Other
studies using rodent models within the literature have shown a mixture of results in regard to
the effect of CP on cognition. Lee at al. (2006) found that 4, 100mglkg doses of CP, 4 weeks
apart, caused an improvement in Morris water maze performance in rat. However, other
authors giving 4 weekly doses of 25mglkg CP found an impairment in a passive avoidance
test a week after treatment in female rats (Konat et al. 2008). Furthermore, Macleod et al.
(2007) found a sub-chronic weekly dose of 40mglkg of CP impaired context specific, but not
cue specific conditioned emotional response in rat a week after the final injection. These
differences may be explained by the different dosages and different behavioural tests used. It
would be interesting to use further behavioural tests to investigate the effect of dosing regimen
used in the present study on different cognitive domains in rat. Studies on mice have found an
acute affect (within 24 hours) on memory but recovery within a period of days (2006; Yang et
al. 2010). The results in the present study demonstrate that CP causes no deficit in the NLR
task 6 days after the final CP injection. However this does not preclude the possibility that CP
may have acute effects on memory which recover over a short time period. It is also possible
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that CP may have longer term effects which have not been examined in the present study.
Such time course issues are further explored in later studies using 5-FU in the present thesis.
New neurons in the dentate gyrus have been shown to be preferentially used in spatial learning
tasks (Kee et at. 2007) and reductions in dentate gyrus neurogenesis impair the ability of
animals to perform these tasks (lmayoshi et at. 2008). It is estimated that over 80% of
dividing cells in the adult rat SGZ are destined to become dentate gyrus neurons (Snyder et al.
2009). In the present study, no significant difference was seen between control and CP treated
groups in levels of DCX in the hippocampus and the frontal cortex. DCX is a protein
expressed in immature neurons so is used as a marker for neurogenesis rather than
proliferating cells (Zhao et al. 2008), suggesting that CP did not reduce the number of newly
generated neurons in the hippocampus. Levels of DCX were also investigated in the frontal
cortex to determine the effect of CP on other brain regions, and again no significant difference
was found between CP and control groups. DCX in the frontal cortex most probably arises
from newborn neurons migrating along the rostral migratory stream from the SVZ to the
olfactory bulb (Zhao et at. 2008). Furthermore, the number of cells proliferating (Ki67-
positive) in the SGZ of the dentate gyrus, a week after the final injection, was not affected by
CP compared to the control group, although the number of Brdl.I-positive cells was
significantly reduced. This reduction suggests that the survival of the cells which were
dividing at the beginning of the experiment was lower in rats that received CP, indicating the
drug is cytotoxic to newly generated hippocampal cells. This might be an explanation for the
acute effects on behaviour found in some studies (Reiriz 2006; Yang et al. 2010). This
conclusion is in line with recent studies showing that cell proliferation is reduced the day after
CP administration (Janel sins et al. 20 I0) but gradually recovers over the following days (Yang
et al. 2010), correlating with cognitive performance. It would be interesting to look at the
effects of CP on cognition, cell proliferation and survival over a longer time period as another
alkylating agent, thioTEPA, caused an initial reduction in hippocampal cell proliferation in
mice, followed by a transient 3 week recovery. This in turn was followed by a long-term
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deficiency in cell proliferation lasting for 3 months and these deficiencies were roughly
correlated with spatial cognitive decline (Mondie et al. ZO 10).
Collectively, the results of different studies of CP on cognition and neurogenesis, still do not
paint a clear picture. Drug delivery, with respect to route of administration, dosage and time
course has differed between studies as have the behavioural tests used. Evidence from the
previous studies suggests that CP may have an acute effect on cells proliferating in the SGZ of
the adult dentate gyrus during which time animals may display cognitive deficits. However, it
appears likely that the reduction in cell proliferation and spatial cognition is subtle and
reversible. CP is broken down by aldehyde dehydrogenase 3 (ALDH3) present in the brain
which converts CP into non-toxic metabolites (Bunting and Townsend 1996). The presence of
this enzyme may make the effects of CP relatively short lasting compared with other
chemotherapy agents.
CP is often administered with MTX and 5-FU, a combination known as CMF. This drug
cocktail has been associated with cognitive impairment in patient studies (Kreukels et al.
2008; Schagen et al. 2002a) and several rodent models have been used to investigate the
individual drugs. In the majority of studies, 5-FU has been shown to chronically impair
memory and reduce proliferation in the dentate gyrus of the hippocampus for weeks after
treatment has ended (EIBeltagy et al. 2010; Gandal et al. 2008; Winocur et al. 2006).
Likewise, the negative effect of MTX on cognition and proliferation has also been shown to
last for weeks (Foley et al. 2008; Gandal et al. 2008; Seigers et al. 2008). Indeed, a previous
experiment within our laboratory demonstrated that 5-FU caused rats to be impaired in the
NLR task and reduced the proliferation and survival of hippocampal cells (EIBeltagy et al.
2010). Furthermore, in experiments which are presented in Chapter 3 and Chapter 4 of this
thesis, administration of both 5-FU and MTX cause cognitive impairment in an identical NLR
task as described in the present study and significantly reduce hippocampal cell proliferation
and survival. When comparing this to the effect ofCP in the present study, it indicates that CP
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is less toxic than the other drugs in the CMF combination. As no dose-response analysis was
executed, it is possible that a higher dose of CP may have yielded different results. However,
the present findings suggest that although CP may acutely impair spatial cognition and reduce
the survival of newly generated hippocampal cells, this is reversible in a matter of days and it
is likely to be the other chemotherapy drugs which cause long-term cognitive impairment.
This work has been recently published (Lyons et al. 2011a).
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Chapter S
Fluoxetine reverses the memory impairment and reduction
in proliferation and survival of hippocampal cells caused by
methotrexate chemotherapy in the rat
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3.1 Introduction
As discussed in the previous chapters of this thesis, many patients who have received adjuvant
chemotherapy to treat cancer have experienced long-lasting cognitive deficits including the
reduced ability to form new memories, lack of concentration and general confusion (Ahles et
al. 2002; Matsuda et al. 2005; Taillibert et al. 2007). There is evidence to suggest that the
effects of cytotoxic drugs on hippocampal neurogenesis is a potential mechanism for the
cognitive impairments seen (ElBeltagy et al. 2010; Mustafa et al. 2008; Seigers et al. 2007;
Yang et al. 2010). The effects of the chemotherapy agent, CP, on cognition and hippocampal
changes were investigated in the previous chapter. In the present chapter the effects of MTX,
another chemotherapy agent from the CMF combination (see section 1.2, Chapter 1), are
examined to investigate whether this chemotherapeutic drug has more significant effects on
spatial memory and cellular changes in the hippocampus. Furthermore, in this chapter, the
reversal of cognitive and cellular deficits caused by MTX, by the co-administration of the
SSRI antidepressant, tluoxetine is demonstrated.
Despite the increasing body of evidence for chemotherapy-induced cognitive impairment, the
mechanisms causing this are still not understood and there have been few attempts to
counteract it. Fluoxetine is an SSRI antidepressant reported to improve the memory deficits
seen in patients with mild cognitive impairment (Mowla et al. 2007), depression (Gallassi et
al. 2006; Levkovitz et al. 2002; Vythilingam et al. 2004), post traumatic stress disorder
(Vermetten et al. 2003) and traumatic brain injury (Horsfield et al. 2002). These results are
supported by rodent investigations showing that tluoxetine increases the levels of brain
derived neurotrophic factor (BDNF) (Alme et al. 2007; Duman and Monteggia 2006), the rate
of neurogenesis (Chen et al. 2006; Duman 2004; Marcussen et al. 2008) and the survival of
new neurons (Duman et al. 1999; Hitoshi et al. 2007) in the hippocampus. All of these factors
are thought to play a role in memory consolidation (Kitabatake et al. 2007; Lledo et al. 2006a;
Zhao et al. 2008). While tluoxetine may not have any beneficial effects on healthy subjects
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(Monleon et al. 2007), a recent study from our group in Nottingham found that it can improve
cognition after 5-FU chemotherapy in rats (EIBeitagy et al. 20 I0).
The present study investigates whether fluoxetine alters the cognitive deficits induced by
MTX chemotherapy in rats, and examines its effect on neurogenesis in the hippocampus.
MTX is an antimetabolite, commonly used to treat several types of cancer including breast
cancer (Rousseau et al. 2000) and is often used in adjuvant chemotherapy combinations which
have been associated with impaired cognition (Falleti et al. 2005; Matsuda et al. 2005) (see
section 1.1.3.1, Chapter 1). When MTX is used in high doses, LCV is often administered
chronically after it to reduce toxicity. MTX is an inhibitor of tetrahydrofolate (THF A)
reductase and THF A is necessary for DNA synthesis. LCV is a THF A which doesn't require
THF A reductase, replenishing pools depleted by MTX (Genestier et al. 2000; Seigers et al.
2007) (see section 1.2.4.1, Chapter 1). The dose of MTX and protocol chosen in the present
study matches that used clinically (Lobo and Balthasar 2002; Peters et al. 1993), and has been
used by Seigers et al. who found that it significantly suppressed hippocampal cell proliferation
in the adult rat (Seigers et al. 2007). Fluoxetine was delivered orally to mimic clinical
administration and to prevent the stress of injection. The dose was chosen from previous work
in our laboratory which showed that it could counteract the memory deficits caused by the
chemotherapy agent 5-FU (EIBeltagy et al. 2010). Fluoxetine was given for 40 days before
during and after MTX treatment as it takes at least 21 days in rat to have anxiolytic effects
(Conley and Hutson 2007) and increase neurogenesis in the hippocampus (Kodama et al.
2004). Spatial memory was tested 6 days after the end of fluoxetine treatment, as it takes 3
days to wash out of the system (Caccia et al. 1990), using the NLR task (Dix and Aggleton
1999) and a further 6 days later using the spontaneous alternation in the T-maze task. The
effects of MTX on both survival and proliferation of new-born hippocampal neurons was
determined.
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3.2 Materials and methods
3.2.1 Animals and treatment
Male Lister-hooded rats (150-200g; Charles River, UK, total n=47) were randomly allocated
to vehicle (n=I2), MTXlLCV (n=I2), fluoxetine (n=I2) or MTx/LCV + fluoxetine (n=II)
groups. Rats were housed as described in section 2.2.1.1, Chapter 1 and allowed to habituate
for 2 weeks prior to drug administration.
Rats in MTX/LCV groups were administered MTX (75mg/kg, two i.v. doses a week apart, at a
volume of 0.5mllkg; Mayne Pharma Pic, UK) and rats in non-MTXILCV groups were given
an identical volume of 0.9% sterile saline (i.v. , Fig. 3.1). LCV (CP Pharmaceuticals, UK), or
saline for non-MTx/LCV groups, was administered i.p.lS h after each MTX injection at
6mg/kg and 26, 42 and 50 h after at 3mg/kg (at a volume of 1ml/kg), BrdU was administered
to all groups immediately after their first injection (250mg/kg, i.p., at a volume of 5mllkg;
pH7; Sigma Aldrich, UK, Fig. 3.1).
Mean water consumption and animal weight were monitored throughout the experiment.
Fluoxetine (Pinewood Healthcare, Ireland, Oral solution) was administered in drinking water
at a dose of 10mglkg/day, estimated from the water consumption within each cage and
calculated on a daily basis. This was seen to be advantageous as it avoided the possible stress
caused by isolation housing (Sharp et al. 2002). Fluoxetine-treated drinking water was
administered to animals in these groups for 40 days, starting 9 days prior to first MTX
injection (Fig. 3.1).
MTX or saline equivalent was administered by i.v. injection to the tail vein in 0.9% saline
under isofluorane anaesthetic. Injection courses began three weeks after animal arrival.
Throughout the experiment, rats were maintained with a 12 h light/dark cycle (7.00/19.00 h)
with ad libitum food and water. Principles of laboratory animal care were in accordance to
UK Home Office Guidance regulations and with local ethical committee approval.
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Figure 3.1 Time line showing protocol of drug administration and behavioural testing.
Arrows represent single i.p. injections of BrdU (fine) and MTX/saline (thick). MTXlsaline
injections were followed by 4 leucovorin/saline i.p. injections 18, 26, 42 and 50 h after (not
shown). The bracket represents the period of time for which fluoxetine was administered in the
drinking water. The day after novel location recognition (NLR) behavioural testing, animals
were killed and their brains were removed.
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3.2.2 Behavioural testing
3.2.2.1 NLR task
The NLR test was carried out (as described in section 2.3.2.2.1., Chapter 2) 6 days after
fluoxetine treatment ended. The task was only carried out after treatment with MTX and not
before so the rats would have no prior experience of the objects and locations before the test
was carried out to avoid any possibility of confounding the results. EthoVision 4.1 was used
to measure the mean velocity of the rats during the 30 min habituation, 24 h prior to testing.
Exploration times of both objects and trials were recorded blind twice and averaged using a
stopwatch from digitised recordings, so no observer was in the room during the trials. The
exploration data of all animals was included in the analysis.
3.2.2.2 Spontaneous alternation in the Tsmaze
The spontaneous alternation in the T-maze task was adapted from Deacon and Rawlings
(2006) and carried out 6 days after completion of the NLR task. It relies on the nature of rats
to preferentially choose the novel path in subsequent trials in the maze (see section 1.10,
Chapter 1). Immediately before the start of the test, the rat was handled for 1 min. The rat
was placed in the base of the T-maze (a black, opaque, Perspex box; dimensions: III total
width x 49 arm length x 42 height x 13 arm width em, Fig 3.2) facing the wall of the maze. It
was left to run down the maze and turn into the left or right arm where a partition was put
down, to trap the rat in the arm for 25 sec (Fig 3.2). The rat was handled in between trials for
30 sec, placed back in the base of the maze and allowed to run. It was again trapped in the
arm of the maze it chose. This was repeated a total 7 times. If the rat chose the opposite arm
from the previous run, it was scored as a correct trial (a total of 6 test trials). If the rat did not
run for 1 min, the trial was restarted. The maze was cleaned with 20% ethanol between
experiments to remove olfactory cues, but not between trials. The percentage of correct trials
was recorded for each animal. The T-maze data of all animals was included in the analysis.
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Figure 3.2 Spontaneous alternation in the T-maze task. Rats were placed in the base of the T-
maze and allowed to run down one arm of the maze, where they were trapped by a partition
for 25 sec. They were then removed for 30 sec, then placed back at the base of the T-maze
and allowed to run down one arm of the maze again. They were then trapped for a further 25
seconds. This was repeated a total of 7 times (6 trials). A rat without impaired memory will
normally alternate between arms each trial.
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3.2.3 Brain tissuepreparation
The day after behavioural testing was completed, rats were terminated by rapid concussion
and confirmed by immediate cervical dislocation. Brains were prepared (as described in
section 2.3.2.3, Chapter 2) and sections were mounted on to APES-coated slides and stored at
-20·C until used for immunohistochemistry.
3.2.4 Ki67 and BrdU immunohistochemistry
Immunohistochemistry, microscopy and quantification of Ki67 and BrdU-positive cells were
carried out as described previously (section 2.3.2.4, Chapter 2). All counting was performed
blind.
3.2.5 Statistical analysis
Statistical analysis and graphs were created using GraphPad Prism 5 and significance was
regarded as p<O.05. Student's paired r-tests were used to compare exploration times of
animals in the familiarisation and choice trials. Preference indices (PI) were created by
expressing time spent exploring the object in the novel location as a percentage of the sum of
exploration time of novel and familiar locations in the choice trial, to create a single value to
compare between groups. PI were compared to 50% chance using a one-sample r-test. One-
way ANOV A was used to compare PI, total exploration time and average velocity of the
animals, percentage correct trials in the T-maze and cells counts. Two-way repeated measures
ANOVA was run to determine difference in animal weight between treatment groups. When
ANOV A was significant Bonferonni post-hoc test was performed.
3.3 Results
3.3.1 MTX andfluoxetlne reduce weightgain andj1uid intake
Rats treated with MTXlLCV, tluoxetine or both in combination gained significantly less
weight compared to vehicle treated controls and this change persisted to the end of the study
(F3,43=4.l6, p<O.OO I, two-way repeated measures ANOV A, Fig. 3.3a and b). This was
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attributed to disruption of intestinal absorption caused by MTX (Cameiro-Filho et al. 2004)
and fluoxetine (Freeman et al. 2006). A significant effect of time and treatment x time
interaction was also confirmed (FS6.2408= 1793, FI68.2408=4.93 respectively, p<O.OOO 1 for both).
Treatment and time significantly affected the amount of water drunk (F3.384=S.82, p<O.OS,
F48.384=29.34, p<O.OOI respectively, two-way repeated measures ANOVA, Fig 3.4). However,
by the last day of fluoxetine treatment no significant difference was seen (one-way ANOVA).
The animals remained in good health throughout the study and never lost more than 10% of
their maximum body weight.
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Figure 3.3 Body weights of rats (mean ± SEM, n= 11-12) from the first day of fluoxetine
administration (a) and during the MTX treatment period only (in detail, b). Arrows at day 9
and 16 indicate MTXlsaline injections (BrdU was also administered on day 9). Fluoxetine
was given in drinking water from day 1 to day 40. Rats treated with MTXILCV, fluoxetine or
both in combination gained significantly less weight compared to vehicle treated controls
(F3,43=4.16, p<O.OOI, two-way repeated measures ANOVA). The effect of time and treatment
x time interaction was significant (F56.:!40s=1793, F168.:!40S=4.93 respectively, p<O.OOOl for
both).
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Figure 3.4 Fluid intake of rats (mean ± SEM, n=11-12) from the first day of fluoxetine
administration represented as ml/kg. Treatment and time significantly affected the amount of
water drunk (F3.384=5.82, p<0.05, F48.384=29.34, p<O.OOl respectively, two-way repeated
measures ANOYA).
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3.3.2 Fluoxetine prevents the spatial working memory deficits in the NLR task caused by
MTX
The NLR test was used to observe the effects of MTXlLCV and fluoxetine on spatial working
memory. None of the treatment groups showed a significant difference in the exploration time
of the two objects in the familiarisation trial (Fig. 3.5), indicating no preference for the
location of either object. In the choice trial, Student's paired z-tests revealed that the vehicle
and tluoxetine-treated groups explored the object in a novel location to a significantly greater
extent (p<0.01, Fig. 3.6), suggesting unaffected spatial working memory (Dix and Aggleton
1999). In contrast, the MTXILCV group showed no preference for either the novel or familiar
object, showing no significant difference between exploration time for each object. This result
indicates that MTX treatment caused a deficit in spatial working memory. The rats which
were administered both MTXlLCV and tluoxetine showed a significant preference for the
object in the novel location (p<O.05) in the choice trial, indicating that this group behaved
similarly to control or tluoxetine-treated rats and did not show the spatial memory deficit
exhibited by the MTX group. Further analysis was carried out on exploration times within the
choice trial by conversion of raw data into a PI (Bruel-Jungerman et al. 2005) (Fig. 3.7). PI
were created by expressing time spent exploring the object in the novel location as a
percentage of the sum of exploration time of novel and familiar locations. The present results
showed that the mean PI of the vehicle, tluoxetine and MTX/LCV + fluoxetine groups were
significantly different from 50% chance (one-sample t-test), while the PI of the MTX group
was not. Using the PI for comparison between groups using ANOV A however, showed no
significant difference between treatment groups (F3,43=1.85). Unexpectedly one-way ANOVA
revealed that the total exploration time in the familiarisation trial (Fig. 3.8a) was significantly
higher for the tluoxetine group compared to each other group (F3,44==12.11, p<O.05),
suggesting that fluoxetine may cause the animals to be more inquisitive. The extra time spent
exploring and learning the object locations in the familiarisation trial may also be an
explanation for their improved performance in the choice trial compared to the controls.
However, no difference was seen between total exploration time in the choice trial
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(F3,44=3.244, one-way ANOVA, Fig. 3.8b). No significant difference between mean
locomotor velocity (recorded during the habituation period) (F3,43=2.70, Fig. 3.9) was found
between the groups indicating that the different treatments did not impair activity of the rats.
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Figure 3.5 Exploration times (mean ± SEM, n=11-12) of the rats for each object in the
familiarisation trial of the novel location recognition (NLR) task. None of the groups spent a
significantly different time exploring either of the two objects (Student's paired t-test).
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Figure 3.6 Exploration times (mean ± SEM, n=11-12) of the rats for each object in the choice
trial of the novel location recognition (NLR) task. Vehicle-treated, tluoxetine-treated and
MTXlLCV administered with t1uoxetine-treated rats spent significantly longer exploring the
object in the novel location compared with the familiar location (*p<O.05, **p<O.Ol, Student's
paired r-test), whereas MTXlLCV failed to show a similar significant discrimination
(Student's paired t-test).
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Figure 3.7 Preference indices (PI) of each treatment group (mean ± SEM, n=11-12) were
created by expressing time spent exploring the object in the novel location as a percentage of
the sum of exploration time of novel and familiar locations in the choice trial (Bruel-
Jungerman et al. 2005). Compared to 50% chance, mean PI of the vehicle, fluoxetine and
MTXlLCV+fluoxetine groups were significantly different (*p<O.OS, **p<O.Ol, one-sample t-
test), whilst the MTXILCV group was not. PI were not significantly different between groups
(one-way ANOVA).
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Figure 3.8 The total exploration time (mean ± SEM, n=11-12) was significantly higher for
the fluoxetine group compared to the control group (F3,44=12.ll, p<O.05, one-way ANOVA,
n=II-12) in the familiarisation trial (a). No significant difference (F3,44=3.244, one-way
ANOVA, n=II-12) was found between groups in the choice trial (b).
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Figure 3.9 Velocity (mean ± SEM) of rats (n=11-12) was not significantly different between
groups (one-way ANOVA),
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3.3.3 MTX andfluoxetine do not alter spontaneous alternation in tile Ti-maze
The spontaneous alternation in the T-rnaze task was also used to assess the effects of
MTXlLCV and fluoxetine on cognition. No significant difference was found between
percentage of correct turns for any of the groups (one-way ANOV A, Fig. 3.10), indicating that
neither MTX nor fluoxetine influence cognition in this task.
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Figure 3.10 Percentage of correct turns (mean ± SEM, n=11-12) in spontaneous alternation in
the T-maze. No significant difference was found between any of the groups (one-way
ANOVA).
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3.3.4 Fluoxetine prevents the reduction in cell proliferation in the SGZ caused byMTX
Ki67 was used to quantify the numbers of dividing cells in the SGZ of the dentate gyrus in all
treatment groups at the end of the experiment (Fig. 3.11). A one-way ANOVA showed
significant differences between mean Ki67-positive cell counts (F3•24=I1.S8, p<O.OOI, Fig.
3.11). Further analysis with a Bonferroni post hoc test revealed that rats treated only with
MTXlLCV had a significantly reduced number of Ki67-positive cells (p<O.OS). In contrast,
rats treated only with fluoxetine had more Ki67-positive cells compared with the controls, a
significant increase (p<O.OS). Rats treated with both MTx/LCV and fluoxetine showed no
significant difference in from the controls, but had significantly more Ki67-positive cells than
the group treated with MTX/LCV alone (p<O.OS) indicating that the fluoxetine had prevented
the reduction in cell proliferation caused by MTXILCV.
3.3.5 Fluoxetine reverses reduction in new-born hippocampal cell survival caused by
MTX
BrdU was administered to rats on the first day of either saline or MTx/LCV injections to label
cells undergoing division at the start of treatment. BrdU-positive cells were quantified at the
end of the experiment to determine the survival of these cells (Fig 3.12a-c). A one-way
ANOVA showed significant differences between mean Ki67-positive cell counts (F3•20=24.34,
p<O.OOI, Fig. 3.12d). Bonferroni post hoc test revealed that MTx/LCV treatment
significantly reduced the number of BrdU-positive cells (p<O.OOI) compared to vehicle-treated
controls indicating that the chemotherapy, as well as reducing cell proliferation was reducing
the survival of cells dividing at the start of treatment. Treatment with fluoxetine alone
significantly increased BrdU-positive cell numbers (p<O.OS). Animals co-treated with
MTx/LCV and fluoxetine showed no significant difference in the BrdU-positive cell numbers
from the control animals, but had significantly more BrdU-positive cells than the group treated
with MTX/LCV alone (p<O.OO 1). These results suggest that fluoxetine can protect newly
dividing precursors in the dentate gyrus from MTX-induced loss.
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Figure 3.11 Representative photographs of the nuclei of cells in the SGZ of the dentate gyrus
from the vehicle group (blue, a), Ki67-positive cells (red, b) and the photos merged (c). Bar
scales indicate 20llm. Total numbers of Ki67-positive cells (mean ± SEM, n=11-12) in the
dentate gyrus were estimated from cell counts (d). Rats receiving MTX/LCY had significantly
fewer Ki67-positive cells (p<O.05, one-way ANOYA) in the subgranular zone (SGZ) and rats
receiving fluoxetine had significantly more (p<O.05, one-way ANOVA) than the saline-treated
control group. Rats treated with both MTX/LCY and fluoxetine did not significantly differ
from the controls but had significantly more Ki67-positive cells than the MTXlLCV group
(tp<O.05, one-way ANOVA).
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Figure 3.12 Representative photographs of the nuclei of cells in the dentate gyrus from the
vehicle group (blue, a), BrdU-positive cells (green, b) and the photos merged (c). Bar scales
indicate 20llm. Total numbers of BrdU-positive cells (mean ± SEM, n=l1-12) in the dentate
gyrus were estimated from cell counts (d). Rats receiving MTXlLCV had significantly fewer
BrdU-positive cells (***p<O.OOl, one-way ANOVA) in the SGZ and rats receiving fluoxetine
had significantly more (*p<O.05, one-way ANOVA) than the saline-treated control group.
Treatment groups receiving both MTXlLCV and fluoxetine did not significantly differ from
the controls but had significantly more BrdU-positive cells than the MTXlLCV group
(tttp<O.OOl, one-way ANOVA).
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3.4 Discussion
In the present study, the effects of MTX chemotherapy on spatial working memory and the
effects of the chemotherapy agent on cell proliferation and survival in the dentate gyrus of the
adult hippocampus were determined. Both the NLR task and spontaneous alternation in the T-
maze task were used to assess spatial working memory. These tasks were chosen as they are
both based upon rats' spontaneous preference towards novelty as opposed to positive and
negative reinforcements and animals are impaired in both tasks after hippocampal lesions
(Deacon and Rawlins 2005; Lalonde 2002; Lee et al. 2005; Mumby et al. 2002). In addition,
it was demonstrated that the SSRI antidepressant, fluoxetine, could counteract the behavioural
and cellular effects of MTX in a rodent model.
The SGZ of the dentate gyrus is one of the brain regions where the formation of new neurons
continues throughout life (Ehninger and Kempermann 2008). Newly formed dentate gyrus
neurons have been shown to be preferentially used in spatial learning tasks (Kee et al. 2007)
and reductions in dentate gyrus neurogenesis cause deficits in the ability of animals to perform
these tasks (lmayoshi et al. 2008). It has been suggested from previous work in our laboratory
and elsewhere that chemotherapy may reduce hippocampal neurogenesis and cause deficits in
the cognitive domains dependent upon this process (Dietrich et al. 2006; EIBeltagy et al. 2010;
Han et al. 2008b; Mustafa et al. 2008; Seigers et al. 2009). It was previously considered that
systemic chemotherapy does not cross the blood brain barrier and so would have little effect
on the brain, however, it has now been shown that many chemotherapy agents, including
MTX when administered in high doses, can access the brain in significant concentrations
(Lassman et al. 2006).
In the present study, animals receiving a 2 week course of MTXlLCV treatment were unable
to recognise an object in a novel location from an object in an old location in the NLR
behavioural test, 5 weeks after treatment had ended. However, animals treated with both
MTXlLCV and fluoxetine were able to distinguish the objects. This indicates that MTX
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causes a decline in spatial working memory compared to vehicle-treated controls or fluoxetine
alone, which is counteracted by the co-administration of fluoxetine. A PI was derived from
the exploration data for each animal in the choice trial to produce a single value for
comparison between groups. Although the PI of each group other than MTX treated animals
significantly differed from chance, consistent with the specific analysis of the group
differences, no significant variation was found between groups by ANOV A, indicating that the
memory deficit seen is subtle. Conversely, no difference was seen between any of the groups
in their ability in the spontaneous alternation in the T-maze task. Both the T-maze and the
NLR task are tasks of spatial working memory, and require an intact hippocampus to be
performed (Deacon and Rawlins 2006; Dere et al. 2007). Therefore this difference in ability
to perform the two tasks was unexpected, possibly because the cognitive impairment caused
by MTX treatment was too subtle for the T-maze task to detect, and hence the task was
modified to be more difficult in the study presented in the subsequent chapter.
The data from the NLR task supports previous reports that chemotherapy can cause spatial
memory deficits in both patients (Ahles and Saykin 2002; Matsuda et al. 2005) and animals
(ElBeltagy et al. 2010; Gandal et al. 2008; Mustafa et al. 2008; Yang et al. 2010). In
particular high doses of MTX have been shown to produce spatial memory deficits in rats as
measured in the Morris water maze, novel object recognition and an instrumental go/no-go
task (Fardell et al. 2010; Seigers et al. 2007; Seigers et al. 2009). Furthermore, Fardell et al.
(2010) demonstrated that these effects were both short and long-term, continuing for 8 months
after treatment, suggesting that MTX has a lasting effect on behaviour.
The present work is consistent with these findings and in addition shows that lower doses are
able to produce significant impairments in the NLR test 5 weeks after termination of the
treatment. These results are comparable to clinical observations of breast cancer sufferers
showing memory deficits after chemotherapy (Matsuda et al. 2005). Most patient studies
which have detected cognitive effects of chemotherapy have looked at breast cancer survivors
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who have received a combination of chemotherapy agents including MTX (Brezden et al.
2000; Wieneke and Dienst 1995). LCV, used here as a recovery drug for the toxic effects of
MTX, has been shown to have subtle cognitive benefits in aged rats with a folate deficiency in
the hippocampal-dependent T-maze task, but not in psychomotor and motor activity and
Morris water maze spatial learning tasks. However LCV is thought not to have a cognitive
effect on rats with sufficient folate (Lalonde et al. 1993) and Seigers et al. (2009) found it had
no effect on neurogenesis when used alone. This allows us to attribute the deficits in memory
and neurogenesis seen in the present study to the MTX chemotherapy.
As spatial learning is thought to depend on both the production and the survival of new-born
neurons in the dentate gyrus (Dupret et al. 2007), the effect of MTX on both were investigated.
In the present study, MTXlLCV reduced the number of dividing cells in the SGZ of the
dentate gyrus compared to the control group. Survival of cells dividing at the time of the first
MTx/LCV injection was also severely reduced at this time point. These results suggest that
the action of MTX on neurogenesis and new neuron survival provides a mechanism for the
long-term cognitive effects produced by this chemotherapy agent.
Fluoxetine is known to improve memory in patients with impaired cognition (Gallassi et al.
2006; Levkovitz et al. 2002; Mowla et al. 2007) and to increase the number of neurons
produced during adult neurogenesis in the rodent hippocampus (Kodama et al. 2004;
Marcussen et al. 2008). For these reasons co-administration of tluoxetine with MTX was
tested to see if it could prevent the changes produced by MTX chemotherapy. The results
show that both the behavioural and cellular deficits were prevented when tluoxetine was given
for 40 days. Fluoxetine alone had no effect on PI, or average velocity, but increased total
exploration time of animals. Work in our group has previously shown that tluoxetine can
prevent the cognitive deficits produced by 5-FU (ElBeltagy et al. 2010), while the present
study is the first to demonstrate a reversal of the cognitive deficit induced by MTX, suggesting
that fluoxetine may be able to prevent the cognitive deficits induced by a range of
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chemotherapy drugs. The mechanism by which fluoxetine is having these effects is unclear.
Fluoxetine may have little effect on cognition or neurogenesis in healthy animals (Huang et al.
2008a; Monleon et al. 2007), but has been shown to be neuroprotective after injury (Chiou et
al. 2006b; Jin et al. 2009) and to up-regulate hippocampal neurogenesis when it is reduced
(Duman 2004; Duman et al. 2001a; Feldmann et al. 2007). Fluoxetine has also been shown to
reduce apoptosis in adult rat dentate gyrus (Egeland et al. 2011) and inhibit apoptosis in stem
cell cultures derived from the adult rat hippocampus (Chen et at. 2007; Chiou et at. 2006a).
Interestingly, unlike the results shown in the present study, previous work from our group
found that fluoxetine did not increase proliferation of cells within the dentate gyrus when
administered without chemotherapy (ElBeltagy et al. 2010). This could be attributed to the
increased length of time that the animals received the antidepressant (from 21 days in the
previous study to 40 in the present) highlighting the importance of the period of time for
which fluoxetine is administered.
Further work is needed in both animals and humans to examine the impact of other
antidepressants and to determine the effects of different chemotherapy agents. In the
following chapter another chemotherapy agent from the CMF combination, S-FU, is
investigated and its effects on spatial working memory and hippocampal changes are
demonstrated. Furthermore, as work in the present chapter has shown that chronic
chemotherapy treatment still affects cognition and cell proliferation in the hippocampus after
treatment has terminated, the time course of when it would be beneficial to administer
antidepressants to reverse these deficits was examined in the following study.
In addition, fluoxetine has been reported to increase levels of BDNF (Alme et al. 2007;
Duman and Monteggia 2006), a neurotrophic factor which regulates neurogenesis (Alme et al.
2007; Duman et al. 2001a). Further work to quantify levels ofBDNF within the hippocampus
may help to understand the pathways by which fluoxetine acts in these situations and this was
investigated in the subsequent chapter.
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In conclusion, this study reveals MTX chemotherapy causes cognitive impairments and a
reduction in both the proliferation and survival of neural precursors in the hippocampus.
Furthermore, these impairments were reversed by the co-administration of the SSRI
antidepressant, tluoxetine, suggesting that it has a neuro-protective effect. If the effects of the
tluoxetine demonstrated in the present study can be translated to patients it could provide a
relatively simple means to alleviate the cognitive effects experienced by some cancer patients.
This finding not only has potential to improve the quality of life for cancer survivors, but
provides further information on chemotherapy-induced cognitive deficits and methods to
counteract it. This work has been recently published (Lyons et at. 2011b).
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Chapter4
Fluoxetine counteracts the cognitive and cellular effects of
5-fluorouracil in the rat hippocampus by a mechanism of
prevention rather than recovery
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4.1 Introduction
CMF (CP: cyclophosphamide, MTX: methotrexate and 5-FU: 5-fluorouracil) is a
chemotherapy combination used clinically for the treatment of breast cancer and has been
reported to cause cognitive impairment in patient studies (Kreukels et al. 2008; Schagen et al.
2002a) (see section 1.1.2, Chapter 1). In the previous chapters of this thesis the cognitive
effects of CP and MTX were determined along with their effects on the generation of new
cells in the adult hippocampus (see Chapters 2 and 3). Furthermore it was shown that the
negative effects on memory and hippocampal cell proliferation and survival caused by MTX
were counteracted with the SSRI antidepressant, fluoxetine, when it was co-administered with
the MTX (Chapter 3). In the study presented in the present chapter, the effects of S-FU, the
final chemotherapy agent in the CMF combination, on cognition and hippocampal cell
survival and proliferation were determined. This is a continuation of studying the effect of 5-
FU and fluoxetine in our group (EIBeltagy et al. 20 I0). In the present study however, various
time periods of fluoxetine administration were compared in order to determine the most
beneficial period to administer fluoxetine to reverse the cognitive and cellular effects of 5-FU.
Although chemotherapy combinations including the antimetabolite, 5-FU, have been
associated with impairment in cognition in patients (Kreukels et al. 2008; Schagen et al.
2002a), there is no clinical evidence that it has this effect when it is administered alone. Its
ability to cross the blood-brain barrier by passive diffusion enables 5-FU to directly affect the
brain when given systemically (Bourke et al. 1973). In the majority of previous studies,
performed in our laboratory and elsewhere it was found that 5-FU impaired cognition and
suppressed hippocampal cell proliferation in rodents (ElBeltagy et al. 20 I0; Mustafa et al.
2008; Walker et al. 2011; Wigmore et al. 2010).
Consequently, the cytotoxic effect of chemotherapy on the proliferation of neural stem and
precursor cells required for adult hippocampal neurogenesis has been considered as a possible
mechanism for chemotherapy-induced cognitive impairment (ElBeltagy et al. 2010; Mustafa et
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al. 2008; Seigers et al. 2009). The SGZ of the dentate gyrus is one of a limited number of
regions where neurogenesis persists throughout adulthood (Lledo et al. 2006b). Memory
formation and spatial memory are both functions of the hippocampus (see section 1.5.2,
Chapter 1) and the proliferation and integration of the neuronal precursors into existing
circuits is thought to playa functional role in this process (Ehninger and Kempermann 2008;
Zhao et al. 2008).
Fluoxetine, has been shown to increase cell proliferation in the hippocampus in both rodents
(Kodama et al. 2004; Marcussen et al. 2008) and humans (Boldrini et al. 2009) and improve
memory in patients with impaired cognition (Gallassi et al. 2006; Levkovitz et al. 2002;
Mowla et al. 2007). Furthermore, recent rodent investigations in our group showed that
fluoxetine can reverse the impaired spatial memory and reduced proliferation of hippocampal
cells caused by treatment with 5-FU (ElBeltagy et al. 2010) and MTX (see Chapter 3) when
administered before, during and after chemotherapy treatment.
In the present study, we utilised a rat model to confirm that co-administration of fluoxetine
during 5-FU treatment counteracts the cognitive deficit and the reduction in proliferation of
cells found in the SGZ and their survival caused by the chemotherapy. To investigate whether
the mode of action of fluoxetine prevents cognitive decline or whether fluoxetine enables
recovery from the cognitive decline and reduced neurogenesis caused by 5-FU, fluoxetine was
given for 3 different time periods (Fig. 4.1); before and during 5-FU administration
(preventative), after 5-FU treatment (recovery), and for both of these periods combined
(throughout). These studies have demonstrated that the action of the antidepressant fluoxetine,
in chemotherapy treatment, prevents the 5-FU induced cognitive deficits and cellular changes
but has no effect in recovery.
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4.2 Materials and methods
4.2.1 Animals and treatment
Male Lister-hooded rats (175-200g; Charles River, UK, total n=72) were randomly allocated
to vehicle, 5-FU, fluoxetine, 5-FU + fluoxetine (throughout), 5-FU + fluoxetine (preventative)
or 5-FU + fluoxetine (recovery) groups (each, n=12). Rats were housed as described in
section 2.2.1.1, Chapter 1 and allowed to habituate for 1 week prior to drug administration.
Rats were administered 5-FU (25 mg/kg, 5 i.p. doses, each 3 days apart, at a volume of
2.5ml/kg, dissolved in 0.9% sterile saline; Medac, Germany) or 0.9% sterile saline at an
equivocal volume. 3 BrdU injections were administered to all groups, 24 h apart starting 2
days prior to their first 5-FU/saline injection (IOOmglkg, i.p., at a volume of 4ml/kg, pH 7.0;
Sigma Aldrich, UK).
Mean water consumption and mean animal weight were determined every 3 days to estimate a
dose of 10mglkglday of fluoxetine (Pinewood Healthcare, Ireland, oral solution) diluted in
drinking water, for the fluoxetine groups of rats. Drinking water treated with fluoxetine was
administered to the 5-FU + fluoxetine (preventative) group starting 5 days before the first
BrdU injection and to the 5-FU + fluoxetine (recovery) group starting the day of the last 5-
FU/saline injection, both for 20 days. The fluoxetine and the S-FU + fluoxetine (throughout)
groups received it for both these periods for 40 days (Fig. 4.1).
Throughout the experiment, rats were maintained in a 12 h light/dark cycle (7.00/19.00 h) and
food and water (some fluoxetine-treated) was provided ad libitum and weighed every 3 days
or daily during 5-FU administration. All procedures were in accordance to UK Home Office
Guidance regulations and with local ethical committee approval.
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Figure 4.1 Time line showing protocol of drug administration and behavioural testing.
Arrows represent single i.p. injections of IOOmglkg BrdU (fine) and 5-FU (2Smglkg)/saline
(thick). Brackets represent the period of time for which fluoxetine was administered in the
drinking water. The day after novel location recognition (NLR) behavioural testing, animals
were killed and their brains were removed.
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4.2.2 Behavioural testing
4.2.2.1 NLR task
The NLR test was carried out (as described in section 2.3.2.4.1, Chapter 2) 7 days after
fluoxetine treatment ended. Animals were video recorded during the behavioural testing and
EthoVision 4.1 was used to measure the mean velocity of the rats during the 30 min
habituation, 24 h prior to testing. Exploration times of both objects and trials were recorded
blind twice and averaged using a stopwatch from digitised recordings, so no observer was in
the room during the trials. The exploration data of all animals was included in the analysis.
4.2.2.2 Spontaneous altematlon in the Ti-maze
Spontaneous alternation in the T-maze was carried out with modifications, 6 days after
completion of the NLR task. The methods were as described in section 3.2.2.2, Chapter 3, but
the amount of time the rat was trapped in each arm was reduced to 5 sec (previously 25 sec)
and the delay between trials was increased to 1 min (previously 30 sec), to make the task more
difficult. The percentage of correct trials was recorded for each animal. The T-maze data of
all animals was included in the analysis.
4.2.3 Brain tissue preparation
The day after behavioural testing was completed rats were put down by concussion and
immediate cervical dislocation. Brains were prepared (as described in section 2.3.2.3, Chapter
2) and sections were mounted on to APES-coated slides and stored at -20·C until used for
immunohistochem istry.
4.2.4 Ki67 and BrdU immunohistochemistry
Ki67 and BrdU immunohistochemistry, microscopy and quantification of Ki67 and BrdU-
positive cells were carried out as described previously (section 2.3.2.4, Chapter 2). All
counting was performed blind.
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4.2.5 Western blot analysis of DCX and BDNF expression in hippocampus and frontal
cortex
4.2.5.1 Sample preparation, Lowry assay and protein separation
Preparation of hippocampus and frontal cortex tissue samples, determination of protein
concentration utilising the Lowry assay and protein separation were as described in section
2.3.2.4.1, Chapter 2, other than 6111of the samples (n=10) rather than 15.,.1was loaded and
they were run on purchased 4-20% SDS-polyacrylamide gels (Fisher Scientific, UK). 1-2.,.1
recombinant BDNF (rBDNF) was also loaded in 2 wells. After protein transfer was confirmed
with Ponceau solution, the membrane was cut to separate DCX and BDNF bands.
4.2.5.2 Immunodetection, quantification ofprotein and data analysis
Immunodection of DCX, BDNF and ~-actin utilised the SNAP i.d. Protein Detection System
(Millipore, UK). The nitrocellulose membrane was placed in a blot holder and blocked with
15ml offish skin gelatine (1.5% in TBST), driven through the membrane by use ofa vacuum.
All antibodies were diluted in TBST with 1.5% fish skin gelatine. Iml of polyclonal rabbit
anti-DC X (l:1000; Cell Signalling) and mouse anti-Bsactin (1: 1000; Cell Signalling) primary
antibodies or Iml of rabbit anti-BDNF (1: 100) covered the membrane for 10 min and was then
vacuumed through. 3 washes of 15ml TBST were vacuumed through, then Iml of IRDye
800CW goat anti-rabbit and IROye 700CW goat anti-mouse or just 800CW goat anti-rabbit
(both 1:20000; LI-COR Biosciences) covered the membrane for 10 min and was vacuumed
through. The membrane was scanned and protein concentration was quantified as described in
section 2.3.2.4.2, Chapter 2.
4.2.6 Statistical analysis
Student's paired r-tests were used to compare exploration times of animals in the
familiarisation and choice trials. Preference indices (PI) were created by expressing time spent
exploring the object in the novel location as a percentage of the sum of exploration time of
novel and familiar locations in the choice trial, to create a single value to compare between
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groups. PI were compared to 50% chance using a one-sample r-test. One-way ANOV A was
used to compare PI, total exploration time and average velocity of the animals, the percentage
of correct trials in the T-maze, cell counts and DCX and BDNF expression from Western
blotting. Two-way repeated measures ANOV A was run to determine difference in animal
weight between treatment groups. When ANDV A was significant Bonferonni post-hoc test
was performed. Statistical analysis and graphs were created using GraphPad Prism 5 and
significance was regarded as p<0.05.
4.3 Results
4.3.1 5-FU andfluoxetlne reduce weight gq,inandfluid intake
Both treatment and time had a significant effect on body weight (Fs.1848=11.50. F28.184S=2040,
p<O.OO I respectively, two-way repeated measures ANOV A. Fig. 4.2a). Both 5-FU and
fluoxetine significantly reduced weight gain which is attributed to disruption of intestinal
absorption by 5-FU (Huang et al. 2002) and fluoxetine (Freeman et al. 2006). Treatment and
time significantly affected the amount of water drunk (Fs,169=17.93, FI4,16S=52.09,p<O.OOI
respectively, two-way repeated measures ANOVA. Fig. 4.2b), However, by the end of the
experiment no significant difference was seen (one-way ANOVA), The animals remained in
good health throughout the study and never lost more than 10% of their maximum body
weight.
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Figure 4.2 Body weights of rats (a) and their fluid intake (b) during fluoxetine treatment
period (mean ± SEM, n=12). Arrows indicate 5-FU (25mg/kg)/saline injections. Fluoxetine
was given in drinking water (lOmg/kg/day) from day 1 to day 20 for the 5-FU + fluoxetine
(preventative) group, from day 21 to day 40 for the 5-FU + fluoxetine (recovery) group and
from day 0 to day 40 for the 5-FU + fluoxetine (throughout) and the fluoxetine alone groups.
Both treatment and time had a significant effect on body weight (FS.1848=11.50,F28.184S=2040,
p<O.OOl respectively, two-way repeated measures ANOVA). 5-FU and fluoxetine
significantly reduced weight gain. Treatment and time significantly affected the amount of
fluid intake (F5•169=17.93, FI4.168=52.09, p<O.OOI respectively, two-way repeated measures
ANOVA). At the end of the experiment there no significant difference between groups in
fluid intake (one-way ANOVA).
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4.3.2 Fluoxetine reverses NLR spatial memory deficits caused by 5-FU when
administered in prevention but not recovery
The NLR test makes use of the preference of rats for novelty to measure the ability of rats to
discriminate between objects in novel and familiar locations. In the familiarisation trial, the
rats explored 2 identical objects and no group showed a significant difference in exploration
time for either object (Student's paired r-test, Fig. 4.3) indicating no preference for either
object's location. During the choice trial (Fig. 4.4) however, the groups of vehicle treated
rats, rats receiving only fluoxetine and rats receiving both 5-FU and tluoxetine throughout or
for prevention were able to perform the memory task, namely spending significantly longer
exploring the object in the novel location compared to the object in the familiar location (all
.p<O.05, ··p<O.OI, Student's paired r-test), In contrast, rats treated with 5-FU only or 5-FU
with fluoxetine after chemotherapy (recovery) showed no object preference, namely no
significant difference in exploration time of either object (Student's paired r-test), indicating
impairment in memory. Conversion of raw exploration times showed the means of the PI of
these 2 groups did not differ from a level of 50% chance, whereas the mean PI of the other
groups was significantly different (·p<0.05, ··p<O.OI, "·p<O.OOI, one-sample r-test, Fig.
4.5).
The total exploration time in the familiarisation trial (Fig. 4.6a) was significantly higher for
the 5-FU treated group compared to the control group (FS•66=3.475, p<O.05), indicating that
the 5-FU treated animals may have been more inquisitive. This could give an advantage in
performance of the task as the animals spent longer learning the locations of the objects,
although this was not the case in the present experiment as 5-FU treated animals performed
worse in the choice trial than the control group. No difference was seen between the total
exploration times of any of the groups in the choice trial (FS.66=2.777, one-way ANOVA,
Fig. 3.Sb). No significant difference was found between groups for mean velocity (Fig. 4.7)
indicating none of the groups were impaired in their locomotor activity.
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4.3.3 5-FU andfluoxetine do not affect spontaneous alternation in the Ti-maze
The spontaneous alternation in the T-maze task was also used to assess the effects of 5-FU
and fluoxetine on cognition. No significant difference was found between any of the groups
(one-way ANOYA, Fig. 4.8), indicating that neither 5-FU nor fluoxetine effected cognition
for this task.
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Figure 4.3 Exploration times (mean ± SEM, n=12) of the rats for each object in the
familiarisation trial in the familiarisation trial of the novel location recognition (NLR) task.
There was no significant difference in exploration time of either object for any group in the
familiarisation trial (Student's paired t-test).
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Figure 4.4 Exploration time times (mean ± SEM, n=12) of the rats for each object in the
choice trial of the novel location recognition (NLR) task. There was no significant
difference in exploration time of either object for any group in the familiarisation trial
(Student's paired z-test). In the choice trial, all groups spent significantly longer exploring
the object in the novel location (*p<O.05, **p<O.Ol, Student's paired r-test), except the
groups receiving 5-FU alone or 5-FU with tluoxetine in recovery (Student's paired r-test).
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Figure 4.5 Preference indices (PI) of each group (mean ± SEM, n=12) were created by
expressing time spent exploring the object in the novel location as a percentage of the sum
of exploration time of novel and familiar locations in the choice trial (Bruel-Jungerman et al.
2005). Compared to 50% chance, PI of all groups was significantly different ("'p<O.05,
*"'p<O.Ol, "'**p<O.OOI, one-sample t-test), other than the groups receiving 5-FU alone or 5-
FU with tluoxetine in recovery (one-sample t-test). PI were not significantly different
between groups (one-way ANOYA).
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Figure 4.6 The total exploration time (mean ± SEM, n=12) was significantly higher for the
group treated with 5-FU compared to the control group (FS•66=3.475, p<O.05, one-way
ANOVA, n=I 2) in the familiarisation trial (a). No significant difference (FS•66=2.777, one-
way ANOVA, n=12) was found between groups in the choice trial (b).
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Figure 4.7 Mean velocity (mean ± SEM, n=12) of rats recorded during the habituation
period using EthoVision 4.1. No significant difference (one-way ANOVA) was found
between the groups.
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Figure 4.8 Percentage of correct turns (mean ± SEM, n=12) in spontaneous alternation in
the T-maze. No significant difference (one-way ANOVA) was found between each group.
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4.3.4 Fluoxetine reverses the reduction of cell proliferation in the dentate gyrus caused
by 5-FU when administered in prevention but not recovery
Cell proliferation in the SGZ at the end of the experiment was quantified using Ki67 (Fig.
4.9a-d). Rats which received only S-FU had a significantly lower number of Ki67-positive
cells (p<O.O 1, one-way ANOV A) and rats which received only fluoxetine had a significantly
larger number compared to the vehicle-treated controls (p<O.OS, one-way ANOVA). The
number of Ki67-positive cells in rats treated with both 5-FU and fluoxetine did not
significantly differ from the controls when fluoxetine was administered throughout and in
prevention (one-way ANOV A). Although rats treated with S-FU and subsequently given
fluoxetine (recovery) did not have significantly fewer Ki67-positive cells compared to the
controls (one-way ANOVA), there does appear to be a reduction of Ki67-positive cells.
Furthermore, the groups which received both S-FU and fluoxetine in the prevention phase or
throughout had a significantly larger number of Ki67-positive cells than the group receiving
S-FU alone (ttp<O.O 1, tttp<O.OO 1, one-way ANOV A) whereas the group receiving S-FU and
fluoxetine in prevention did not. These results indicate that S-FU has a long-term effect (at
least 30 days) in reducing cell proliferation in the SGZ. This effect can be counteracted by
fluoxetine only if it is administered before and during the S-FU treatment period, but the
deleterious effects of S-FU chemotherapy are not counteracted if fluoxetine is only
administered after chemotherapy treatment.
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Figure 4.9 Representative photographs of the nuclei of cells in the SGZ of the dentate gyrus
from the vehicle group (blue, a), Ki67-positive cells (red, b) and the photos merged (c). Bar
scales indicate 20llm. Total numbers of Ki67-positive cells (mean ± SEM, n=12) in the
dentate gyrus were estimated from cell counts (d). Rats receiving 5-FU had significantly
fewer Ki67-positive cells (**p<O.Ol, one-way ANOYA) in the subgranular zone (SGZ) and
rats receiving fluoxetine had significantly more (*p<O.05, one-way ANOYA) than the
saline-treated control group. Groups receiving both 5-FU and fluoxetine in the prevention
phase or throughout had a significantly larger number of Ki67-positive cells than the group
receiving 5-FU alone (ttp<O.Ol, tttp<O.OOI, one-way ANOVA) whereas the group receiving
5-FU and fluoxetine in prevention did not.
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4.3.5 Fluoxetine reverses the reduction of cell survival in the dentate gyrus caused by 5-
FU when administered in prevention but not recovery.
A course of 3 BrdU injections was given to the rats preceding and on the first day of 5-FU or
saline injections, to be recruited into cells at the beginning of the experiment. The BrdU-
positive cells were counted in the dentate gyrus after the experiment was completed to
quantify the survival of these cells (Fig. 4.lOa-d). There were significantly more BrdU-
positive cells in rats treated with only fluoxetine (p<O.OO1, one-way ANOV A) compared
with the control group and significantly fewer in rats treated with 5-FU (p<O.OI, one-way
ANOYA). The rats treated with both 5-FU and fluoxetine did not have a significantly
different number of BrdU-positive cells than the controls when fluoxetine was administered
throughout and in prevention (one-way ANOYA), but when fluoxetine was only
administered in recovery, the rats had a significantly smaller number (p<O.OOl, one-way
ANOYA). Furthermore, the groups which received both 5-FU and fluoxetine in prevention
phase or throughout the study had a significantly larger number of BrdU-positive cells than
the group receiving 5-FU alone (p<O.OO1, one-way ANOY A) whereas the group receiving 5-
FU and fluoxetine in prevention did not. These results suggest that when administered
before and during, but not after 5-FU treatment, fluoxetine can protect neural precursors
from cell loss induced by 5-FU.
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Figure 4.10 Representative photographs of the nuclei of cells in the dentate gyrus from the
vehicle group (blue, a), Brdl.l-positive cells (green, b) and the photos merged (c). Bar scales
indicate 20llm. Total numbers of Brdl.l-positive cells (mean ± SEM, n=12) in the dentate
gyrus were estimated from cell counts (d). Rats receiving 5-FU had significantly fewer
Brdl.I-positive cells (p<O.OOI, one-way ANaVA) in the SGZ and rats receiving fluoxetine
had significantly more (p<O.OI, one-way ANaVA) than the saline-treated control group.
Treatment groups receiving both 5-FU and fluoxetine throughout and in prevention did not
significantly differ from the controls but had significantly more Ki67-positive cells than the
group receiving 5-FU alone (tttp<O.OOI, one-way ANaVA). The group receiving 5-FU
with fluoxetine in recovery had significantly fewer BrdU-positive cells than the controls
(***p<O.OOI, one-way ANa VA) but did not differ from the group receiving 5-FU alone.
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4.3.5.1 Expression ofDXC
Western blotting analysis was performed to determine the effects of 5-FU and fluoxetine on
levels of DCX in the hippocampus and frontal cortex (Fig. 4.11). Whole brain was used as a
positive control for DCX, but it is not shown on this immunoblot. Protein levels of DCX
were normalised in comparison with ~-actin loading control. A one-way ANOY A showed
no significant difference in DCX expression between any of the treatment groups in either
the hippocampus (one-way ANOYA ,Fig. 4.12a) or the frontal cortex (one-way ANOVA,
Fig.4.12b).
4.3.5.2 Expression of BDNF
Expression of BDNF levels in the hippocampus and frontal cortex were also quantified by
Western blotting analysis (Fig. 4.11). Whole brain was used as a positive control for BDNF,
but is not shown on this immunoblot. Protein levels of BDNF were normalised in
comparison with ~-actin loading control. No significant difference in BDNF expression was
found between any of the treatment groups treated with 5-FU, fluoxetine, or both in
combination in either the hippocampus (one-way ANOYA, Fig. 4.13a) or the frontal cortex
(one-way ANOVA, Fig. 4.13b).
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Figure 4.11 Example photomicrograph ofimmunblot bands from Western blotting showing
expression of ~-actin (green, at 43 kDa), DCX (red, at 47 kDa) and BDNF (green, at 14
kDa). Samples from hippocampus and frontal cortex were loaded at 6111 into the lanes as
follows:
Lane 1: Molecular weight marker (1111, Fermentas, USA)
Lane 2: Vehicle group, hippocampus
Lane 3: Vehicle group, frontal cortex
Lane 4: 5-FU treated group, hippocampus
Lane 5: 5-FU treated group, frontal cortex
Lane 6: Fluoxetine treated group, hippocampus
Lane 7: Fluoxetine treated group, frontal cortex
Lane 8: 5-FU + fluoxetine (throughout) treated group, hippocampus
Lane 9: 5-FU + fluoxetine (throughout) treated group, frontal cortex
Lane 10: 5-FU + fluoxetine (preventative) treated group, hippocampus
Lane 11: 5-FU + fluoxetine (preventative) treated group, frontal cortex
Lane 12: 5-FU + fluoxetine (recovery) treated group, hippocampus
Lane 13: 5-FU + fluoxetine (recovery) treated group, frontal cortex
Lane 14: 2111 recombinant BDNF (rBDNF)
Lane 15: 1111 rBDNF
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Figure 4,12 Levels of DCX (mean ± SEM, n=10) in the hippocampus (a) and frontal cortex
(b) of all groups of animals, normalised by p-actin loading control, were not significantly
different (one-way ANOVA).
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Figure 4,13 Levels of BDNF (mean ± SEM, n=10) in the hippocampus (a) and frontal
cortex (b) of all groups of animals, normalised by ~-actin loading control, were not
significantly different (one-way ANOVA).
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4.4 Discussion
The present study showed that the chemotherapy agent, 5-FU, caused a memory impairment
measured by the NLR task which was associated with the reduction in both the proliferation
and survival of neural precursors in the SGZ of the dentate gyrus. These effects were
counteracted when the SSRI antidepressant fluoxetine was co-administered before and
during (preventative) but not after (recovery) 5-FU treatment.
Similar to the study in the previous chapter, the NLR and spontaneous alternation in the T-
maze memory tasks were chosen in the present study to assess spatial memory. The
spontaneous alternation in the T-maze task was modified in an attempt to make it more
difficult, however as the control groups' ability to perform the task did not differ in the T-
maze tasks in the previous and present chapters, it did not appear that this was successfully
achieved. In the present study, 5-FU-treated animals were unable to recognise an object in a
novel as opposed to a familiar location, suggesting a memory deficit compared to saline
treated controls, supporting clinical observations of chemotherapy-induced cognitive
impairment in patients. The dose of 5-FU chosen was 25mg/kg administered chronically to
the animals as it is clinically relevant and it is comparable to the 20mg/kg dose used
previously in our laboratory which caused cognitive impairment in rats (ElBeltagy et at.
2010). In the previous chapter fluoxetine was shown to have cognitive benefits for rats
treated with chemotherapy when given for a total of 40 days, before, during and after
chemotherapy treatment. In the present study, the 5-FU-induced cognitive impairment was
prevented when fluoxetine was administered 40 days before, during and after the period of
5-FU treatment. This positive effect on cognition remained when the co-administration of
fluoxetine was before and during the 5-FU treatment for 20 days. However, the rats
remained cognitively impaired when fluoxetine was only administered after the final 5-FU
injection for 20 days. This indicates the importance of the timing of the fluoxetine
administration, indicating a mechanism of prevention and not recovery.
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Conversely, none of the treatment groups significantly differed in their ability to perform the
spontaneous alternation in the T-maze task. It is possible that this could be due to the task
not being able to detect the subtle difference in cognitive impairment induced by 5-FU,
despite modifications to make it more difficult from the task used in the previous chapter by
amending the time the animal was trapped in the arm and between trials (see section 4.4.2 of
the present chapter).
Fluoxetine treated animals initially had a lower fluid intake than controls, which is likely to
be due to a taste aversion to fluoxetine (Prendergast et al. 1996). However, by the end of
the experiment, all groups had the same fluid intake. It is unlikely that differences in fluid
intake would have affected their performance in the NLR task. Fluoxetine concentration in
the drinking water was adjusted to take account of the animal's weight and differing levels
of water consumption.
Disruption of neurogenesis is a possible mechanism by which 5-FU causes cognitive
impairment (ElBeltagy et al. 2010). Production and survival of new neurons in the
hippocampus is thought to be essential for spatial memory and learning (Ehninger and
Kempermann 2008; Zhao et al. 2008) and cognitive impairments are seen when
neurogenesis is disrupted by irradiation (Madsen et al. 2003; Snyder et al. 2005),
chemotherapy drugs (ElBeltagy et al. 2010; Lyons et al. 2011 b; Seigers et al. 2008) or
genetic manipulation (Dupret et al. 2007). In the present study, the effects of 5-FU and
fluoxetine on the production and survival of new hippocampal neurons were examined. The
5-FU treatment had a significant negative effect on both the survival of newly born
hippocampal cells in the saz of the dentate gyrus and their proliferation as measured 30
days after the completion of treatment, suggesting that 5-FU has a long-term effect on the
newly-born cells. Rats administered with both 5-FU and fluoxetine in the present study did
not significantly differ from the controls when fluoxetine was administered for the
"preventative" and "throughout" periods. When fluoxetine was only administered after the
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final 5-FU injection, the rats still had significantly reduced survival of newly-born neurons
and a subtle reduction in proliferation was also evident. Rats administered with fluoxetine
alone also showed increased proliferation and survival as reported in Chapter 3.
The results in the present study are the first to examine the time course of the effects of
fluoxetine on the response to the chemotherapy agent, 5-FU. The cognitive effects of 5-FU
found here are consistent with earlier work from our group (EIBeltagy et al. 2010; Mustafa
et al. 2008) and other studies which show that 5-FU affects memory 2 days (Foley et al.
2008) to 5 weeks (Gandal et al. 2008) after drug administration. 5-FU has also previously
been shown to have a negative effect on hippocampal cell proliferation (EIBeltagy et al.
2010; Mustafa et al. 2008). However one study showed no effect of this chemotherapy
agent on hippocampal cell proliferation (Mignone and Weber 2006) but this may be because
the effects of 5-FU were examined the day following treatment, not allowing enough time
for the drug to affect the population of newly born cells. The proliferation, survival and
apoptosis of neural progenitors are all involved in memory formation and the stage of
growth of newly born neurons when learning and memory takes place is an important factor
(Dupret et al. 2007). In the present study, memory ability and neurogenesis were affected 4
weeks after the 5-FU chemotherapy treatment period indicating that 5-FU had a chronic
effect on both these features. The association between the decline in cognition and
neurogenesis provides further evidence that these processes are linked and that the impact of
chemotherapy on neurogenesis is a likely mechanism for the changes in cognition. The
present results show that fluoxetine alone increased the survival of cells and that it exhibits
properties which enable it to protect the population of new neurons from 5-FU. However
once 5-FU has a negative impact, fluoxetine is not able to replenish the population of
neurons.
The mechanisms by which fluoxetine exhibits its neuroprotective properties are unclear.
However, fluoxetine has been shown to increase levels of BDNF which influences the
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regulation of neurogenesis (Alme et al. 2007; Duman and Monteggia 2006) and increases
proliferation of neural precursors in the dentate gyrus (Pinnock et al. 2010) (see section
1.4.3, Chapter I). In addition, fluoxetine has been shown to directly increase proliferation of
hippocampal derived-neural stem cells and to prevent Iipopolysaccharides-induced apoptosis
in vitro (Chiou et al. 2006a). However, results from Western blotting in the present study
indicate that there was no significant difference in levels of BDNF in the hippocampus or
frontal cortex between any of the treatment groups. This suggests that neither fluoxetine nor
5-FU alters levels of BDNF. However, it is also a possibility that the Western blotting
technique was not sensitive enough to detect subtle concentration changes of BDNF across
whole brain regions.
Furthermore, levels of the microtubule associated protein DCX in the hippocampus or
frontal cortex did not significantly differ between any of the treatment groups. DCX is
present in young neurons so it is perhaps surprising that there was no difference in
hippocampal levels considering that the present study also revealed that the proliferation and
survival of hippocampal cells was significantly altered by fluoxetine and 5-FU. An
explanation for this could be that the newly generated cells detected were not indeed
neurons. However this is unlikely as it has been reported that more than 80% of dividing
cells in the SGZ in the adult rat become neurons (Snyder et al. 2009). This could therefore
provide evidence that the Western blot quantification techniques used in the present study
may not be sensitive enough to detect subtle chemical changes. Further studies to more
precisely quantify BDNF and DCX would be necessary to enable conclusions to be drawn.
It would also be interesting to quantify apoptosis and in the hippocampus to provide further
information to help understand the detailed mechanism of how fluoxetine is acting against 5-
FU.
The period of administration for fluoxetine was at least 20 days as this is sufficient to have
anxiolytic effects (Conley and Hutson 2007) and increase hippocampal neurogenesis
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(Kodama et al. 2004) in rats. Behavioural testing was carried out a week after termination of
tluoxetine treatment, as tluoxetine and its primary metabolite nortluoxetine have a long half-
life and take 3 days to wash out of the system (Caccia et al. 1990). Although levels of serum
tluoxetine and nortluoxetine were not measured in the present study, a comparable study by
Thompson et al. showed that Wistar rats treated with 6-7ml/kg/day of tluoxetine in drinking
water for 37 days had tluoxetine and nortluoxetine serum levels of 281 ::I:44 and 1209 ± 123
nmolll respectively (Thompson et al. 2003) . These levels are comparable to previous studies
when the drug has been administered by injection (Caccia et al. 1990). Clinical reports have
suggested that studies of chemotherapy-induced cognitive impairment in patients could be
confounded by stress (Wefel et al. 2004). In the present study, stress to the animals was kept
to a minimum, by giving tluoxetine in drinking water rather than injection, regular handling
and group housing of the animals. Furthermore, administering tluoxetine in the drinking
water is clinically relevant as it is administered to patients orally.
The results of the present study show that tluoxetine exhibits effects which can protect
newly born hippocampal neurons from the cytotoxic effects of S-FU which would
subsequently cause cognitive decline. Furthermore, this is the first time to show that these
effects are only demonstrated when tluoxetine is given before and during the S-FU treatment
and that tluoxetine cannot initiate recovery of the chemotherapy-induced reduction in
neurons and cognitive ability in animals after it has occurred. It is premature to estimate the
extent to which these results are translatable to humans, but if similar effects of prevention
of chemotherapy-induced memory deficits by tluoxetine are apparent in patients, these
results may offer a relatively simple way to counteract cognitive impairment and suggest
that the antidepressant should be delivered before and during chemotherapy treatment to
prevent cognitive impairment.
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Chapter 5
The effect of 5-fluoruracil, fluoxetine and norfluoxetine
on the viability and proliferation of neural stem cells
isolatedfrom the adult mouse hippocampus
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5.1 Introduction
Adjuvant chemotherapy is reported to negatively affect cognition in cancer survivors for
years after treatment has ended (Janelsins et al. 2011). There is evidence to suggest that this
may be at least in part due to the effects of certain chemotherapy agents on hippocampal
neurogenesis (ElBeltagy et al. 20 I0; Lyons et al. 2011 b; Seigers and Fardell 20 II). In the
previous chapter presented in the thesis, it was shown that treatment with 5-fluorouracil (5-
FU) can cause an impairment in the rats' ability to perform the novel location recognition
(NLR) spatial memory task and reduces both the proliferation and survival of newly
generated cells in the dentate gyrus of the hippocampus. Furthermore, these negative
cognitive and cellular effects are reversed when the selective serotonin reuptake inhibitor
(SSRI) antidepressant, fluoxetine, is co-administered for a period of time before and during
the 5-FU treatment regimen, but the mechanism by which fluoxetine has this neuroprotective
effect remains unclear. In the present study the direct effects of 5-FU, fluoxetine and its
metabolite norfluoxetine on mouse hippocampal neural stem cells (NSC) were investigated
in vitro.
5-FU is an antimitotic agent which has been shown to decrease cell proliferation by
inhibition of the enzyme thymidine synthetase (Longley et al. 2003) (TS; see section 1.2.3.1,
Chapter I) and has been shown to be cytotoxic to human HB I.F3 .CD NSC cancer cell lines
in vitro and in vivo (100 et al. 2009). Furthermore, previous work in our laboratory and
work from the present thesis has shown that 5-FU reduces proliferation of non-cancerous
hippocampal cells in the subgranular zone (SaZ) of the rat dentate gyrus. However, the
effects of 5-FU on viability and proliferation on primary hippocampal NSC in vitro have not
yet been investigated and are demonstrated in the present chapter.
Conversely, work in our laboratory has shown that fluoxetine upregulates the proliferation of
cells in the adult rat hippocampus (see Chapters 3 and 4). In addition, fluoxetine increases
the proliferation of isolated rodent NSC in vitro (Chen et al. 2007; Manev et al. 200 I;Zusso
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et al. 2008). Fluoxetine has also been previously shown to increase cell proliferation in vitro
after administration in vivo following chronic stress (Hitoshi et al. 2007). In the present
study the effects of different concentrations of fluoxetine on both the viability and
proliferation of mouse primary hippocampal NSC in vitro were investigated. In vivo,
fluoxetine is metabolised by the liver to norfluoxetine. Therefore, the direct effect of
norfluoxetine on viability of isolated hippocampal NSC was determined in the present study.
5.2 Materials and methods
5.2.1 Isolation and propagation of adult mouse hippocampal NSC
Although rats were used in the previous in vivo experiments of this thesis, in the present
experiment NSC from the hippocampus of mice were used due to unavailability of rat NSC
and the amount of time available. Three brains of male and female adult 129 and ME 1 mice
(Biomedical Service unit (~MSU), University of Nottingham) were dissected and immersed
in ice cold PSB. The hippocampi were dissected, diced (into <Imrrr' pieces), pooled in a
30ml universal tube and the PBS was removed. lml of accutase (O.5mM in PBS, Millipore,
USA) was added to the tube and incubated for 45 min at 37°C to digest the tissue. To
facilitate dissociation, the tissue was gently pipetted using a PI 000. 1Oml of PBS was added
and the tube was shaken to ensure complete dissociation of the tissue. The cells were
pelleted by centrifugation (5 min, 200G), PBS was removed and the tissue was resuspended
in NSC medium [Dulbecco's Modified Eagles Medium/Ham's FI2 (DMEM/FI2),
neurobasal media, N2 supplement, B27 supplement, Pen/Strep, epidermal growth factor
(EGF) and fibroblast growth factor-2 (FGF-2)] (see Appendix II). 2ml of the suspension
was placed in a 6 well plate and cultured at 37'C in 5% CO2• The next day the cells were
collect and passaged (see below) and placed in T25 flasks.
5.2.2 Culturing and passaging of hippocampal NSC
Mouse hippocampus NSC were maintained in sterile conditions at 37°C, with 5% CO2• in
NSC medium in a T25 flask and passaged every 4-7 days. To passage the NSC, the medium
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and cells were centrifuged (5 min, 200G) to pellet the cells. They were resuspended in
0.5ml accutase, incubated for 5 min at 37'C and gently pipetted with a PIOOOto dissociate
the neurospheres and again pelleted by centrifugation in 10ml of PBS. The cells were
resuspended in Iml NSC medium and transferred into new T25 flasks with 5ml of fresh
NSCmedium.
5.2.3 Proliferation of hippocampal NSC
After dissociation of the neurospheres, the cells were plated in sterile 6 well plates at a
density of 5 x lOS per well in NSC medium treated with 0, 0.1, I or 10J.lM of fluoxetine.
Cells were incubated at 37"C, with 5% CO2 for 1,3 and 7 days. The neurospheres were then
centrifuged and dissociated (as described in section 5.2.2 of the present chapter) and the
density of single cells was assessed using an Improved Neubar Hemocytometer (see
Appendix III). Quantification ofNSC was performed in triplicate.
5.2.4 MTT assay
The MIT [3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide] assay was used
to test the effects of a range of concentrations of 5-FU, fluoxetine and norfluoxetine on the
viability of hippocampal NSC. This is a colourimetric assay based on the ability of viable
cells to reduce a soluble yellow tetrazolium salt MIT to a blue formazan crystal by
mitochondrial succinate dehydrogenase activity of viable cells. This test is a good index of
mitochondrial activity and thus of cell viability (Mosmann 1983).
After dissociation of the neurospheres, the cells were plated out in sterile 96 well plates at a
density of 5 x 103 in 200J.l1of MIT NSC medium [DMEMIF 12 and FBS](see Appendix II)
per well, 8 days prior to the MIT assay. 24 h, 4 or 7 days prior to the MIT assay, the
medium was carefully removed with an aspirator and cells were treated with different
concentrations (0, 0.01, 0.1, I, 10 and 100J.lM) of 5-FU, fluoxetine or norfluoxetine (n=8) in
fresh MIT NSC medium and incubated at 37"C. 2 h prior to the end of the incubation, 20111
MIT (2.5mglml in PBS) was added to each well. At the end of incubation NSC media was
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removed and 200~1 of dimethyl sulfoxide (DMSO) was added to each of the wells and
gently agitated. The optical density of each well was read at 570nm wavelength using a
Dynex MRX Model 96 Well Plate Reader (MTX Lab Systems Inc., USA). Cell counting
required to seed a specific number of cells was performed using an Improved Neubar
Hemocytometer (see Appendix III).
5.2.5 Statistical analysis
Statistical analysis and graphs were created using GraphPad Prism 5 and significance was
regarded as p<0.05. Cell viability is presented as the optical density as a percentage of the
control. For cell proliferation, the number of cells per ml was estimated from a 1O~I sample.
Cell viability and proliferation were analysed using two-way ANOV A. When ANOV A was
significant Bonferonni post-hoc test was performed.
5.3 Results
5.3.1 5-FU reduces viability of adult mouse hippocampal NSC
MIT assays were performed to assess viability of NSC after treatment with a range of
concentrations of 5-FU (0, 0.01, 0.1, 1, 10 and 100~M), following an incubation of 1, 4 or 7
days. Optical densities were read and normalised against the control (O~M 5-FU). None of
the concentrations of 5-FU had a significant effect on cell viability after 1 day (two-way
ANOV A, Figure 5.1a). All concentrations of 5-FU caused significantly fewer viable NSC
after 4 or 7 days exposure compared to the control (·p<0.05, "p<O.OI, ·"p<O.OOI, two-
way ANOVA, Figure 5.Ia) with the exception of4 day exposure to O.OI~M 5-FU, which
did not significantly differ from the control.
5.3.2 Fluoxetine reduces proliferation of adult mouse hippocampal NSC
In the present study hippocampal NSC were quantified to investigate the direct effect of
various concentrations of fluoxetine on cell proliferation after incubations of 1, 3 and 7 days
(Figure 5.2 and 5.3). Counts were analysed using a two-way ANOVA. After 1 day, none of
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the concentrations (0.1, 1 or lO~M) of fluoxetine significantly reduced the number of cells,
compared to the control. After 3 days incubation, cells treated with 0.1 ~M of fluoxetine did
not differ from the control group, but cells treated with 1 and 1O~M showed a significant
decrease in proliferation (p<0.00 1). After 7 days of incubation, all the concentrations of
tluoxetine caused a significant decrease in cell number (*p<0.05, ***p<O.OOI).
5.3.3 Fluoxetine and norfluoxetlne reduces viability adult mouse hippocampal NSC
The direct effects of fluoxetine and its major active metabolite on NSC cell viability were
also assessed using the MIT assay. A range of concentrations of either tluoxetine or
nortluoxetine were used (0, 0.01, 0.1, 1, 10 and 1OO~M), after an incubation of I, 4 or 7
days. 0.0 I f.1Mof tluoxetine had no significant effect on the viability of NSC after I day
(two-way ANOVA, Figure 5.lb), but significantly reduced the number of viable cells after
an incubation of 4 and 7 days (p<0.00 1, two-way ANOV A, Figure 5.1b). All the other,
higher concentrations of tluoxetine reduced the number of viable cells compared to the
control (O~M tluoxetine), after each incubation period (p<0.001, two-way ANOVA, Figure
5.lb).
Nortluoxetine did not significantly affect the viability of NSC at a concentration of 0.0 1~M
compared to the control group (O~M nortluoxetine) at any time point (two-way ANOVA,
Figure S.lc). The higher concentrations (0.1-100~M) all significantly reduced the NSC
viability after each incubation period (*p<0.05, **p<O.Ol, ***p<O.OOl, two-way ANOVA,
Figure 5.lc). These results show that both tluoxetine and norfluoxetine have a dose-
dependent negative effect on viability of adult mouse hippocampal NSC.
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Figure 5.1 Viability of adult mouse hippocampal NSC assessed by optical density at 570nm
wavelength (normalised as a proportion of the control (OflM of 5-
FU/fluoxetine/norfluoxetine, n=8) from the MIT assay after exposure to a range of
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concentrations (0,0.01,0.1, I, 10 and 1001lM) of 5-FU (a), fluoxetine (b) or norfluoxetine
(c). Cell viability was not affected by any 5-FU concentration (0.01 - 1001lM) after an
exposure time of I day compared to the control group (two-way ANOVA). After an
exposure time of 4 days, concentrations of 0.1-1OOIlM 5-FU significantly decreased NSC
viability (**p<O.OI, ***p<O.OOI, two-way ANOVA) but cells treated with O.OIIlM 5FU did
not differ from the controls. At 7 days exposure time, aIl5-FU concentrations (O.OI-iOOIlM)
reduced NSC viability (*p<0.05, ***p<O.OOI, two-way ANOVA). All concentrations of
fluoxetine (0.0 I-I OOIlM) significantly reduced the viability of the NSC at each exposure
time (I, 4 and 7 days), (p<0.001, two-way ANOVA) with the exception of I day's exposure
to O.OIIlM fluoxetine, which did not differ from the control group. Exposure to O.OIIlM
norfluoxetine did not significantly differ from the controls at any exposure time. Exposure
to higher concentrations ofnorfluoxetine (0.1 - IOOIlM) decreased the viability ofNSC at all
exposure times (I, 4 and 7 days), (·p<0.05, "p<O.OI, ···p<O.OOI, two-way ANOVA).
159
Figure 5.2 Photographs showing the effect on the formation of neurospheres from adult
mouse hippocampal NSC after an incubation time of I week in different concentrations of
fluoxetine: 0 (a), 0.1 (b), 1 (c) or 10 (d) J..lM.
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Figure 5.3 The number (mean ± SEM, n=3) of adult mouse hippocampal NSC (dissociated
neurospheres) per ml grown in culture after incubations of 1, 3 and 7 days in different
concentrations of t1uoxetine (0.1, 1 or 10J.lM). At 1 day, none of the concentrations of
t1uoxetine reduced the number of cells/ml (two-way ANOVA) compared to the control
group (OIlM tluoxetine). After 3 days incubation in 0.1 J.lMt1uoxetine did not differ from the
control group, but concentrations of 1 and 1OIlM t1uoxetine significantly reduced the number
of cells/m) (p<O.OOI, two-way ANOVA). At 7 days of incubation, all concentrations of
t1uoxetine (0.1, 1 or 10J.lM) significantly reduced the number of cells/ml compared to the
control group (*p<O.05, ***p<O.OOI, two-way ANOVA).
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5.4 Discussion
The aim of the present study was to establish an in vitro model of adult hippocampal NSC
proliferation and viability in response to 5-FU, fluoxetine and its active metabolite
norfluoxetine to further understand the mechanisms of chemotherapy and antidepressants in
vivo. In the previous chapters presented in this thesis, it was shown that chronic 5-FU
treatment reduced cell proliferation and survival in the hippocampus of the adult rat.
Administration of fluoxetine to the rats had the reverse effect, promoting the proliferation
and survival of hippocampal cells and preventing the negative cognitive and cellular effects
of 5-FU when it was co-administered before and during 5-FU treatment. In the present
study, the direct effects of 5-FU, fluoxetine and norfluoxetine on viability of hippocampal
NSC isolated from the hippocampus of the adult mouse were determined.
The viability of hippocampal NSC, shown by the MIT colourimetric assay, was not affected
by exposure to 5-FU for a single day at any of the concentrations used (0.1 - 100J.lM).
However, at 4 days exposure to the drug, the cell viability decreased as the concentration of
5-FU increased and the effect was even more pronounced at 7 days, demonstrating that 5-FU
has a dose and exposure time dependent effect on the hippocampal NSC. The
concentrations used in the present study cover the range of 0.3-71 J.lM found in the CSF of
primates 5 to 60 min after i.v. infusion of 5-FU, so are therefore clinically relevant. The
results from this study indicate that in vitro hippocampal NSC could be a good model for
what is happening in the hippocampus in vivo as 5-FU administration has been shown to
reduce cell proliferation in the hippocampus in animal models (EIBeltagy et al. 20 I0)
(results from Chapter 4).
There has not yet been a dose-dependent study in an animal model investigating the effects
of 5-FU on neurogenesis. However, 5-FU has previously been shown to reduce the viability
of human colon cancer cell lines, COLO-205 and HT-29 in vitro at concentrations of3.2J.lM
and 1.3J.lM (Wiebke et al. 2003) and also mouse brain melanoma cell line F3.CD by 0.5 flM
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of 5-FU (loo et al. 2009). Furthermore, 5-FU has a similar effect on primary NSC from the
mouse CNS in vitro reducing viability of oligodendrocytes at concentrations of 0.5-5~M,
although, unlike the present study, this effect was seen after an exposure time of just 24
hours. 5-FU is toxic to cancerous cells by inhibiting the production of thymidine (Longley
et al. 2003). Since 5-FU is able to cross the blood-brain barrier (Patel et al. 1998), it is
probable that it enters the hippocampus and causes the proliferating NSC to apoptose by a
similar mechanism to its cytotoxicity to cancerous cells, by inhibition of the enzyme TS
(Longley et al. 2004).
Conversely, the effects of fluoxetine and norfluoxetine treatment on the hippocampal NSC
did not accurately reflect the result seen in vivo. When administered to adult rats in the
studies shown in previous chapters, fluoxetine increased the proliferation and survival of
hippocampal cells. However, the in vitro study performed in the present chapter showed
that fluoxetine significantly reduced the viability (shown by the MIT assay) of adult mouse
hippocampal NSC at all concentrations (O.OI-IOOJiM) at all exposure times (1-7 days) with
the exception of exposure to 0.01 ~M fluoxetine for I day. The reduction in viability was
also demonstrated to be dose and time dependent. Furthermore, the rate of proliferation of
the cells assessed by cell counts was reduced with concentrations of I and 10JiM fluoxetine
at 3 days and O.I-IO~M at 7 days. Fluoxetine's primary active metabolite, norfluoxetine,
also decreased the viability of cells at concentrations of 0.1-1 OO~Mat all exposure times (1-
7 days) but showed no effect at 0.01 JiM. The concentration range used for these drugs in the
present study covered therapeutic plasma concentrations (Ayelli Edgar et al. 1999;
Thompson et al. 2003).
The present results were unexpected, firstly because they do not correlate with the earlier in
vivo work presented in this thesis and secondly because it is not in accordance with other
literature investigating the affects of antidepressants on primary NSC. One previous study
used NSC derived from the hippocampus of the adult rat and found that their proliferation
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rate was up-regulated after 7 days incubation in 20f.1M fluoxetine (Chen et al. 2007). In
another experiment the proliferation of adult rat hippocampal NSC was decreased by 48 h
exposure to 1f.1Mfluoxetine after they had been in vitro for I day, but increased after the
same exposure time and fluoxetine concentration when the cells had grown for 10 days in
vitro (Manev et al. 2001). Similar results have also been shown in isolated rat cerebellum
NSC showing that 1f.1Mfluoxetine up-regulating cell proliferation (Zusso et al. 2008; Zusso
et al. 2004).
One reason for the decrease in proliferation of the hippocampal NSC in the present study
may be the comparatively short exposure time to fluoxetine, compared to previous in vivo
studies of this thesis. In vivo fluoxetine takes up to 4 weeks to alter hippocampal
neurogenesis and have beneficial cognitive effects (Conley and Hutson 2007; Kodama et al.
2004). However, the results from the present study show that cell viability still decreased
between 4 and 7 days exposure to both fluoxetine and norfluoxetine, which suggests that if
fluoxetine induces any increase in proliferation in vitro, a much longer time period would be
necessary to see these effects.
Alternatively, the species from which the NSC are derived could have an impact on the
proliferation of the isolated NSC as, unlike the present experiment, none of the previous
studies investigating the effect of fluoxetine on NSC in vitro derived the cells from mice.
Fluoxetine has been shown to increase the rate of hippocampal neurogenesis in vivo in the
adult rat (Chen et al. 2007; Manev et al. 2001; Zusso et al. 2008; Zusso et al. 2004), but not
in adult mice (Holick et al. 2007; Huang et al. 2008b). Furthermore, it has been reported
that in vivo that neurons from the adult rat hippocampus are more numerous, differentiate
faster and have a higher survival rate than neurons in the mouse hippocampus (Snyder et al.
2009) and it is possible that this may also effect cell proliferation and viability for cultured
hippocampal NSC.
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The results from the present study suggest that isolated mouse hippocampal NSC grown in
vitro is not a suitable model to investigate the effects of fluoxetine on cell proliferation in
vivo. It is perhaps not possible to create an accurate model in vitro due to the complex in
vivo factors excluded from cell culture methods. For example, fluoxetine has been shown to
protect against caspase-rnediated apoptosis by activating anti-apototic proteins such as the
cellular FLICE-inhibitory protein, Bcl-2 and Bcl-x in culture studies where NSC have been
isolated from the adult rat hippocampus (Chen et al. 2007; Chiou et al. 2006a). This could
indicate that fluoxetine protects against the apoptotic effects of 5-FU, but does not increase
proliferation alone. Moreover, the process of neurogenesis in vivo is highly regulated by
BDNF, in a complex feedback and feed-forward mechanism (Castren and Rantamaki 2010;
Duman et al. 200 Ib; Scharfinan et al. 2005) (Chapter 1.2).
It is possible, that the mechanism by which fluoxetine stimulates neurogenesis in vivo
involves the CREB, BDNF pathway (Duman et al. 200Ib). BDNF is produced in vivo by
mature granule cell neurons (Conner et al. 1997), glia and endothelial cells (Linnarsson et al.
2000), and therefore may not be present in immature NSC grown in culture and is likely not
be stimulated by fluoxetine directly, which could be an explanation as to why it does not
increase their proliferation and survival in vitro. In the present study S-HT was not within
the growth medium but the expression of 5-HT and the serotonin reuptake transporter,
SERT, in the NSC was not investigated. The expression of SERT and 5-HT has been
revealed in NSC isolated from the rat cerebellum (Zusso et al. 2008) and in 10 week old
NSC isolated from the midbrain region of embryonic mice (Ren-Patterson et al. 2005).
Therefore, it is likely that SERT would be expressed in the NSC of the present study and
they would release 5-HT. However the pharmacological mechanism by which fluoxetine
acts in this model remains to be determined but would help to understand the in vitro effect
of fluoxetine and norfluoxetine on hippocampal NSC.
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In conclusion, although isolated adult mouse hippocampal NSC appear to be a potential
model of the effects of 5-FU on cell proliferation in the rat hippocampus, they are not a
suitable model of the long-term in vivo effects of fluoxetine. In future studies it would be
interesting to directly compare the effects of fluoxetine and 5-FU on both rat and mouse
hippocampal NSC to see the extent of variation between species. To create a viable model
of work presented in this thesis, it would also be necessary to observe the effects of
antidepressants and chemotherapy in combination to investigate if antidepressants exhibit a
neuroprotective effect to hippocampal NSC directly exposed to antidepressants and 5-FU. It
remains important to establish a cell culture model of hippocampal neurogenesis to help
determine the mechanisms of action of the drugs involved and in particular how fluoxetine is
able to prevent chemotherapy induced-cognitive impairment.
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Chapter 6
General discussion
167
Cognitive impairment is a common experience of patients following chemotherapy
treatment (see section 1.1, Chapter I). The principle aim of the studies in the present thesis
was to develop a model of chemotherapy-induced cognitive impairment using the adult rat
and apply this to understanding the causes and treatments of this condition. This model was
used to investigate the effects of the individual chemotherapies, from the CMF breast cancer
treatment combination, on hippocampal dependent spatial memory and to determine if
changes in adult hippocampal neurogenesis may underlie the observed behavioural deficits.
In the second part of the thesis, the potential effects of the SSRI antidepressant, fluoxetine,
in counteracting the cognitive and cellular deficits induced by chemotherapy, were
investigated. In particular, the optimum time period to administer fluoxetine was
determined which not only indicates how this treatment might be applied clinically, but also
provides an insight into the possible mechanism of action of fluoxetine.
To investigate if the effects of chemotherapy and fluoxetine on NSC could be reproduced in
vitro, NSC were isolated from the hippocampus of the adult mouse and their viability and
proliferation was determined after direct treatment with 5-FU, fluoxetine or its active
metabolite norfluoxetine.
6.1 Principalfindings
The principal findings of the present project are summarised and presented in Table 6.1 and
6.2. In the preliminary study (section 2.2, Chapter 2) the NOR and NLR tasks were used to
test the effect of CP on working memory in the adult rat. However, the animals in the
control group failed to show a preference for the novel stimuli in both tasks, indicating that
higher numbers of animals were needed per group to make the tasks valid. In the second
experiment (section 2.3, Chapter 2) the parameters of the NLR task were altered resulting in
validation of the task. CP treated animals in the revised NLR task were not impaired in
spatial memory. The NOR task was not used in this study to avoid confounding results from
recognising the objects or locations between tasks. Animals treated with CP did not have
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reduced levels of cell proliferation but had reduced cell survival in the dentate gyrus, or
reduced levels of DCX in the hippocampus or frontal cortex compared to the control group.
This work has been published in Lyons et al. 2011 a (The effect of cyclophosphamide on
hippocampal cell proliferation and spatial working memory in the rat. PLoS ONE 6(6».
The next experiment (Chapter 3) showed that in contrast to CP, MTX significantly reduced
spatial memory performance in the NLR task, but not in the spontaneous alternation in the
T-maze task compared to the control group. The memory deficit was reversed when
fluoxetine was co-administered before, during and after MTX treatment. Furthermore, MTX
significantly decreased the proliferation and survival of hippocampal cells, effects which
were also reversed by co-administration of fluoxetine. This work has been published in
Lyons et al. 2011b (Fluoxetine reverses the memory impairment and reduction in
proliferation and survival of hippocampal cells caused by methotrexate chemotherapy.
Psychopharmacology 215: 105-115).
Treatment with 5-FU reduced the animals' ability to perform the NLR task, but did not alter
their behaviour in the spontaneous alternation in the T-maze task. The behavioural effects of
5-FU were associated with decreased hippocampal cell proliferation and cell survival
compared to the control animals (Chapter 4). The behavioural and cellular deficits seen after
5-FU treatment were prevented when fluoxetine was co-administered before and during the
5-FU treatment regimen (preventative) but not when fluoxetine was administered only after
5-FU treatment had finished (recovery). Levels of DCX and BDNF in the hippocampus and
frontal cortex were not altered by 5-FU or fluoxetine. This work has been submitted for
publication in PLoS ONE.
The MIT assay was used to assess the viability of NSC isolated from the hippocampus of
the adult mouse in vivo (Chapter 5). 5-FU, fluoxetine and norfluoxetine all caused cell
viability to decrease with increasing concentrations (0 to 1OO~M) and exposure time (1 to 7
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days). Fluoxetine also reduced cell proliferation, as quantified by cell counts, in a dose (0 to
10~M) and time (I to 7 days) dependent manner.
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Drug Effect on viability of adult Effect on proliferation of adult
hippocampal rat NSC hippocampal rat NSC
S-FU Dose and time dependent reduction nla
Fluoxetine Dose and time dependent reduction Dose and time dependent reduction
Nornuoxetine Dose and time dependent reduction nla
Table 6.2 Summary of results from the in vitro experiment presented in Chapter 5 of this
thesis. Abbreviations; S-FU: S-fluorouracil, NSC: neural stem cell
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6.2 Cognitive effects of chemotherapy
Evidence from clinical studies has indicated that a number of chemotherapy treatment
combinations are able to induce long-term deficits in memory, attention and cognitive ability
in cancer survivors (reviewed in section 1.1.2, Chapter 1). This has led to several studies in
rodents to test the effect of various chemotherapy drugs, used individually or in combination
on different behavioural paradigms that model learning and memory (reviewed in section
1.1.3, Chapter 1). Furthermore, the use of animal models has provided insight into the
mechanisms by which chemotherapy agents may cause cognitive deficits including their
effects on adult hippocampal neurogenesis (reviewed in Fardell et al. 2010). Proliferation
and survival of neurons within the dentate gyrus have been reported to be involved in certain
types of hippocampal-dependent memory formation (section 1.5, Chapter 1) and previous
work within our group and elsewhere, has shown correlations between chemotherapy-
induced cognitive impairment and a reduction in hippocampal neurogenesis (EIBeltagy et al.
2010; Fardell et al. 2010).
Studies in the present thesis investigated the effects of three chemotherapy drugs from the
CMF treatment combination; CP, MTX and 5-FU, on working memory and cellular changes
in the hippocampus in the adult rat. Animals treated with MTX or S-FU showed a reduction
in their ability to perform the NLR spatial working memory task which is consistent with
much of the previous literature which reports chemotherapy-induced cognitive decline in
animal models of chemotherapy (as described in section 1.1.3, Chapter 1). Furthermore,
findings from the present studies provide evidence that it is the chemotherapy itself causing
the cognitive impairment, rather than factors such as stress, depression or fatigue which have
been suggested to confound clinical studies, in patients, of these parameters (Hermelink et
al. 2007; Jenkins et al. 2006). However, the ability of animals to perform the spontaneous
alternation in the T-maze task was not altered by treatment with MTX or 5-FU in the
experiments carried out in the present thesis. This may be because the task assesses a
different cognitive domain from the NLR task and this domain is not affected by MTX or 5-
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FU, even though both tasks require spatial working memory and an intact hippocampus to be
performed (Deacon and Rawlins 2005; Dere et al. 2007; Mumby et al. 2002). An alternative
explanation could be that the ability to perform the spontaneous alternation in the T-maze
task is not sensitive enough to detect the subtle cognitive impairment in spatial memory
produced by MTX and 5-FU.
One of the interesting findings of the present study was that CP did not cause the same
spatial memory deficit in animals that was induced by MTX and 5-FU, as measured by the
NLR task using exactly the same parameters. Although, the dose of CP and the behavioural
task used cannot be discounted as a reason for this, it may indicate that CP does not have a
substantial effect on spatial cognition. Previous studies in rodents have shown varied results
in the cognitive effects of CP administered alone (Lee et al. 2006; Reiriz 2006; Yang et al.
2010) (see Table 1.2), but results from the present study would suggest that even if CP does
cause impairment in hippocampal-dependent memory, it is not as substantial as that induced
by MTX or 5-FU.
When chemotherapy-induced cognitive impairment has been investigated clinically, it is
rarely discussed with respect to particular chemotherapy agents or combinations which may
contribute to the cognitive defects (Table 1.1). However, it is evident from the results in the
present study that the effects of individual chemotherapies need to be taken into account.
Furthermore, there is evidence from animal studies which reports that the cognitive deficits
induced by chemotherapy agents are potentiated when administered in combination (Foley et
a1. 2008; Walker et al. 2011).
6.3 Effects of chemotherapy on adult hippocampal neurogenesis
All three of the CMF chemotherapy drugs are able to cross the blood-brain barrier when
delivered in high doses (Lassman et al. 2006; Patel et al. 1998; Perry 2008), allowing them
to have a direct effect on the brain. Studies from the present thesis showed that MTX and 5-
FU decreased the number of dividing cells in the neurogenic region (SaZ) of the dentate
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gyrus in the hippocampus and furthermore, reduced the survival of the new dentate gyrus
cells which were proliferating at the beginning of the drug administration period. This is
consistent with previous work in our laboratory and elsewhere reporting that MTX and 5-FU
can inhibit neurogenesis (see Table 1.2).
In contrast to MTX and 5-FU, CP showed no significant effect on the proliferation of
hippocampal cells. These results are interesting because they correlate with the effects of
the CMF drugs on spatial memory and provide evidence that a reduction in neurogenesis
may playa role in the memory impairment observed. However, it remains unclear why CP
does not alter neurogenesis and cognition to the same extent as MTX and 5-FU. CP is an
alkylating agent whereas MTX and 5-FU are antimetabolites (see section 1.2, Chapter 1). It
is possible that this difference in mechanism of cytotoxicity is responsible for the differences
seen between the drugs' effects, although a previous study found that another alkylating
agent, thioTEPA impaired the ability of mice to perform the NLR and NOR tasks and also
reduced the proliferation of hippocampal cells (Mondie et al. 2010). In the present study,
CP significantly reduced the survival of newly formed cells involved in hippocampal
neurogenesis suggesting that it has a toxic effect on these cells. This reduction could
possibly lead to long-term cognitive effects which may become more evident with higher
doses. However, the present findings suggest that CP is less neurotoxic than the other drugs
in the CMF combination with which it is used.
6.4 Effects of'fluoxetine on cognition and neurogenesis in the hippocampus
Despite the amount of evidence supporting chemotherapy-induced cognitive impairment,
very little work has been carried out into potential methods to prevent or counteract it. In
the present project it was demonstrated that the spatial cognitive deficits induced by MTX
and 5-FU are reversible by the co-administration of the SSRI antidepressant, fluoxetine.
This is in line with previous literature which showed that fluoxetine is beneficial when non
chemotherapy-induced cognitive impairments are present in rodents (El Hage et al. 2004;
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ElBeltagy et al. 2010; Li et at. 2009; Monleon et al. 2007) and humans (Gallassi et al. 2006;
Levkovitz et al. 2002; Mowla et al. 2007; Vythilingam et al. 2004). If the results from the
present project are translatable to humans, this could explain some of the variation in
chemotherapy-induced cognitive impairment observed in clinical studies, since the co-
administration of antidepressants to patients undergoing chemotherapy has not been
previously taken into account (see Table 1.1).
Moreover, it has been reported in previous studies that fluoxetine increases hippocampal
neurogenesis and this may be the basis of the reversal of the cognitive deficit (EIBeltagy et
at. 2010). The upregulation of hippocampal cell proliferation and survival was clearly
demonstrated in the present studies. However, it is still not fully understood how t1uoxetine
exhibits these neuroprotective and behavioural effects. One way this question was addressed
in the present project was to investigate if t1uoxetine acted by a mechanism of prevention or
reversal. Fluoxetine counteracted the spatial memory deficit and cellular alterations in the
hippocampus when it was administered before and during 5-FU treatment, but not when it
was only administered after treatment, indicating a prevention process. This indicates that
once 5-FU has affected neurogenesis and cognition, it cannot be reversed by later
administration of fluoxetine. This needs to be considered if clinical trials to prevent
chemotherapy-induced cognitive impairment by fluoxetine are to be carried out, since it
would be important to start the administration of fluoxetine before the onset of
chemotherapy treatment.
A further approach to understanding fluoxetine's neuroprotective effect was to directly
expose cultured NSC isolated from the adult mouse hippocampus to fluoxetine and its
primary active metabolite, norfluoxetine in vitro. However, like the cytotoxic agent, 5-FU,
both fluoxetine and norfluoxetine reduced the viability of the NSC and fluoxetine also
reduced their proliferation. Other studies have shown that fluoxetine increases proliferation
in vitro of NSC from rats (Chen et al. 2007; Manev et al. 2001; Zusso et a1. 2008; Zusso et
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al. 2004), but this effect was not mirrored in the present study using NSC from mice. It has
been reported that there are significant species differences in vivo between rats and mice in
the cytokinetics of the cell proliferation involved in hippocampal neurogenesis (Snyder et al.
2009). The work from the present study highlights the importance of considering species
when modelling this type of process in vitro. It would be beneficial to complete further
studies investigating the direct effects of chemotherapy in vitro on NSC cultures isolated
from the rat hippocampus to establish a cell culture model for chemotherapy-induced
cognitive impairment. It would be interesting to directly compare the effects of different
chemotherapy agents and fluoxetine on NSC isolated from both species and to ideally create
a model where fluoxetine prevents the 5-FU induced reduction in proliferation, to further
understand the mechanisms by which fluoxetine acts.
6.5 Experimental critique andfuture considerations
6.5.1 The use of a larger range of behavioural tasks
In clinical studies, a range of cognitive domains have been reported to be affected by
chemotherapy (see Table 1.1) including working memory and visuospatial ability in which
the hippocampus is thought to play a role (Baddeley et al. 2011; Loureiro et al. 2011;
Sharma et al. 2010). One approach to further investigate the effects of 5-FU and MTX on
hippocampal-dependent memory would be to use the MWM spatial memory task (Sharma et
al. 2010). Previous studies in rodents have reported that MTX impairs ability in this task
(Seigers et al. 2008; Seigers et al. 2009), but 5-FU was shown to improve animals'
performance in the MWM in one study (Lee et al. 2006). When 5-FU and MTX were
administered together, they also impaired animals' ability in this task (Winocur et al. 2006).
Patient studies have also shown that other types of memory which are thought to be more
reliant on brain regions other than the hippocampus such as executive function and language
(Lum et al. 2011) are also affected (see Table 1.1). For this reason it would be interesting to
investigate the effects of MTX and 5-FU on the ability of animals to perform non-
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hippocampal dependent tasks to determine if the cognitive deficit observed extends to other
brain regions.
6.5.2 The use offemale animals
The majority of clinical studies investigating chemotherapy-induced cognitive impairment
have been carried out on breast cancer patients, who are therefore females (see Table 1.1).
However, the majority of studies in rodents including those in the present thesis were carried
out in males (see Table 1.2). This was done to avoid any influence of the oestrogen cycle,
which can affect neurogenesis in rodents (Galea et al. 2008; Mazzucco et al. 2006; Tanapat
et al. 1999) and cognitive behaviour in humans and rodents (Galea et al. 2008; Maki and
Dumas 2009; Sundermann et al. 2010). Although chemotherapy-induced cognitive
impairment is not exclusive to females and has been reported in survivors of testicular
cancer (Fung and Vaughn 2011), more studies using female rodents need to be considered
for future work to make the results more relevant to breast cancer patients.
6.5.3 Drug interactions and the use of other antidepressants
It is important when administering more than one drug in vivo, to consider interactions
between them. Fluoxetine inhibits cytochrome P450 enzymes (Alfaro et al. 2000) which are
involved in the metabolism of a number of anti-cancer agents including 5-FU (Komatsu et
al. 2000; Yamazaki et al. 2001) and CP (Kivisto et al. 1995; Rae et al. 2002). Indeed, the
majority of SSRI antidepressants are reported to affect cytochrome P450 enzymes
(Nemeroff et al. 1996). Therefore the efficacy of chemotherapy agents needs to be
monitored when t1uoxetine is co-administered. It would also be beneficial to examine the
effects of other antidepressants, as they are also likely to affect cognition and hippocampal
cell proliferation, when co-administered with chemotherapy. Researchers have already
shown that cognitive performance and neurogenesis can be upregulated by antidepressants
other than fluoxetine or SSRls, including tianeptine (Akyurek et al. 2008; Kasper and
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McEwen 2008) and imipramine (Hitoshi et al. 2007). A likely common factor is the action
of antidepressants in increasing BDNF levels.
6.5.4 Alternative potential methods to counteract chemotherapy-induced cognitive
impairment
Antidepressants are not unique in being able to act as neuroprotectants and a number of
growth factors including CTNF and IGF-l have been shown to act this way (Cool et al.
2005; Grunbaum-Novak et al. 2008; Janelsins et al. 2010; Lee and Son 2009; Shimazaki et
al. 2001). It would be interesting to see if these agents can prevent the cellular and cognitive
effects of chemotherapy and provide alternative strategies in helping patients with this
treatment. In the present study we investigated the effects of the chemotherapy on BDNF
and this is discussed in the next section (6.5.5).
A recent study demonstrated that donepezil, a cognitive-enhancing drug normally used for
the treatment of Alzheimer's disease, was effective in reversing the cognitive impairments
caused by a combination ofMTX and S-FU in a battery of memory tests in mice (Winocur et
al. 2011). Although this finding needs confirmation, as only a single study has been carried
out, it provides a promising alternative to tluoxetine as a potential pharmaceutical treatment
for chemotherapy-induced cognitive impairment.
Another potentially useful approach to counteract the effects of chemotherapy-induced
cognitive impairment could be to increase exercise. Physical activity has been shown to
enhance hippocampal dependent cognition (Creer et al. 2010) and neurogenesis (Kim et al.
2010; Uda et al. 2006) in rodents and has been reported to be beneficial to sufferers of
depression (Babyak et al. 2000). One study also reported that running had a greater effect
on neurogenesis when compared to fluoxetine (Marlatt et al. 2010). Although it would be
unlikely that patients undergoing chemotherapy would be able to perform vigorous exercise,
it would be interesting to investigate if gentle exercise could positively enhance their
cognition.
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6.5.5 The role 0/BDNF
Measurement of the levels of BDNF and the microtubule associated protein, DCX, in the
hippocampus and frontal cortex carried out in the present study did not show any effect of 5-
FU or fluoxetine given alone or in combination. This was surprising, as DCX expression
has been reported to reflect neurogenesis in the adult mammalian brain (Couillard-Despres
et al. 2005). It is possible that the results found in the present study do indicate that there is
no difference in hippocampal levels of DCX and BDNF. However it is also possible that the
Western blotting technique used was not sensitive enough to detect the subtle concentration
differences of these proteins when using whole brain structures. The availability of BDNF is
regulated by fluoxetine (Duman et al. 2001 b; Merz et al. 2011) and could be involved in the
mechanism by which fluoxetine protects new hippocampal neurons. It would therefore be
interesting to use more sensitive quantitative techniques such as real time polymerase chain
reaction or immunohistochemistry to clarify if levels of DCX and BDNF, and the locations
of the cells containing these proteins, are altered by chemotherapy or fluoxetine. These
techniques could also be used in future studies to better determine the levels of other growth
factors which are reported to influence neurogenesis (see Table 1.3).
6.5.6 The effect 0/ stress on cognition and neurogenesis
Stress can affect both neurogenesis and cognition (reviewed in Dranovsky and Hen 2006;
Samuels and Hen 20 II) (see section 1.4.1, Chapter 1). Therefore, in the present study,
measures were taken to minimise the stress experienced by the animals. However, as many
of the animals were administered with chemotherapy agents or fluoxetine and all animals
received multiple injections, it is possible that they experienced some stress or anxiety
during the experiments. It would have been interesting to monitor stress or anxiety levels in
the experiments by behavioural tests such as the open field, forced swim or tail suspension
tests. However, it is likely that these tests in themselves may have caused a large amount of
stress and affected the animals' behaviour and neurogenesis.
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An alternative method would have been to measure blood levels of corticosterone which are
elevated in stressed animals (Heine et al. 2004). This would have allowed comparison of
stress levels between treatment groups to determine the stress induced by chemotherapy.
Corticosterone can effect plasticity in the hippocampus (Maggio and Segal 2010) and it
would therefore it would be beneficial to investigate the effect of stress in future studies.
6.5.7 Immunohistochemistry of the hippocampus
In the present studies, cell proliferation was quantified by counting Ki67-positive cells and
cell survival by quantifying the number of BrdU-positive cells after the end of treatment.
Both Ki67 and BrdU antibodies are markers for dividing cells, however they are not specific
to neurons (Kempermann 2006; Scholzen and Gerdes 2000). Therefore, it is likely that
some of the proliferating cells detected were destined to become glial cells, although it has
been estimated that 89% of dividing cells in SGZ of the adult rat hippocampus become
neurons (Snyder et al. 2009). It would be useful in future studies to double label the cells
with glial and neuronal markers, to see the exact extent .of the effects of chemotherapy and
tluoxetine on neurogenesis and whether these treatments are affecting the ratio of neurons to
glia generation.
Furthermore, it would be beneficial to determine the regional specificity of chemotherapy
and fluoxetine within the hippocampus as distinct regions .of the hippocampus are involved
in different behaviours (Bannerman et a1. 2004; Bast et al. 2003). The dorsal hippocampus
has connections to the prefrontal cortex, amygdala and hypothalamus and is associated with
emotional state and anxiety (Kjelstrup et al. 2002), whereas the temporal hippocampus is
primarily involved in spatial learning, receiving connections from the dorsolateral entorhinal
cortex (Fyhn et al. 2007; Moser and Moser 1998). Neurons in the intermediate region of the
hippocampus encode rapid place learning and behavioural performance (Bast et al. 2009).
Therefore it would be interesting to determine if chemotherapy primarily decreases
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neurogenesis only in the temporal hippocampus or consistently throughout the structure and
to observe the protective effects of fluoxetine in different regions.
6.6 Conclusion
The findings from the present project revealed that the chemotherapy agents, 5-FU and
MTX, but not CP, negatively affect hippocampal dependent spatial learning. In addition,
this reduction in cognitive ability correlated with a decrease in the proliferation and survival
of new cells in the dentate gyrus of the hippocampus. This provides evidence that adult
neurogenesis may be involved in the mechanism of chemotherapy-induced cognitive
impairment. Furthermore, it was demonstrated that the behavioural and cognitive deficits
observed could be counteracted by the SSRI antidepressant, fluoxetine, when it was co-
administered before and during chemotherapy treatment but not when administered only
after. However, the exact mechanism by which fluoxetine has neuroprotective effects needs
further work and clarification.
In conclusion, the findings of the present thesis highlight the importance of considering
individual agents when investigating the effects of chemotherapy on cognition.
Furthermore, these findings provide insight into the mechanisms underlying chemotherapy-
induced cognitive impairment and if the results shown in the present animal model are
translatable to humans, they have the potential to offer a relatively simple method to
alleviate the cognitive problems experienced by cancer survivors.
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Appendix I
Reagents for Western blotting
(All materials for Western blotting are from Sigma-Aldrich, USA, unless otherwise
indicated).
Lysis buffe,.
20mM Tris (Invitrogen, USA)
ImM Ethylene Glycol Tetraacetic Acid (EGTA)
(Sigma-Aldrich, USA)
320mM Sucrose (BOH Laboratory supplies, UK)
1% Triton XIOO
ImMNaF
10mM Beta glycerophosphate
12.1g
1.9g
51.7g
500~1
0.021g
1.08g
The above reagents were dissolved in 500ml of dH20 and the solution was adjusted to pH
7.6. One mini protease inhibitor tablet (Roche, Germany) was dissolved in 10ml of lysis
buffer prior to use.
2X Solubilisation buffer
0.5M Tris
Glycerol
10% SOS
Beta mercaptoethanol
2.5% Bromophenol Blue
dH20
Lowry solution A
100mM NaOH (Fisher Chemicals, UK)
7mM SOS
187mM NaC03
dH20
2.5ml
2.0ml
2.0ml
1.0ml
40~1
500ml
2g
Ig
109
500ml
Lowry solution B
1.0% CUS04 (Fisons Scientific Apparatus, UK) 100111
2.0% NaK Tartrate (BOH Laboratory supplies, UK) 100111
dH20 40ml
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10X Electrophoresis buffer
250mM Tris (Invitrogen, USA)
1.92 Glycine
35M SDS
30.3g
144g
109
The above components were dissolved in Iltr of dH20. To prepare a working solution of
electrophoresis buffer, 50ml of lOX buffer was diluted in 450mh dH20.
Transfer buffer
25mM Tris (Invitrogen, USA)
1.92M Glycine
dH20
Methanol
The transfer buffer was stored below 4'C.
30.3g
144g
8Ltr
2Ltr
TBSTO.1%
25mM Tris (Invitrogen, USA)
125mM NaCI (Fisher chemicals, UK)
30.29g
73.12g
The above reagents were dissolved in Iltr dH20 and adjusted to pH 7.6 then made up to 10ltr
with dH20 and 10ml Tween 20 added.
One 10% SDS-polyacrylamide gel is comprised of thefollowing:
4% Stacking gel
30% Acrylamide
0.5M Tris-HCI
10% SDS
10% Ammoniumpersulphate (APS)
Tetramethylethylenediamine (TEMED)
dH20
3.12ml
6ml
0.24ml
0.12ml
0.024ml
14.6ml
10% Resolving gel
30% Acrylamide
Resolving gel-buffer 1.5M Tris-HCI
10% SDS
10% Ammoniumpersulphate (APS)
Tetramethylethylenediamine (TEMED)
dH20
10.12ml
8ml
0.32ml
0.16ml
0.032ml
13.12ml
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Appendix II
Reagents /01' cell culture
(All materials for cell culture are from Sigma-Aldrich, USA, unless otherwise indicated).
Growth medium
Dulbecco's Modified Eagles Medium (DMEM)
FBS
L-glutamine
PenlStrep
SOOml
SOml
10ml
10ml
Serum free medium with O.3mMdibutyryl cAMP
Dulbecco's Modified Eagles Medium (DMEM) ISml
L-glutamine 300!!1
PenlStrep 300!!1
30mM dibutyryl cAMP IS0!!1
Neural stem cell (NSC) medium
Dulbecco's Modified Eagles Medium/Ham's F12 48ml
(DMEMlFI2 1:1, Invitrogen, USA)
Neurobasal media (Invitrogen, USA) 48ml
N2 supplement (Invitrogen, USA) 1ml
B27 supplement (Invitrogen, USA) 2ml
0.5% Pen/Strep O.Sml
The above components were kept as stock and EGF and FGF (both 20ng/ml) were added
fresh prior to use).
NSC medium/or MTT assay
Dulbecco's Modified Eagles Medium/Ham's F12 9ml
(DMEMlFI2 1:1, Invitrogen, USA)
FBS Iml
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Appendix III
Jlaen1atocytOn1et~
To count the cells, firstly the cell suspension was thoroughly mixed. A lOll1 sample was
taken from the suspension and transferred of the chamber of an Improved Neubauer
Hemocytometer where it was drawn under the cover slip from the pipette by capillary action.
The fluid should run to the edge of the grooves bordering the chamber but not over. The
viable cells, with a bright round appearance, within the 5 diagonal squares within the central
1mm2 were counted. The viable cell concentration was counted calculated using the
following equation.
c = (n x d)/v
c was the cell concentration (cells/ml)
n was the average number of cells counted (from each square)
v was the volume counted (ml)
d was the dilution of the cell suspension
The depth of the chamber was O.lmm and v was O.lmm', or I x 10-4ml.
The total number of cells = sample concentration (cells/ml) x original volume of cell
suspension from which the sample was taken.
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